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1 .1  Structural  elements in supramolecular peptide architectures 
The structure of the first proteins and their secondary elements was elucidated in the 1950s by 
Pauling, Crick and others.[1] This was promptly followed by a series  of structural studies on 
synthetic peptides as protein mimics, leading to the preparation of the first synthetic peptide 
supramolecular assembly (collagen mimic) in 1961.[2] However, despite this early onset it took 
more than 30 years before the first macroscopic peptide-based materials were prepared by 
Ghadiri and Zhang.[3] These two pioneers exploited one particular structural element, the -
sheet, found in proteins as disclosed by Pauling 40 years earlier, to make a peptide nanotube and 
a macroscopic membrane, respectively. Later, others exploited other structural elements such as 
the -helix and the collagen triple-helix (polyproline II helix element) to develop various peptide-
based supramolecular architectures.[4] In the following sections these structural elements will be 
presented along with examples of their use in supramolecular peptide architectures. 
 
1 .1 .1  Architectures based on -helix elements 
The -helix was discovered in 1950-51 and is probably the most famous structural element 
found in proteins and peptides.[1a,5] This structural element attains a helical structure via 
hydrogen-bonding between backbone NH and C=O in residues i and i+4 leading to formation 
of a helix with 3.6 residues and a rise of 5.4 Å per turn, respectively (Fig. 1.1A). An interesting 
characteristic of this helix is that the peptide side chains project out from the -helix,[1b,6] which 
together with its high degree of regularity can be exploited in the design of peptide architectures 
since the position of the individual amino acids in the helix can be predicted.[7] In this regard, 
schematic representations of the alpha-helix to provide an overview of the arrangement of the  
amino acid residues are very useful for such design ventures. One very useful representation is 
 
 
Figure 1.1 Common structural elements in peptides. Carton representations of A) an -helix, B) a -sheet, 
and C) a polyproline II helix are shown in grey with the peptide backbones shown as sticks. Hydrogen 
bonds are represented as black dotted lines.   
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the so-called helical wheel helix representation, in which the alpha helix is viewed along its helical 
axis, so the amino acids can be represented as interconnected dots around this axis forming a 
‘wheel’ (Fig. 1.2A). A special case is observed for helices containing hydrophobic (H) and polar 
(P) amino acids in repeats of (HPPHPPP)n which entails formation of a continuous hydrophobic 
face of the helix, inducing self-assembly of these amphiphilic peptides in water. Further, as the 
periodicity of the hydrophobic amino acids is 3.5 (on average) and hence does not match the 
helical periodicity of 3.6, the hydrophobic face winds slowly around the helix. When two helices 
self-assemble, the winding of their hydrophobic faces leads to twisting of the helices around each 
other to optimize their hydrophobic contact interface. X-ray studies have revealed that the 
amino acids in this hydrophobic face are engaged in a tight ‘knobs-into-holes’ packing, as termed 
by Crick,[6] which contributes significantly to the overall helix-helix binding strength.[8] The 
resulting supercoil, also known as a coiled coil, is often denoted (abcdefg)n in which a and d are the 
hydrophobic (H) amino acids (Fig. 1.2). Frequently, charged amino acids are installed at 
positions e and g to tune the helix-helix interaction, that is, to define the specificity of the 
interaction (hetero- or homo-oligomerization) as well as further stabilization of the coiled coil.[8] 
 
 
Figure 1.2 Assembly of coiled coils. A) Helical wheel representation of a coiled coil. When an -helix is 
viewed from the end of its helical axis, the amino acids can be represented as interconnected dots forming a 
‘wheel’. In this representation the hydrophobic interactions (brown) between residues a and d as well as the 
ionic interactions (grey arrows) frequently occurring between residues e and g can easily be rationalized. B) 
Cartoon representation of a coiled coil with the hydrophobic residues a and d shown as brown sticks at the 
interface of the two slightly twisted helices. 
Assembly of -helices into supra-molecular structures is not limited to association of two 
helices.[9] This is demonstrated most clearly by Woolfson and co-workers who currently hold the 
record for preparation of the largest stand-alone coiled coil oligomer containing six helices.[10] 
Starting from a known tetrameric coiled coil, Ac-G(ELAAIKX)4GAG-NH2 at gabcdef (where X is 
Q, K, W and Q in turn), Woolfson et al. engineered a new coiled coil forming peptide with a few 
subtle but influential changes. By interchange of the lysine residues at e positions with alanine at 
b positions affording Ac-G(ELKAIAX)4GAG-NH2, they expanded the hydrophobic interface 
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between the helices. This allowed the assembly of multiple helices, and it was indeed observed by 
X-ray diffraction and analytical ultracentrifugation that six helices packed together in one 
structure. Because of the large number of helices, the coiled coil architecture could not adopt a 
tightly packed supercoil but rather a ring with a central channel and open ends. This feature 
might be employed to develop membrane-spanning channels, as suggested by Woolfson and co-
workers. 
 
1 .1 .2 Architectures based on -sheet elements 
The -sheet was first rationalized by Astbury in 1931 based on molecular weight determinations 
of insulin and albumin and it was proposed as a general inter-/intra polypeptide interaction.[11] 
Twenty years later, Pauling showed by X-ray diffraction that -sheets indeed are structural 
elements in proteins and that these are formed via backbone hydrogen bonds between two 
peptide strands.[12] In addition, this hydrogen-bonding and -strand assembly can be within the 
same peptide or between individual peptides and either in an anti-parallel or parallel fashion 
depending on the directionality of the peptide backbones (Fig. 1.1B). Extensive -sheet formation 
may result in formation of so-called amyloid structures which are insoluble aggregates forming the 
basis for materials like spider silk, eggshells and fungal coat formation,[13] but also diseases such 
as Alzheimer’s.[14] In the -sheet structure the amino acid side chains project outwards 
perpendicularly above and below the sheet in an alternating fashion, which is often exploited in 
the design of -sheet based materials to modulate their properties.[7a]  
A very illustrative example of the utilization of the alternating nature of the -sheet element 
was provided by Zhang and Rich et al. in their work on zuotin, a DNA binding protein from 
yeast.[3a] They synthesized the peptide AEAEAKAKAEAEAKAK (hydrophobic residues in 
bold), which is part of zuotin, and studied its structure in solution. The alternating pattern of 
hydrophobic and hydrophilic residues in the peptide provided the ideal framework for 
adaptation of a -sheet structure, and, as expected, -sheets could be observed by means of 
circular dichroism spectroscopy. By serendipity, however, they discovered that these -sheets 
assembled into macromolecular membrane structures when salts were added. Presumably, this 
assembly is facilitated by three different forces working in two different planes: conventional -
sheet hydrogen bonding works between the peptide backbones in one plane while hydrophobic 
attraction forces between the alanine side-chains and ionic bonding forces between the glutamic 
acid and lysine residues work in a perpendicular plane (Fig. 1.3). Altogether this results in 
stacking of the -sheets in one plane and interconnection of these stacks in another. The 
resulting macroscopic membranes turned out to be very stable as they were resistant to acid, 
base, high temperature, denaturing agents and proteolytic enzymes.  
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Figure 1.3. Interactions in AEAEAKAKAEAEAKAK leading to formation of a macroscopic assembly. A view 
along the Y-axis (left) shows the ionic and hydrophobic interactions, which keep the individual -sheets 
together in the X-Z plane. Conventional -sheet hydrogen bonding is responsible for stacking of the beta-
sheets in the X-Y plane (right). Redrawn from ref. [3a]. 
 
1 .1 .3  Architectures based on polyproline II helix elements 
The polyproline II helix was first observed in collagen fibers and imprecisely described by 
Ramachandran as a coiled coil consisting of three -helices.[15] Later refinements by Rich and 
Crick[16] as well as Cowan, who found the same structure in their polyproline peptides (hence the 
term polyproline helix), led to the currently accepted model.[17] The polyproline II helix is less 
compact than the -helix with 3.3 residues and a rise of 9.4 Å per turn, respectively (Fig. 1.1C). 
Hence, the polyproline II helix adapts a more stretched helix which must associate with other 
polyproline helices to form a stable trimeric coiled coil, because of its extended structure. This 
tight coiled coil structure has rather strict restrictions on the amino acid sequence and hence the 
generic sequence (Y-X-Gly)n must contain a glycine residue at every third position to allow 
coiling of three helices.[17] Furthermore, X and Y are most often proline and hydroxyproline 
(obtained via post-translational hydroxylation of proline), respectively. 
The polyproline II helix element has not received as much interest in peptide-based 
architectures as the -helix and -sheet discussed above.[18] Nonetheless, very elegant examples 
of peptides architectures based on this element do exist, such as the work by Chaikof and co-
workers on collagen-mimetic microfibers.[19] They prepared a peptide based on the polyproline 
II helix with arginine residues at position X in the first one third of the peptide and glutamate 
residues at position Y in the last one third of the peptide: (ProArgGly)4(ProHypGly)4( 
GluHypGly)4. The incorporation of oppositely charged residues led, after self-assembly of the 
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peptides, to formation of a polarized homotrimeric helix. Chaikof and co-workers showed via 
electron microscopy that these triple helices associated with each other in a head-to-tail manner to 
form fibers, presumably facilitated by electrostatic interactions between the triple helices. 
Moreover, the fibers displayed a periodic band, which is present in natural collagen as well. In a 
related example, Hartgerink and co-workers used a collagen-mimic similar to the one designed 
by Chaikof with lysine and aspartate instead of arginine and glutamate as electrostatic 
interactions.[20] This replacement supposedly resulted in improved electrostatic interactions 
between the oppositely charged residues, and consequently higher quality fibers were formed, 
which furthermore were able to form hydrogels in contrast to the original collagen-mimic 
designed by Chaikof. Hence, these approaches might be an important step towards synthetic 
collagen, which might have great implications in medicine. 
 
1 .1 .4 Peptide amphiphiles 
Hydrophobic interactions play an important role in the formation of peptide secondary elements 
as discussed above. This holds for peptide amphiphiles in particular, which consist of a 
hydrophilic region (hydrophilic amino acids) and a hydrophobic region (hydrophobic amino 
acids or hydrophobic non-amino acid elements).[21] In the case of peptide amphiphiles consisting 
of amino acids only, these hydrophobic/hydrophilic regions can be arranged either as blocks or 
in an alternating manner.[21a] Examples of such all-amino acid peptide amphiphiles include 
natural antimicrobial peptides like magainin, pardaxin and gramicidin S,[22] which exploit a 
hydrophobic patch in their structures to form pores in biological membranes. 
The versatility of peptide amphiphiles was demonstrated by Zhang and co-workers in their 
work on hydrophobic peptide hexamers (valine or leucine) containing one or two hydrophilic 
end groups (C- or N-terminal histidine or lysine).[23] Rather than destroying membranes (like the 
antimicrobial peptides) they showed that their peptide amphiphiles could form a range of 
structures, vesicles and nanotubes e.g., depending on the exact amino acid sequence. These 
structures, however, were only stable when pH was above the pI of the end-groups, which 
ensured electrostatic repulsion between these to balance the attractive interaction between the 
hydrophobic regions. 
The first polypeptide amphiphiles containing non-amino acid elements were prepared by 
Yamada and co-workers in 1984, probably inspired by the work done by Murakami and 
Kunitake on amphiphiles containing a single amino acid residue.[24] Yamada and co-workers 
prepared two oligo-glutamic acid amphiphiles containing two alkyl-chains at the C-terminal 
glutamic acid residue: (Glu)mGlu(NHCnH2n+1)NHCnH2n+1.[25] When the two peptide amphiphiles 
(n = 12, mav  6 and n = 16, mav  14) were dispersed in water they observed via electron 
microscopy formation of ordered lamellar assemblies. In the case of peptide amphiphiles with 
the short (C12) alkyl-chains, helical and tubular structures were also observed. However, circular 
dichroism spectra of the helical structures did not exhibit any spectral features reminiscent of a 
helical conformation, so the exact nature of the assemblies remains unclear. 
A similar framework was used by Stupp and co-workers in their ingenious design of a fiber-
assembling peptide amphiphile. This peptide amphiphile contained multiple functional features 
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each with their distinct purpose (Fig. 1.4),[26] which were brought together in the simple 
molecular structure: palmitoyl-(Cys)4-(Gly)3-Ser(OPO3)-Arg-Gly-Asp. The hydrophobic 
palmitoyl chain and the hydrophilic amino acids provide the overall framework for the peptide 
amphiphile and driving force for the fiber-assembly. From electron microscopy and modeling 
data Stupp et al. rationalized that the fiber assembled into cylindrical micelles in which the 
palmitoyl chains packed together in the micelle core while exposing the peptide on the exterior. 
The five cysteine residues were included to allow covalent linkage of the peptide amphiphile 
units by means of disulfide bridge formation. In this regard, Stupp showed that these cysteine 
residues indeed led to formation of stable fibers under conditions, which caused disassembly of 
non-linked peptide amphiphile units. The tri-glycine unit was included as a linker to provide 
flexibility to the hydrophilic head group from the more rigid cross-linked region. The 
phosphoserine residue was incorporated as nucleation site for calcium mineralization and the 
Arg-Gly-Asp unit was added to facilitate cell-adhesion. Together these two functional units 
allowed calcium mineralization in a cellular environment thereby mimicking bone 
mineralization. 
 

 
Figure 1.4. The peptide amphiphile developed by Stupp and co-workers. The chemical structure (top) 
shows the five regions of the peptide amphiphile: 1) palmitoyl provides hydrophobicity, 2) four cysteine 
residues enable covalent linkage of the assembled peptides, 3) three glycine residues provide flexibility 
between the hydrophobic and hydrophilic ends, 4) phosphoserine serves as a nucleation site for calcium 
mineralization, and 5) Arg-Gly-Asp sequence facilitates cell-adhesion. The cartoon representation (bottom) 
illustrates how multiple peptide amphiphiles can assemble into a macroscopic fiber. Adapted from ref. [26a]. 
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1 .2  Supramolecular peptide architectures with biological  functions 
Most supramolecular peptide architectures are designed for biological applications. This is a 
logical result of the fact that many structures are based on sequences found in natural proteins 
and are developed to mimic the functionality of their natural counterparts in a biological setting. 
Secondly the biological nature of peptide architectures means that they are often compatible 
with a biological environment. In the design of peptide architectures, two principal approaches 
are usually taken, namely mimicking of biological macromolecules, e.g. Stupp’s synthetic bone 
scaffold discussed above, or addition of (new) functions to (bio)macromolecular systems. An 
example of the latter is also provided by Stupp and co-workers in their work on synthetic peptide 
amphiphiles, which they functionalized with epitopes involved in differentiation of cells.[27] In 
their simple but very elegant design, Stupp et al. fused a neurite-sprouting epitope, IKVAV, 
which is known to induce differentiation of neurite cells, to a palmitoyl-modified AAAAGGGE 
sequence yielding the final peptide amphiphile C16-AAAAGGGEIKVAV. In aqueous media the 
peptide amphiphiles self-assembled into fibers, which further bundled into macroscopic gel-like 
structures. A sufficient number of IKVAV epitopes were presented on the fibers in the gel-
structure to not only support growth of neurite-cells, but also direct their differentiation into 
neurons. 
In a related study, Stupp et al. prepared the peptide amphiphile (HSNGLPLGGGSEEE-
AAAVVV)-Lys(lauroyl), which upon self-assembly displays the TGF-1 binding epitope 
HSNGLPL, introduced at the N-terminus of the peptide amphiphile.[28] They demonstrated that 
the resulting gels could bind TGF-1 growth factors and, as a result of this, support growth and 
differentiation of stem cells in vitro and in vivo. 
Hence, by combination of the self-assembly ability of a peptide-amphiphile and the 
biological function of epitopes, it was demonstrated that a specialized platform to address a 
particular biological challenge could be designed.  
 
1 .2.1  Introduction to cell -penetrating peptides 
The introduction of so-called cell-penetrating peptides (CPPs) into supramolecular peptide 
architectures yields materials with a particularly interesting biological function. CPPs enable 
transport of the entire architecture into cells where it may fulfill another function, if applicable. 
Hence, this section will be devoted to a brief introduction to CPPs and their use in 
supramolecular peptide architectures. 
Most CPPs are rather short peptides, cationic and often rich in arginine residues. These 
peptides are, as their name suggests, able to penetrate cells by means of adhesion to the cell 
membrane and traversing it, so the CPPs eventually reach the cytosol. This characteristic applies 
in every respect to the first CPP that was identified, the Tat peptide, which was discovered in 
1988 as a protein domain responsible for transduction of the HIV transactivator protein into 
cells.[29] Hence, CPPs derived from proteins are also called protein transduction domains. Since then 
many different CPPs have been exploited to transport a large variety of different cargos into cells 
like small molecules,[30] quantum dots,[31] oligonucleotides[32] and liposomes[33]. 
Supramolecular peptide architectures 
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The exact mechanism of cell-penetration is still under debate and several uptake pathways 
appear to be operative, of which endocytosis and direct permeation are the two commonly 
accepted main pathways (Fig. 1.5).[34] Endocytosis includes the energy-dependent processes of 
cell membrane invagination of membrane-bound CPPs as well as macropinocytosis, in which 
the cell membrane engulfs a part of the extracellular fluid. In both cases, internalization leads to 
encapsulation of the CPP and its cargo in intracellular vesicles, from which the CPP and cargo 
have to escape. This may limit the efficiency of CPPs in delivery applications. 
Direct permeation, the other uptake pathway, is energy-independent and works by adhesion 
of the CPPs to the membrane where they form small pores in the membrane, through which 
they can enter the cell, thereby bypassing vesicular entrapment. The actual pathway in 
operation, however, depends on several factors such as cell-type, CPP and cargo, which make 
the prediction of pathway almost impossible. 
Since their discovery, many other CPPs have been identified or designed, so the number of 
known CPPs has reached around 100 at present.[34a] This CPP family spans a rather diverse 
collection of peptides with respect to structure and cell-penetration mode, and accordingly CPPs 
can be subdivided into three main types: i) primary amphiphilic, ii) secondary amphiphilic, and 
iii) non-amphiphilic.[34a]  
 
 
 
Figure 1.5. Uptake pathways of cell-penetrating peptides. The first step (step 1) of cellular uptake of CPPs is 
binding of the peptide to the cell-membrane. The next step is uptake via endocytosis (step 2a) or via a direct 
permeation mechanism (step 2b). The latter involves clustering of the CPPs on the cell-membrane 
eventually leading to pore formation, while the former leads to encapsulation of the CPPs in intracellular 
vesicles (endosomes), from which they might escape (step 3). Adapted from ref. [35]. 
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Primary amphiphilic CPPs are peptides typically longer than 20 amino acids, which consist of a 
distinct positively charged, hydrophilic region and a hydrophobic region. These CPPs tend to 
self-associate on cell-membranes and penetrate deeper into the bilayer membrane than the other 
CPP classes. This characteristic may provide the premise for the direct permeation uptake 
pathway.  
Secondary amphiphilic CPPs are typically shorter than the primary amphiphilic CPPs and 
do not display distinct hydrophobic and hydrophilic regions. However, upon association with 
cell-membranes they adapt a secondary conformation (-helix or -sheet), which does have 
distinct hydrophobic and hydrophilic regions. These CPPs, however, do not penetrate deep into 
the cell membrane and rely on ionic interactions between the positively charged, hydrophilic 
region and the anionic cell-membrane as well. 
Non-amphiphilic CPPs are the shortest type and usually have a very high content of 
arginine residues. Consequently, this type binds exclusively to cell-membranes via electrostatic 
interactions and does not penetrate into the membrane. That is, direct permeation is not very 
likely to occur unless very high concentrations of the CPP are used. 
 
 
Table 1.1 Selected cell-penetrating peptides 
Type‡ Name Sequence Origin Reference 
Primary Pep-1 KETWWETWWT-EWSQPKKKRKV Designed 
[36] 
Primary TP-10 AGYLLGKINLKAL-AALAKKIL Transportan 
[37] 
Primary Transportan GWTLNSAGYLLGK-INLKALAALAKKIL Fusion peptide* 
[38] 
Secondary Polyproline (Pro)14-Amp
†-(Pro)14 Designed 
[39] 
Secondary Penetratin RQIKIWFQNRRMKWK Antennapedia, D. melanogaster 
[40] 
Secondary MAP KLALKLALKALKAALKA Designed [41] 
Non-amph. Nona-
arginine 
RRRRRRRRR Designed [42] 
Non-amph. Tat YGRKKRRQRRR Transactivator protein, HIV-virus 
[29a] 
‡ Type refers to primary amphiphile, secondary amphiphile or non-amphiphilic. 
* Chimera of two natural peptide fragments from Galanin (S. s. domesticus) and Mastoparan (V. lewiisi) 
† Amp = 4-amino-proline. The two Pro14 were connected via the two amine groups in Amp 
 
1 .2.2 Supramolecular cell -penetrating peptide architectures 
Amongst CPP supramolecular architectures, Pep-1 stands out as one of the pioneering examples 
of CPP assemblies capable of delivering proteins or small drugs into cells.[36] Pep-1 is an 
archetypal example of an (primary) amphiphilic CPP consisting of a tryptophan-rich 
hydrophobic region, a hydrophilic lysine-rich region and a small spacer (SQP) to provide 
flexibility between the two regions (Table 1.1). Divita, Morris and co-workers showed that Pep-1 
formed small nanoparticles of around 100 nm in diameter consisting of 6 to 14 Pep-1 molecules 
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per cargo molecule when mixed with peptide or protein cargos. [36,43] Interestingly, they showed 
that the associated cargos were delivered into cells via a non-endocytotic pathway thereby 
circumventing entrapment in intracellular vesicles. Hence, supramolecular assembly of Pep-1 
with cargo molecules serves as an alternative to conventional covalent linkage of the CPPs to the 
cargo. 
An example, in which peptide secondary elements were exploited in a more direct manner, 
was provided by Lee and co-workers, who prepared a nano-ribbon from CPP-functionalized -
sheets (Fig. 1.6B).[44] They used a -sheet forming peptide, FKFEFKFEFKFE, as the structural 
element responsible for formation of the -sheet scaffold and fused a Tat peptide (via a GSGG 
linker) to it. Incorporation of the Tat peptide did not affect the formation of -sheets, and Lee et 
al. were able to identify one-dimensional nano-ribbons of several micrometers in length and 6 
nm in width. Furthermore, it was demonstrated that small hydrophobic molecules could be 
encapsulated in the nano-ribbon and delivered into cells together with it. 
The polyproline II helix element has also been used as a scaffold for CPP architectures,[45]  
and one example of such a CPP is The Sweet Arrow Peptide (SAP) with the sequence 
(VRLPPP)3.[46] SAP was designed by Giralt and colleagues, who also studied its properties 
 
 
Figure 1.6. Cell-penetrating peptide architectures developed by Lee and co-workers. A) di- or tetra-palmi-
toylation of Tat yielded spherical micelles and nanorods, respectively (left). When Tat was modified with 
isoleucine-functionalized amino-caproic acid, long indefinite fibers formed instead of discrete micelles or 
nanorods (right). Functionalization of Tat with a -sheet forming peptide, FKFEFKFEFKFE, or a polyproline 
helix forming peptide, Pro10 yielded a nano-ribbon (B) or vesicle (C), respectively. A flexible linker, shown 
in bold, was included between the Tat peptide and the structural peptides. Adapted from ref. [44,47]. 
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extensively and found that SAP formed structures with a high polyproline II helical content that 
further assembled into fibers. Furthermore they showed that cells were able to internalize these 
structures, though the exact nature of the internalized species was not disclosed. That is, it is not 
known at present whether the fibers were internalized as intact entities or as smaller 
substructures. 
Most CPP supramolecular architectures are indefinite structures such as fibers, whereas 
examples of discrete structures are less common. An example of such discrete structures is 
micelles formed from primary amphiphilic CPPs.[47a,48] Lee and Hartgerink both linked long 
alkyl-chains to a (hydrophilic) CPP, and observed by electron microscopy that micelles had 
formed in their aqueous peptide solutions.[47a,48a] Lee and co-workers demonstrated that they, 
moreover, were able to control the shape of the architectures formed from their CPP 
amphiphiles (Fig. 1.6A). By means of increasing the number of stearoyl chains (C18) linked to a 
Tat-peptide from two to four, they were able to steer the assembly from a spherical micelle into a 
nanorod. Similarly, by replacement of the four stearoyl chains with four isoleucine-
functionalized amino-caproic acid units (C6), the peptides assembled into long fibers rather than 
nanorods. Furthermore, Lee et al. studied the cellular uptake of the micelles and nanorods and 
found that the micelles were highly toxic with an LD50 of around 10 8M. The nanorods on the 
other hand, showed successful uptake in HeLa cells and their toxicity was at the same low level 
as unimolecular Tat. 
Discrete vesicular structures have also been prepared from amphiphilic CPPs by Lee and 
co-workers. As an extension on their work on nanoribbons (discussed above), they designed and 
synthesized an interesting amphiphilic CPP, a decaproline functionalized Tat peptide, Pro10-
Tat.[47b] In this peptide the proline sequence did not serve as a CPP, but rather as a structural 
element facilitating assembly of the peptides into polyproline II helices. As a result, the Tat 
peptides were presented at the ends of trimeric coils, thereby demonstrating that another 
structural element, the polyproline II helix, can be used as a scaffold for presentation of CPPs. 
These coils further assembled into bilayered vesicles with the proline region as the hydrophobic 
core in the membrane and the Tat peptides as the inner and outer surfaces (Fig. 1.6C). 
Moreover, Lee et al. showed that hydrophobic molecules could be encapsulated in the CPP 
vesicles and delivered into cells. 
These CPP vesicles bear a remarkable resemblance to Tat-functionalized liposomes and 
may be regarded as a fully peptide-based alternative to Tat-liposomes.[33] However, the 
versatility of liposomes as peptide modifiable transport vesicles is unparalleled as a large variety 
of different peptides are tolerated without affecting the integrity of the vesicles.[49] The 
decaproline scaffold might not display the same versatility regarding choice of peptide. 
 
1 .3  Switchable peptides 
Secondary structural elements serve as scaffolds for further assembly into larger architectures, as 
discussed above; hence conformational integrity at the secondary level is crucial for preparation 
of functional peptide architectures. This interrelation can, however, be exploited to create 
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peptide architectures with switchable properties, provided that the secondary structures can be 
controlled and switched between different structural elements. For this reason, research on 
activity-switchable peptide architectures has focussed on manipulating the secondary structures 
of peptides in endeavours to develop new biosensors, drug delivery vehicles and so-called smart 
materials, i.e. materials with well-defined and switchable properties. Examples of stimuli that can 
induce these desired changes include pH, temperature, redox-potentials, metal ions, light, and 
enzymes.[50] In the following sections, a non-exhaustive selection of switchable peptides involving 
some of these stimuli is discussed.  
 
1 .3.1  pH stimulus 
To date, a vast number of peptides which respond to changes in pH by switching conformation 
has been investigated.[51] The principal strategy in most approaches is to introduce amino acids 
with side chains having acid-base properties. For example, Tirrell et al. introduced glutamate 
residues at the interfaces of several coiled coil structures in an artificial protein (e and g positions 
in an abcdefg heptad) to create an alkaline-mediated disruption of the peptide structure,[51a] while 
Conticello et al. likewise introduced histidine residues into a trimeric coiled coil (position d) to 
enable an acidic-mediated peptide disassembly.[51b] In both cases formation of repulsive charges 
in the coiled coils (deprotonation of glutamate residues or protonation of histidine residues) led to 
unfolding of the coiled coil. 
The same strategy was also employed in the design of a membrane active peptide, GALA. 
This 30-meric peptide is based on a glutamate containing coiled coil, and it switches from a 
random coil structure to an -helix when pH is lowered from 7.5 to 5.0.[51c] In the -helical 
form, the GALA peptide is able to insert into lipid bilayers and form oligomeric pores of a 
defined size – an aspect that has been exploited as a mechanism for endosomal escape in drug 
delivery strategies.[52] By minor modifications in the GALA sequence, it is possible to tune the 
transition pH value, as demonstrated by Haas and Murphy. They showed that deletion of two 
glutamic acid residues and substitution of one residue with 3,5-diiodotyrosine increased this 
transition pH value from 5.7 to 6.7.[53] 
 
1 .3.2 Light stimulus 
Another mode of conformational switching can be achieved by exploiting molecules that change 
configuration or constitution upon absorption of light, the so-called photochromic molecules. By 
incorporation of photochromic molecules at strategic positions in peptides, the configuration/ 
constitution change of the photochromic molecule can be transformed into a conformational 
change of the peptide. The advantage of this approach is that it does not require addition of 
reactants to induce a transition, the response is fast plus the light can be applied both 
homogenously in bulk and confined to a specific area of a sample.  
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Figure 1.7. Common photochromic molecules used to design photo-responsive peptides. Azobenzene can 
switch between cis and trans configurations, fulgides and spiropyrans can switch between ring opened and 
ring closed states by means of UV-irradiation. 
The most common photochromic molecules employed in light responsive peptides are shown in 
Fig. 1.7.[54] Of these, azobenzene is the most extensively studied because of its high (photo)-
stability and large extent of photo-induced cis-trans isomerization, which is fast and reversible.[55] 
Azobenzene can be incorporated in peptides in three principally different ways as shown in Fig. 
1.8A-C.  
The intra-molecular cross-linking approach has been employed mainly by Woolley and co-
workers to develop reversible photo-controlled -helices.[55a,56] By introducing cysteine residues 
at positions i and i+7 in helices of different model peptides, Woolley and co-workers were 
able to append azobenzene molecules to the exterior of these helices. When forced into a cis-
configuration by photoisomerization the peptides exhibited a high helix content. However, after 
photoisomerization into a trans-configuration no helix signals could be observed by circular 
dichroism spectroscopy. 
 
 
Figure 1.8. Illustration of three principally different ways of incorporating azobenzene into peptides. A) 
Appendage to the peptide side-chains. B) Conjugation to an -helix via cysteine residues. C) Incorporation 
in the peptide backbone. 
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The side chain approach was used by Feringa and co-workers to control the mechano-sensitive 
channel of large conductance (MscL)[57] from E. coli.[58] The 22nd amino acid (glycine) of the 
MscL was replaced with cysteine and then functionalized with a spiropyran group. Irradiation at 
366 nm resulted in photochemical ring opening, which led to appearance of a hydrophilic 
zwitterionic merocyanine structure. After irradiation with visible light (>460 nm) the spirophan 
state could be observed again. The merocyanine state was found to be more hydrophilic and this 
characteristic was believed to induce opening of the MscL channel. 
A different approach to develop photo-responsive peptides involves modification of the 
peptide of interest with photo-labile moieties. This prevents, temporally, the peptide from 
exerting its natural function until irradiation is applied. Hence, this way of inactivation is also 
known as caging, as the peptide can be considered to be functionally ‘trapped’.[59] Several photo-
labile groups have been used to cage peptides, of which the most commonly used moiety is the o-
nitrobenzyl group (Fig. 1.9).[59-60] When a leaving group, such as a peptide functional group, is 
connected to the benzyl-position, UV-irradiation leads to irreversible cleavage of this bond 
thereby releasing the functional group. In a very illustrative example of caging, del Campo and 
colleagues exploited an o-nitrobenzyl cage to direct cell-growth in two-dimensions.[61] By 
functionalization of a silica surface with a cyclic RGD-peptide, which had been caged at the 
side-chain carboxyl group, they were able to prevent cell-adhesion to the surface. However, after 
UV-irradiation leading to removal of the cage, cell-adhesion was restored, but only at areas, 
which had been UV-irradiated. 
 
 
 
Figure 1.9. The photo-labile o-nitrobenzyl group can be used to temporally mask functional groups. Upon 
UV-irradiation the o-nitrobenzyl group undergoes a rearrangement leading to release of the functional 
group (LG = leaving group). 
 
Caging has also been used to study and manipulate folding of peptides, as demonstrated by 
Chan and co-workers, who investigated the folding of the coiled-coil forming peptide, GCN4-
pl.[62] In their proof-of-concept study, they mutated a single asparagine residue into aspartate at 
position a (shown in bold; Section 1.1.1) in the coiled coil forming peptide (Ac-
RMKQLEDKVEELLSKDYHLEVARLKKLVGER-NH2). This led to electrostatic repulsion 
between the aspartate residues and disruption of the coiled coil. However, if the carboxyl group 
of the aspartate side-chain was caged with the photo-labile 3’,5’-dimethoxybenzoin electrostatic 
repulsion was prevented and coiled-coil formation was re-established. After removal of the cage 
by UV-irradiation the aspartate carboxyl groups were exposed and disruption of the coiled coil 
was achieved once more.  
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1.3.3  Metal- ion stimulus 
Addition of metal-ions has been a very popular stimulus for switching the conformation of 
peptides.[63] Though the different approaches for development of metal-ion induced peptide 
switches are very diverse the underlying principles are quite similar: One or more metal-binding 
groups are incorporated in the peptide sequence at positions that will favour formation of a 
desired secondary structure upon binding of a metal; i.e. for formation of an -helix requires 
metal-binding groups in positions i and i+4 or i+5, while intramolecular -sheets or turns can be 
induced when the binding sites are further apart from each other.[63] 
One of the most frequently used metal-ion binding moieties is histidine along with some 
other closely related compounds like imidazole, pyridine and bipyridine.[63-64] Common for these 
N-heterocycles is the ability to coordinate to metal-ions via a nitrogen lone-pair. 
An example of a histidine metal-ion switch is provided by Dublin and Conticello, who 
engineered a 41-meric peptide coiled coil based on a five abcdefg-heptad repeat with three 
histidine residues at alternating d positions instead of the normal isoleucine.[64] This isoleucine to 
histidine substitution resulted in formation of a random coil below pH 5.6 instead of the normal 
coiled coil. However, upon addition of silver(I) ions, circular dichroism spectroscopy showed 
formation of -helices and electron microscopy showed the presence of long fibrils indicating 
that coiled coils had formed. In addition, the authors demonstrated that removal of silver(I) ions 
by complexation with thiosulfate anions led to unfolding of the coiled coil and re-emergence of a 
random coil. Decreasing pH below 5.0 had the same effect as removing silver(I) ions indicating 
that protons and silver(I) ions compete for the same nitrogen lone pair in histidine. Thus, this 
conformational switch is reversible and can be controlled by varying two different parameters, 
pH and the concentration of silver(I) ions.      
 
1 .3.4 Enzymatic stimulus 
Inspired by the success of isopeptides in the synthesis of difficult peptide sequences, the Mutter 
and Kiso groups designed a switchable element based on the same ON-acyl migration 
principle as applied in isopeptides.[65] This element consists of a switch (blue) and an inducer 
(red), which together comprise an O-acyl isopeptide, as well as an N-terminal protecting group 
(Y) (Fig. 1.10). The rationale behind this design is that the inducer, when connected to the 
peptide side-chain via an O-acyl bond, prevents the peptide from adapting its natural 
conformation. However, when an ON-acyl migration is triggered by removal of the protecting 
group, a native N-acyl (peptide) bond is formed and the peptide can adopt its natural 
conformation. In the simplest case the protecting group is a proton (to afford a non-nucleophilic 
ammonium group) but more complex protecting groups have also been used by Mutter and 
colleagues such as enzyme-cleavable dipeptides.[66] The latter was used to facilitate the transition 
of a neuropeptidase Y peptide fragment from a random coil into an -helix. This peptide was 
separated into two parts by an O-acyl isothreonine switch protected with an N-arginylprolyl 
dipeptide (Fig. 1.10). The entire peptide adopted a random coil conformation, which after
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Figure 1.10. Enzyme-switchable peptides developed by Mutter and colleagues. An inducer (red) is linked to 
the side chain (blue) of a peptide via an O-acyl linkage. Here, the inducer is an acetyl group linked to a 
threonine side chain. When the protecting group (Y) is removed (enzymatically), an ON-acyl migration 
occurs, which positions the inducer at the N-terminus, where it induces folding into a secondary structure. 
 
deprotection of the threonine amino group by the enzyme dipeptidyl peptidase IV, led to a 
conformational transition into an -helix. 
Since enzymes play key roles as selective catalysts in cellular pathways and diseases, enzyme 
switchable peptide architectures might face a bright future as smart biomaterials. Fields like 
implant technologies or drug delivery, for example, might exploit switchable peptides that 
respond to biological stimuli to ensure that these materials function at the right place and at the 
right time. 
 
1 .4 Aim and outline of  this  thesis  
Cell-penetrating peptides (CPPs) have since their discovery established themselves as a very 
powerful tool for delivery of cargos into cells. They have one major limitation seen from a drug 
delivery perspective, however, as they show virtually no cell-type specific penetration behavior, 
which seriously limits their use in targeted delivery systems. Hence, by controlling the activity of 
the CPPs such cell-type specific or localized delivery might be achieved, provided that the 
appropriate stimulus is present or applied, respectively. Inspired by molecular switches designed 
to switch peptide architectures between different conformations (reviewed in chapter 1), we 
embarked on a project focused on the development of CPPs, which can be activated by 
application of different stimuli to allow for temporal and spatial control. The results of this 
endeavor form the backbone of this thesis, of which an outline is given below. 
The first activatable CPP developed in this project was designed for delivery of liposomes 
into cells when a UV-stimulus was applied (chapter 2). This UV-activatable CPP-delivery system 
relied on a novel way of silencing CPPs by means of ‘hiding’ the CPPs in a loop-structure on the 
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surface of liposomes thereby making the CPPs inaccessible to cells. When a UV-stimulus was 
applied the loop-structure was broken leading to exposure of the CPP, and hence uptake of the 
CPP-liposomes. During this investigation it was found that the use of UV-irradiation  bleached 
the fluorescent reporters used to label the liposomes for detection purposes. This inspired us to 
develop a novel method for easy preparation and purification of fluorescently-labeled liposomes 
using quantum dots, which are known to be very photostable (chapter 3). 
Delivery of proteins to cells can be achieved by means of functionalization of the protein of 
interest with a CPP. However, conventional functionalization methodologies involve either 
expression of the protein as CPP-fusion proteins or post-expression functionalization, which both 
suffer from their own respective drawbacks. To address this functionalization issue and to 
provide a way to easily replace the CPP in case multiple CPPs are to be studied, we designed a 
novel modular delivery system involving a non-covalent association of the CPP with the protein 
cargo (chapter 4). This system was based on coiled coil formation between two complementary 
leucine zipper peptides, of which one was fused to the protein of interest and the other 
conjugated to the CPP via click chemistry. The latter entailed preparation of an azide-
functionalized CPP, which was prepared via a novel solid phase procedure described and studied 
in detail in chapter 5. Furthermore, it was attempted to make the non-covalent delivery system 
activatable by conjugation of an anionic leucine zipper to the cationic CPP expecting the 
attractive electrostatic forces to induce folding of the peptide conjugate, leading to CPP 
inactivation. Re-activation was envisioned to occur upon association with the complementary 
leucine zipper bearing the cargo protein. This attempt is also described in chapter 4. 
CPPs which can be activated by local stimuli present in vivo are particularly interesting as no 
complicated or imprecise external stimuli need to be applied. Hence CPPs, which can be 
activated by enzymes only present on or around the cells of interest, serve as an attractive way to 
achieve activation in vivo and cell-specific delivery. In chapter 6 the development of such an 
enzyme-activatable CPP via a new and simple approach is described. By branching two lysine 
residues in a CPP with enzyme-cleavable sequences, it was demonstrated how the CPP lost the 
ability to enter cells, an ability which could be regained by enzymatic removal of the branches. 
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2.1  Introduction 
Over the past decades, numerous drug carriers have been developed from a wide range of 
materials.[1] A common goal for most of these carriers is to address some of the inherent 
problems associated with administration of drugs, such as toxicity, instability and unfavorable 
biodistribution. To deal with these issues, encapsulation of the drug in a carrier is often the 
method of choice, as this serves to protect the drug from the body environment and vice versa, 
and to shift the biodistribution towards the target site to increase the stability, safety and 
targeting efficiency of the drug. In this respect, liposomes have received a fair amount of 
attention as carriers drugs,[2] because of their easy preparation (at lab scale), their composition of 
natural and relatively inexpensive starting materials, as well as approval of several liposome 
products by the FDA.[3] Of particular interest are the so-called Stealth liposomes, which are 
coated with poly (ethylene glycol; PEG) to evade immune system interactions and thereby 
achieve a long circulation time in the bloodstream.[4] 
However, while encapsulation provides a solution for an unfavorable biodistribution, 
toxicity and instability of drugs, encapsulated drugs on the other hand have to escape from the 
interior of the carrier to exert their activity. To gain control over this release, a plethora of 
triggers has been employed such as reduction,[5] ultrasound,[6] light,[7] pH,[1f,8] temperature,[9] 
magnetic[10] and enzymatic activity[1b,11]. Of these triggers, pH, temperature and enzymatic 
triggers have been used to target drug carrier systems specifically to diseased tissues, as the latter 
areas often exhibit a decreased pH, elevated temperature or express specific enzymes.[12] The 
most precise control, however, is achieved when external triggers such as ultrasound, magnetism 
and light are employed as these can be applied to defined localized areas to induce drug 
release.[13] The drawback is that most external triggers are restricted to superficial tissues, though 
deep-seated tissue may be reached with the aid of laparoscopy.[13-14] 
Up to now, most triggered-release carrier systems (including light-triggered systems) work via 
a destabilization of the carrier causing release of the encapsulated drug in the extra-cellular 
space. This, however, may lead to poor cellular uptake of the released drugs in the case of 
macromolecular and/or hydrophilic drugs, which do not easily cross the cell membrane (e.g. 
oligonucleotides).[15] Hence, cellular uptake of the carrier before releasing its contents is desirable. 
To facilitate uptake, the carrier can be functionalized with cell-penetrating peptides (CPPs), such 
as Tat peptides, as this class of peptides is capable of inducing cellular uptake of almost any kind 
of cargo to which they have been attached.[16] 
Regrettably, modification of the liposome surface with Tat-peptides leads to aspecific uptake 
in non-target cells.[17] Moreover, its positive charge leads to interaction with blood components 
and enhances clearance via the reticuloendothelial system,[18] thereby compromising the stealth 
property that is essential for prolonged circulation. To combine stealth behavior and Tat-
mediated cellular uptake, a UV-activatable cell-penetrating peptide was designed by constrain-
ing the peptide and ‘hiding’ it on the surface of a liposome. Reactivation of the peptide could 
later be achieved by releasing the constraint via UV-irradiation. Further, it was demonstrated in 
a proof-of-concept experiment how this novel methodology for controlling CPP activity could be 
used for irradiation-induced cellular uptake of liposomes and delivery of cytotoxic drugs. 
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2.2 Results  and discussion 
As CPP, we used a Tat peptide derived from an HIV Transactivator protein,[19] and imposed 
the UV-activatable property on the Tat peptide by incorporating it into a loop anchored to the 
surface of a PEG-ylated liposome via two alkyl-chains of which one contained a UV-cleavable 
linker (Fig. 2.1). While being in this loop, the surface PEG-chains shield the CPP from cells and 
thus enable stealth behavior by opposing interactions with target cells and thereby cellular 
uptake of the liposome. However, once in vicinity of target cells, irradiation can be applied to 
cleave the anchor, followed by loop-opening and exposure of Tat, which can now bind to cells 
and mediate the cellular internalization of the entire liposome particle. 
 
 
 
 
Figure 2.1. Schematic overview of the UV-activatable Tat-liposome delivery system. A cell-penetrating 
peptide, Tat (YGRKKRRQRRRGC), is incorporated in a PEG-loop and anchored to the surface of a liposome 
with two lipid anchors, of which one can be cleaved by UV-light. Upon irradiation, the UV-cleavable 
anchor is cleaved leading to opening of the loop and exposure of the Tat-peptide. This enables uptake of 
the liposome as a result of the Tat-peptide being able to interact with cells. Dark grey box = Tat-peptide, 
light grey = UV-cleavable linker, black = PEG, yellow = fatty acids and blue = phosphate head groups. 
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Hence, to incorporate Tat in a surface-anchored loop on a liposome two alkyl anchors were 
required – a C-terminal and an N-terminal one. C-terminal anchoring was achieved via 
conjugation of a C-terminal cysteine thiol (introduced in Tat for this purpose) to a maleimide-
PEG2000-functionalized distearoyl phosphatidylethanolamine, which was introduced into the 
liposomes during their preparation (see Materials and Methods). Liposomes containing 10 mol% 
PEG of which half was terminated with a maleimide group were reported to be optimal for Tat-
functionalization.[16d,20] N-terminal anchoring was achieved by coupling either a UV-cleavable 
or non-cleavable anchor to the N-terminus of the Tat-peptide to afford a UV-activatable and 
non-activatable Tat-peptide, respectively (see below). In order to provide insight into the 
influence of the alkyl chain-length on anchoring into the liposomes two alkyl-chains with 
different lengths (C12 or C16) were used to prepare both the UV-cleavable (C12-UV-Tat and 
C16-UV-Tat) and non-cleavable anchors (C12-Tat and C16-Tat). 
 
2.2.1  Synthesis of  Tat peptides with cleavable and non-cleavable anchors 
Two UV-cleavable anchors with different alkyl lengths (C12 and C16) were synthesized from a 
common and commercially available starting material, 4-(bromomethyl)-3-nitrobenzoic acid 2.1 
(Scheme 2.1).  
 
 
Scheme 2.1. Synthesis of the UV-cleavable anchors. The two UV-cleavable anchors were synthesized from 
the commercially available 4-(bromomethyl)-3-nitrobenzoic acid in three steps. 
First, the bromide was substituted with a hydroxy group under basic, aqueous conditions 
affording 4-(hydroxymethyl)-3-nitrobenzoic acid 2.2 in excellent yield.[21] Next, two different 
alkyl anchors were introduced by coupling either dodecylamine or hexadecylamine to the 
carboxyl group using BOP (benzotriazol-1-yl-oxy-tris-[dimethylamino]-phosphonium hexa-
fluorophosphate) as a coupling reagent providing anchor 2.3a and 2.3b in good yields.  
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Scheme 2.2. Coupling of UV-cleavable and non-cleavable anchors to Tat. The activated UV-cleavable 
anchors were coupled to the N-terminus of the Tat peptide (YGRKKRRQRRRG) on solid phase catalyzed by 
DMAP. The non-cleavable anchors were prepared by coupling lauric or palmitic acid to the N-terminus of 
Tat.  
Subsequently, the two anchors 2.3a and 2.3b were activated with 4-nitrophenyl chloroformate 
for coupling to the Tat peptide (Scheme 2.2). 
The Tat peptide was prepared via solid phase peptide synthesis on a Wang-resin using 
standard Fmoc chemistry.[22] After the final Fmoc removal with 20% piperidine in DMF, the 
activated anchors 2.4a and 2.4b were coupled to the free N-terminus using DMAP as a 
catalyst. A negative Kaiser-test[23] confirmed that the coupling was complete. Global 
deprotection and cleavage of the peptides 2.6a and 2.6b from the solid support were achieved 
by suspension of the immobilized peptides in trifluoroacetic acid. After removal of the resin by 
filtration, the crude peptides were precipitated in diethyl ether, air-dried, lyophilized and 
purified by HPLC affording the UV-anchor-Tat peptides 2.7a and 2.7b.  
Tat peptides with non-cleavable C12 and C16 anchors were synthesized and included in this 
study as negative controls, as these peptides were expected to form loops, which cannot be 
opened by UV-irradiation. Tat peptides with C12 and C16 anchors were synthesized by coupling 
lauric acid and palmitic acid, respectively, to the free N-terminus of Tat using BOP as a coupling 
reagent. Completion of the coupling reaction was confirmed with a Kaiser-test and the peptides 
were cleaved off their resins and treated as described above.  
 
2.2.2 Coupling of peptides to l iposomes 
Liposomes were prepared from egg-derived phosphatidylcholine and 10 mol% PEG2000-
distearoyl phosphatidylethanolamine of which half of the PEG chains was terminated with 
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maleimide and half with a methoxy group.[16d] The Tat peptides with UV-cleavable and non-
cleavable anchors were coupled to maleimide-functionalized liposomes via their C-terminal 
cysteine residue (Fig. 2.2A). In addition, Tat and Tat with three ArgAla mutations (Tat R > 
A) both without alkyl anchors were included as a positive and negative control (lip-Tat and lip-
Tat R>A) respectively. Coupling of the peptides to the liposomes was evaluated by measuring 
the zeta-potential of the liposomes (Fig. 2.2B). 
Unfunctionalized liposomes have a negative zeta-potential in water because of the 
presence of negatively charged phosphate head groups. However, after coupling of the positively 
charged Tat peptides to the liposomes all, except the Tat mutant (Tat R > A), had a positive 
zeta-potential, which indicated that the couplings were successful. The Tat mutant, on the other 
hand, yielded liposomes which still had a negative zeta-potential, although less negative than 
unfunctionalized liposomes. This might be due to the smaller positive net charge on the mutant 
Tat, though a less efficient coupling cannot be ruled out.  
 
 
Figure 2.2. Coupling of the Tat-peptides to liposomes. A) The Tat-peptides were coupled via a C-terminal 
cysteine residue and a liposome-PEG-maleimide group. B) Because of the positive charge of the Tat-
peptides the coupling can be assessed as an increase in the zeta-potential of the liposomes. 
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2.2.3 Optimization of UV-irradiation 
To evaluate the cell adhesion and uptake capabilities of the Tat-liposomes (via confocal laser 
scanning microscopy, CLSM, and flow cytometry, respectively; see below), it is necessary to 
include a fluorescent marker in the liposomes. However, since UV-irradiation is used to activate 
the liposomes photo-bleaching of the marker could become a problem, which would severely 
hamper accurate cell-adhesion and uptake studies. Hence, the effect of irradiation time on the 
extent of bleaching and cleavage of the UV-cleavable anchor was studied first to establish a 
compromise between sufficient cleavage of the UV-anchor and minimal photo-bleaching of the 
fluorescent marker. From Fig. 2.3B it is clear that the fluorescent marker used herein, carboxyl-
Atto655, does bleach markedly upon irradiation. After 5 min of irradiation quantitative cleavage  
 
 
Figure 2.3. Optimization of UV-irradiation time. A) Irradiation-mediated cleavage of UV-C16-Tat was 
followed over time by HPLC. The peak at 24.45 min corresponding to intact UV-C16 decreased while free 
Tat at 2.85 min increased when the irradiation-time was increased. B) Steady-state fluorescence of the dye 
Atto655 was monitored as a function of increasing irradiation time. C) Cell-adhesion of UV-C16 liposomes 
as a function of increasing irradiation time was studied by flow cytometry. 
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of UV-C16-Tat was observed, as determined by analytical HPLC, whereas ~50% fluorescence 
remained (Fig 2.3A). 
Thus, irradiation-mediated cleavage of the UV-cleavable anchor is feasible without 
bleaching the fluorescent marker completely. 
To determine the optimal irradiation time, a flow cytometry experiment was performed, in 
which the adhesion of UV-C16 liposomes to cells as a result of increased irradiation times was 
studied (Fig. 2.3C). Here a steep increase in the (apparent) adhesion from zero to two min was 
observed, after which it decreased gradually as a result of increased photo-bleaching of the 
encapsulated carboxyl-Atto655 fluorescent marker. That is, irradiation for two min results in the 
most intense fluorescence read-out, even though more substantial cell-adhesion might be 
achieved by prolonged irradiation, as all the UV-cleavable anchors are not cleaved after 2 min. 
(Fig. 2.3B). However, the availability of more Tat peptides is masked by the increasing photo-
bleaching of the carboxyl-Atto655 fluorescent marker. Therefore, in the following flow 
cytometry and CLSM experiments two min of irradiation were applied.  
 
2.2.4 Cell-adhesion and uptake of Tat-l iposomes 
The cellular uptake of all Tat-liposome conjugates was investigated via flow cytometry analysis 
using an encapsulated Atto655 dye as fluorescent marker (Fig. 2.4).  
No unspecific uptake was observed for unfunctionalized liposomes (negative control), whereas 
substantial and dose-dependent uptake was observed for Tat-modified liposomes (lip-Tat). Lip- 
 
 
Figure 2.4. Cellular uptake of Tat-liposomes. Flow cytometry study of cellular uptake of the different Tat-
liposomes before and after irradiation. Two different concentrations of liposomes were used – 0.5 and 1 
mM (phosphate equivalents) – except for lip-Tat-UV-C16 for which only 1 mM was measured. 
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Tat (R > A) showed limited cellular uptake (Fig. 2.4). Importantly, cell-adhesion and cellular 
uptake of lip-Tat-UV-C16 were marginal before irradiation. However, after irradiation cell-
adhesion increased more than 10-fold (more than 15-fold, when corrected for photo-bleaching) 
to the same high level as observed for lip-Tat (positive control). The same trend was evident in 
the cellular adhesion and uptake of the liposomes as demonstrated by CLSM (Fig 2.5). This 
clearly showed cellular adhesion and uptake of lip-Tat but barely of lip-Tat (R > A), and 
unfunctionalized liposomes were undetectable. It should be noted, that the decreased 
fluorescence intensity of Tat-liposomes observed after irradiation is merely a result of photo- 
 
 
Figure 2.5. Cellular adhesion and uptake. The cellular adhesion and uptake of the different Tat-liposomes 
were studied by confocal laser scanning microscopy before (top) and after irradiation (bottom). The 
liposomes were visualized by means of the encapsulated dye, Atto655 (red color).  
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bleaching and does not reflect an actual decrease in adhesion. Together, this implies that the  
cell-adhesion and uptake observed for the series of Tat–liposomes are indeed mediated by 
functional Tat-peptides on the liposomes, as expected. 
Labelling of the cell membrane with CellMask showed some co-localization with the 
liposomal dye (Atto655) suggesting that some of the liposomes were adhered to the plasma 
membrane and not internalized (Fig. 2.6). However, a large part of the liposomes were found 
inside the cells and separate from the membrane label, serving as a proof that these liposomes 
are indeed taken up by the cells.  
 
 
Figure. 2.6. Laser scanning confocal microscopy – colocalization. The cell membranes of HeLa cells were 
stained with CellMask (red) and potential colocalization with liposomal Atto655 (green) was assessed for 
Tat-liposomes (Lip-Tat).   
A strong cell-adhesion before irradiation was also, but unexpectedly, observed for lip-Tat-
C12 and lip-Tat-C16 as well as lip-Tat-UV-C12, suggesting that shielding of the Tat-peptide 
was incomplete in these cases. However, inspection of the corresponding CLSM images revealed 
the presence of large liposomal aggregates on the surfaces of the cells in the case of lip-Tat-C12 
and lip-Tat-C16 and modest aggregation in the case of lip-Tat-UV-C12. In all of these cases 
cells also seemed to be less viable (as discerned by the transmission images) than cells treated 
with the other Tat-liposome conjugates. This implies that the observed cell-adhesion should not 
be considered as a simple adhesion of the Tat-liposomes to the cells but rather be regarded as 
the propensity to aggregate caused by incomplete loop insertion of the N-alkyl chain into the 
liposome membrane, leading to sedimentation of liposomes on cells rather than specific 
adherence and uptake. Interestingly, this propensity seemed to decrease going from lip-Tat-C12 
to lip-Tat-C16 to lip-Tat-UV-C12 suggesting that the hydrophobic driving force for 
spontaneous insertion of the N-alkyl anchor into the liposome membrane increases along this 
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series. In the case of lip-Tat-UV-C12, a substantial part of the Tat peptide was effectively 
shielded in the loop conformation, as this system exhibited an increased cell-adhesion after 
irradiation (even without taking photo-bleaching into account). The improved shielding 
observed for lip-Tat-UV-C12 implies that the aromatic ring in the UV-cleavable anchors 
provides a considerable additional hydrophobic driving force for loop-formation. Indeed, the lip-
Tat-UV-C16, containing both the aromatic ring and the longer alkyl-chain showed the most 
efficient anchoring as can be inferred from the superior irradiation-triggered increase in cell-
adhesion.  
 
2.2.5 Dynamic l ight scattering – aggregation of l iposomes 
To shed light on the aggregation behavior of the Tat-liposomes their sizes were monitored by 
dynamic light scattering (DLS) in buffer and in cell medium. In HEPES buffer all liposomes had 
the expected mean size of approximately 175 nm, though lip-Tat-UV-C16 and lip-Tat-C16 
showed a somewhat broader size distribution (PDI < 0.25; Fig. 2.7). 
 
 
 
Figure 2.7. Aggregation of Tat liposomes. Aggregation of lip-Tat-C12, lip-Tat-UV-C12, lip-Tat-C12 and lip-
Tat-UV-C16 was monitored by dynamic light scattering in cell culture medium and in HEPES buffer. 
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However, when the same DLS measurements were conducted in cell medium, lip-Tat-C12- and 
lip-Tat-UV-C12 liposomes increased markedly in size thus serving as a strong indication that the 
medium is responsible for the aggregation observed in the CLSM experiments. For lip-Tat-C16 
liposomes the already broad size distribution makes it difficult to draw firm conclusions about 
their aggregation behavior, though it seems that the size of these liposomes does not increase as 
much as observed for lip-Tat-C12. Because the medium used in the experiments is rich in 
bovine serum albumin (BSA), it was speculated that this might play an important role in the 
aggregation process. In serum, the function of BSA is to bind fatty acids (to solubilize these), so it 
is reasonable to expect that BSA can bind to N-alkyl chains that failed to insert into the liposome 
membrane. Since BSA has six fatty acid binding sites[24] cross-linking and aggregation of 
liposomes with non-inserted N-alkyl chains would be possible. To test this hypothesis, lip-Tat-
C12 liposomes were diluted into a HEPES buffer containing BSA at the same concentration as 
in the medium. Immediately, the solution turned turbid and DLS showed the presence of 
particles (Fig. 2.7) strongly suggesting that BSA is profoundly involved in the aggregation 
observed via CLSM possibly by binding to the non-inserted N-alkyl chains. 
Lip-Tat-UV-C16, on the other hand did not increase in size at all, neither in HEPES buffer 
nor in medium, indicating that the loop-formation is complete in this case. 
 
2.2.6 Cell  viability – delivery of  doxorubicin 
To evaluate the ability of our UV-activatable liposomes to deliver drugs to cells, the viability of 
cells treated with liposomes loaded with the cytotoxic drug doxorubicin was studied. Lip-Tat-
UV-C16 were loaded with doxorubicin using a transmembrane ammonium sulphate gradient[25] 
and the cell viability was assessed via an MTT assay[26]. For this study, liposomes were prepared 
from distearoyl phosphatidylcholine (DSPC) instead of egg-derived phosphatidylcholine to 
minimize doxorubicin leakage from the liposomes by decreasing the fluidity of the liposomes 
(DSPC has a higher transition temperature than egg-derived phosphatidylcholine; 55 vs. 41 
°C).[2b] Tat-liposomes were also prepared this way and loaded with doxorubicin (results not 
shown). Unfortunately, the loading was significantly different than the loading of lip-UV-C16 
making comparisons futile; and due to the reactivity of the maleimide moiety it was not possible 
to prepare a common batch of doxorubicin-loaded liposomes and then functionalize this batch 
with the different Tat-peptides. In this regard, a more robust conjugation method, such as azide-
alkyne click chemistry, might be applied to overcome these doxorubicin loading issues. 
From the MTT assay (Fig. 2.8) it is evident that non-irradiated lip-Tat-UV-C16 loaded with 
doxorubicin did not elicit any toxicity to the treated cells at any of the two doxorubicin 
concentrations tested. This indicates that no leakage of doxorubicin takes place. Only when 
doxorubicin-loaded liposomes were pre-irradiated (before addition to the cells), a pronounced 
decrease in the cell viability could be observed, indicating the occurrence of cellular 
internalization of Dox-containing lip-Tat-UV-C16. The reason why a total loss of cell viability is 
not observed is most likely due to entrapment of the liposomes inside intracellular endosomes, 
from which doxorubicin has to escape. This process is rather inefficient and may be the limiting 
factor in this case. To test this hypothesis the cell viability in the presence of chloroquine, a 
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compound known to induce endosomal escape, was also studied (results not shown). This did 
lead to an even greater difference in cell viability between non-irradiated and irradiated lip-UV-
C16. However, chloroquine itself also induced cell-death making firm conclusions on the effects 
of chloroquine dubious. 
This proof-of-concept experiment, however, does suggest that UV-activatable liposomes can 
be used for triggered delivery of doxorubicin-liposomes inside target cells to kill these in an 
irradiation-dependent manner. 
 
 
Figure 2.8. UV-triggered delivery of doxorubicin into cells. Delivery of the cytotoxic doxorubicin into cells 
was assessed via an MTT cell viability assay. HeLa cells were incubated with irradiated and non-irradiated 
doxorubicin-loaded lip-Tat-UV-C16 liposomes at two different doxorubicin concentrations (15 and 100 *M) 
and the cell viability was evaluated. 
 
2.3 Conclusion 
Herein, the synthesis of a UV-cleavable lipid-anchor was described and it was demonstrated 
how this anchor can be used to constrain a cell-penetrating peptide (CPP) onto a liposomal 
surface. Further, it was shown that when the CPP was engaged in this loop formation no cellular 
adhesion or uptake did take place. However, upon irradiation opening of the loop and exposure 
of the CPP induced cellular adhesion and uptake. It was also demonstrated in a proof-of-concept 
experiment that this UV-activatable delivery system can be used to trigger internalization of 
doxorubicin-loaded liposomes by applying an external UV stimulus. 
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2 .5  Experimental  procedures 
General 
Wang resin was purchased from Novabiochem and Fmoc-L-amino acids were from Bachem (Bubendorf, 
Switzerland) or Novabiochem (EMD Chemicals, Gibbstown, USA). Lipids were from Avanti Polar Lipids 
(Alabaster, USA) or Lipoid (Steinhausen, Switzerland). Atto655 was purchased from ATTO-TEC 
(Siegen, Germany). CellMask Orange was purchased from Invitrogen (Carlsbad, CA, USA). Hepes (99%) 
was obtained from Acros Organics BVBA (Geel, Belgium). Phosphate-buffered saline (PBS) was 
purchased from B. Braun (Melsungen AG, Melsungen); fetal bovine serum (FBS) was from Integro, 
Zaandam, The Netherlands, Trypsin/EDTA, Plain DMEM (Dulbecco’s modification of Eagle’s 
medium, with 3.7 g/L sodium bicarbonate, 1 g/L L-glucose, L-glutamine) and antibiotics/antimycotics 
(penicillin, streptomycin sulfate, amphotericin B) were all from PAA Laboratories (Pasching, Austria). 
Human epithelial ovarian carcinoma (HeLa) cells were kindly given by the Institute of Biomembranes 
(Utrecht University, The Netherlands). All other chemicals were purchased from Baker, Fluka or Sigma 
Aldrich and used as received, except for dichloromethane and THF, which were distilled before use. 
Mass spectra were recorded on a Bruker Biflex MALDI-TOF (Bruker Daltronik, Bremen, Germany) or 
on a Thermo Finnigan LCQ-Fleet ESI-ion trap (Thermo Fischer, Breda, The Netherlands). 
Lyophilization was achieved using an ilShin Freeze Dryer (ilShin, Ede, The Netherlands).  
Reactions were conducted under an atmosphere of argon, whenever anhydrous solvents were used. All 
reactions were monitored by thin-layer chromatography (TLC) using silica gel coated plates (analytical 
SiO2-60, F-254). The TLC plates were visualized under UV light and by dipping in a solution of KMnO4 
(7.5 g/L) and K2CO3 (50 g/L) in 0.1% aqueous NaOH (v/v) followed by heating with a heat gun. 
Column chromatography using moderate pressure was performed with Silica gel 60 (particle size 0.040–
0.063 mm, Merck). Evaporation of solvents was carried out under reduced pressure at 40 °C or below. 
After column chromatography, appropriate fractions were pooled and dried at high vacuum for at least 
12 h to give obtained products in high purity (>95%) ascertained by 13C NMR unless stated otherwise. 
1H NMR and 13C NMR were recorded at 400 MHz (Varian Inova) and 75 MHz (Bruker DMX300), 
respectively. Chemical shifts are reported in ppm relative to deuterated solvent as internal standard (H: 
CDCl3 7.26 ppm; C: 77.0 or H: DMSO-d6 2.50 ppm; C: DMSO-d6 39.43 ppm. The designation used to 
assign the peaks in the spectra is as follows: singlet (s), doublet (d), triplet (t), multiplet (m), doublet of 
doublets (dd) and broad (br).  
 
4-(hydroxymethyl)-3-nitrobenzoic acid (2.2)[21] 
4-(bromomethyl)-3-nitrobenzoic acid 2.1 (1.01 g, 3.88 mmol) and Na2CO3 (2.68 g, 13.6 mmol) were 
dissolved in water-acetone (1:1, 30 mL) and refluxed for 3 h. Acetone was then removed in vacuo and the 
resulting aqueous phase was extracted with diethyl ether (2×5 mL). Conc. HCl was added until pH was 1 
or below causing a yellow precipitate to form, which re-dissolved upon addition of ethyl acetate (20 mL). 
The organic and aqueous phases were separated and the aqueous phase extracted with ethyl acetate 
(2×20 mL). The combined organic phases were washed with water (1×20 mL), dried over MgSO4 and 
evaporated to dryness under reduced pressure affording nitrobenzyl alcohol 2.2 as a yellow solid (0.75 g, 
98%). Rf = 0.5 (1% AcOH, 7.5% MeOH in CH2Cl2, v/v); ESI-MS [M-H]- m/z 196.12 (calcd 196.03); 
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1H NMR (DMSO-d6)  = 13.53 (br s, 1H, COOH), 8.47 (d, J = 1.7 Hz, 1H, HAr), 8.27 (dd, J = 8.1, 1.7 
Hz, 1H, HAr), 7.97 (d, J = 8.1 Hz, 1H, HAr), 5.69 (br s, 1H, OH), 4.88 (s, 2H, CH2Bn); 13C NMR (DMSO-
d6)  = 165.55 (C=O), 146.63 (CAr), 143.17 (CAr), 133.91 (CAr), 130.45 (CAr), 128.83 (CAr), 124.96 (CAr), 
59.97 (CH2Bn). 
 
N-dodecyl-4-(hydroxymethyl)-3-nitrobenzamide (2.3a) 
Nitrobenzyl alcohol derivative 2.2 (1.00 g, 5.07 mmol), dodecylamine (1.22 g, 6.58 mmol) and DIPEA 
(1.73 mL, 10.2 mmol) were dissolved in anhyd CH2Cl2. Benzotriazol-1-yl-oxy-tris-(dimethylamino)-
phosphonium hexafluorophosphate (BOP; 2.24 g, 5.07 mmol) was added producing a brown solution, 
which was stirred at rt for 21 h. The solvent was removed from the reaction mixture in vacuo producing an 
oil, which was redissolved in EtOAc (100 mL).  This solution was washed with 1 M NaOH (2×50 mL), 
water (50 mL), 1 M HCl (2×50 mL), and brine (50 mL). The organic phase was dried over anhyd 
Na2SO4, preadsorbed on celite and purified by silica column chromatography (0-6% MeOH, 1% AcOH 
in CH2Cl2) affording dodecyl-nitrobenzamide 2.3a as a yellow/brownish solid (1.67 g, 90%). Rf = 0.60 
(1% AcOH, 7.5% MeOH in CH2Cl2, v/v); ESI-MS [M-H]+ m/z 365.20 (calcd 365.24); 1H NMR 
(DMSO-d6)  = 8.74 (t, J = 5.6 Hz, 1H, NH), 8.50 (d, J = 1.8 Hz, 1H, HAr), 8.21 (dd, J = 8.1, 1.8 Hz, 
1H, HAr), 7.92 (d, J = 8.1 Hz, 1H, HAr), 5.65 (t, J = 5.5 Hz, 1H, OH), 4.87 (d, J = 5.5 Hz, 2H, CH2Bn), 
3.27 (dd, J = 12.8, 6.9 Hz, 2H, NHCH2), 1.57-1.48 (m, 2H, NHCH2CH2), 1.33-1.18 (m, 22H, 9×CH2), 
0.84 (t, J = 6.9 Hz, 4H, CH3); 13C NMR (DMSO-d6)  = 163.81 (C=O), 146.54 (CAr), 141.14 (CAr), 
134.05 (CAr), 132.03 (CAr), 128.41 (CAr), 122.99 (CAr), 59.87 (CH2Bn), 39.27, 31.28, 29.00, 28.90, 28.70, 
26.44, 22.08, 13.92. 
 
N-hexadecyl-4-(hydroxymethyl)-3-nitrobenzamide (2.3b) 
The title compound was prepared as described above for dodecyl-nitrobenzamide derivative 2.3a from 
nitrobenzyl alcohol derivative 2.2 (1.32 g, 6.70 mmol), hexadecylamine (3.23 g, 6.70 mmol) and DIPEA 
(2.28 mL, 13.4 mmol) affording hexadecyl-nitrobenzamide 2.3b as a light yellow solid (2.61 g, 92%). The 
only noteworthy difference was that the reaction mixture was a light brown slurry rather than a brown 
solution. Rf = 0.46 (1% AcOH, 7.5% MeOH in CH2Cl2, v/v); ESI-MS [M-H]+ m/z 421.36 (calcd 
421.31); 1H NMR (DMSO-d6)  = 8.74 (t, J = 5.6 Hz, 1H, NH), 8.50 (d, J = 1.8 Hz, 1H, HAr), 8.21 (dd, 
J = 8.2, 1.8 Hz, 1H, HAr), 7.92 (d, J = 8.1 Hz, 1H, HAr), 5.65 (t, J = 5.5 Hz, 1H, OH), 4.87 (d, J = 5.5 
Hz, 2H, CH2Bn), 3.27 (dd, J = 12.9, 6.8 Hz, 2H, NHCH2), 1.57-1.46 (m, 2H, NHCH2CH2), 1.32-1.19 
(m, 31H, 13×CH2), 0.85 (t, J = 6.8 Hz, 4H, CH3); 13C NMR (DMSO-d6)  = 163.80 (C=O), 146.53 
(CAr), 141.18 (CAr), 134.06 (CAr), 132.04 (CAr), 128.39 (CAr), 123.01 (CAr), 59.90 (CH2Bn), 39.39, 36.45, 
36,42, 31.32, 29.07, 29.03, 29.02, 29.00, 28.94, 28.78, 28.73, 26.49, 22.11, 13.92. 
 
4-(dodecylcarbamoyl)-2-nitrobenzyl (4-nitrophenyl) carbonate (2.4a) 
Dodecyl-nitrobenzamide derivative 2.3a (1.63 g, 4.48 mmol) and pyridine (0.72 mL, 8.96 mmol) were 
dissolved in THF and cooled to 0 °C. Then 4-nitrophenyl chloroformate (1.81 g, 8.96 mmol) was added 
producing a yellow slurry. The reaction mixture was stirred for 5 h while heating to rt. The reaction 
mixture, which had turned brown, was evaporated to dryness and redissolved in CH2Cl2. The organic 
phase was washed with brine (2×50 mL) and 1 M HCl (2×50 mL) and dried over anhyd Na2SO4. The 
crude was purified by silica column chromatography (0-100% CH2Cl2 in heptane then 0-1.5% MeOH in 
CH2Cl2) affording activated nitro-benzyl alcohol 2.4a as a white solid (1.93 g, 81%). Rf = 0.51 (1% 
MeOH in CH2Cl2, v/v); ESI-MS [M-H]+ m/z 530.20 (calcd 530.25); 1H NMR (DMSO-d6)  = 8.83 (t, J 
= 5.5 Hz, 1H, NH); 8.62 (d, J = 1.8 Hz, 1H, HAr), 8.36-8.30 (m, 2H, HAr), 8.28 (dd, J = 8.1, 1.8 Hz, 1H, 
HAr), 7.88 (d, J = 8.1 Hz, 1H, HAr), 7.64-7.57 (m, 2H, HAr), 5.72 (s, 2H, HBn), 3.31-3.24 (m, 2H, CH2), 
1.57-1.49 (m, 2H, CH2), 1.34-1.19 (m, 18H, 9 × CH2), 0.84 (t, J = 6.8 Hz, 3H, CH3); 13C NMR (DMSO-
d6)  = 163.46 (C=O), 155.12 (C=O), 151.67 (CAr), 146.95 (CAr), 145.29 (CAr), 135.57 (CAr), 132.97 (CAr), 
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132.64 (CAr), 129.39 (CAr), 125.46 (CAr), 123.60 (CAr), 122.58 (CAr), 66.76 (CH2Bn), 39.44, 31.29, 29.04, 
29.01, 28.99, 28.97, 28.87, 28.74, 28.70, 26.45, 22.09, 13.93.  
 
4-(hexadecylcarbamoyl)-2-nitrobenzyl (4-nitrophenyl) carbonate (2.4b) 
The title compound was prepared as described above for activated nitrobenzyl alcohol 2.4a from 
hexadecyl-nitrobenzamide 2.3b (1.78 g, 4.23 mmol), 4-nitrophenyl chloroformate (1.70 g, 8.45 mmol) 
and pyridine (682 GL, 8.45 mmol) affording activated benzyl alcohol 2.4b as a white solid (1.92 g, 78%). 
The only noteworthy difference was that the crude was preadsorbed on celite prior to purification by 
silica column chromatography. Rf = 0.46 (1% AcOH, 7.5% MeOH in CH2Cl2, v/v); ESI-MS [M-H]- 
m/z 586.36 (calcd 586.31); 1H NMR (DMSO-d6)  = 8.84 (t, J = 5.6 Hz, 1H, NH), 8.61 (d, J = 1.7 Hz, 
1H, HAr), 8.37-8.31 (m, 2H, HAr), 8.28 (dd, J = 8.1, 1.7 Hz, 1H, HAr), 7.88 (d, J = 8.1 Hz, 1H, HAr), 7.64-
7.58 (m, 2H, HAr), 5.72 (s, 2H, HBn), 3.31-3.25 (m, 2H, CH2), 1.58-1.48 (m, 2H, CH2), 1.33-1.15 (m, 
26H, 13 × CH2), 0.84 (t, J = 6.8 Hz, 3H, CH3), 13C NMR (DMSO-d6)  = 163.44 (C=O), 155.12 (C=O), 
151.66 (CAr), 146.94 (CAr), 145.29 (CAr), 135.57 (CAr), 132.96 (CAr), 132.64 (CAr), 129.38 (CAr), 125.46 
(CAr), 123.59 (CAr), 122.57 (CAr), 66.75 (CH2Bn), 39.43, 31.28, 29.03, 29.00, 28.98, 28.96, 28.87, 28.74, 
28.70, 26.45, 22.08, 13.92. 
 
General peptide synthesis 
Peptides were synthesized on Wang resins[27] using a Labortec640 peptide synthesizer (Labortec, 
Bubendorf, Switzerland) and employing a standard Fmoc solid-phase peptide synthesis (SPPS) 
protocol.[22] Briefly, the resin was swollen in DMF for 20 min prior to use. The first and subsequent Fmoc 
groups were removed by washing the resin with piperidine in DMF (20%, v/v) and then shaking for 25 
min with another portion of piperidine in DMF. The desired sequence of amino acids was coupled to the 
resin using Fmoc-L-amino acids (3.0 eq), diisopropylcarbodiimide (DIPCDI, 3.3 eq) and N-hydroxy 
benzotriazole (HOBt, 3.6 eq). Peptide couplings were followed to completion using the Kaiser test.[23] 
After the final Fmoc removal the resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2, and Et2O and 
air-dried for at least 2 h. 
 
Reverse phase HPLC peptide purification and analysis 
Analytical and semi-preparative HPLC was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu, ‘s-Hertogenbosch, The Netherlands) equipped with a ReproSil column (Screening Devices, 
Amersfoort, The Netherlands). Semi-preparative RP-HPLC purification of peptides was performed using 
a C18 column (250×10 mm, particle size 5 Gm, 4 mL/min flow or 150×20 mm, particle size 10 Gm, 
8mL/min flow) and a MeCN/water gradient containing 0.1% trifluoroacetic acid (5-100%, 1-31 min). 
The fractions were analyzed by ESI-ion trap mass spectrometry and analytical RP-HPLC using a C18 
column (150×3 mm, particle size 3 Gm, flow 0.4 mL/min) and a MeCN/water gradient containing 0.1% 
trifluoroacetic acid (5-100%, 1-50 min). Fractions containing the desired peptide were pooled, evaporated 
until the volume was halved and lyophilized. Finally, the purity of the lyophilized peptide was assessed by 
analytical RP-HPLC. 
 
Synthesis of Tat 
The following sequence was synthesized by standard SPPS, as described above: YGRKKRRQRRRGC. 
Tat on Wang resin (204 mg, loading 0.59 mmol/g, 35.4 Gmol peptide) was suspended in cleavage 
mixture (2 mL, trifluoroacetic acid/water/triisopropylsilane/thioanisole 90:5:2.5:2.5) for 18 h. The resin 
was filtered off and the filtrate was precipitated from Et2O, redissolved in water and lyophilized yielding 
the crude peptide as a white powder. The crude peptide was purified by semi-preparative HPLC 
affording Tat as a white powder after lyophilization (20 mg, 33%). MALDI-TOF [M + H]+ m/z: 1718.3 
(calcd. 1718.0). 
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Synthesis of Tat (R > A) 
The following sequence was synthesized by standard SPPS and cleaved off the resin as described above: 
YGAKKARQRRAGC. Tat (R > A) resin (140 mg, loading 0.59 mmol/g, 29.7 Lmol peptide) afforded 
Tat (R > A) as a white powder after HPLC purification (6 mg, 13%). MALDI-TOF [M + H]+ m/z: 
1463.3 (calcd. 1462.8). 
 
Synthesis of C12-UV-Tat (2.7a) 
Tat on Wang resin (200 mg, loading 0.59 mmol/g, 34.7 Lmol peptide) was suspended in DMF for 5 min, 
then DMF was removed and the resin re-suspended in fresh DMF. DMAP (5 mg, 40.9 Lmol) and 
activated nitro-benzyl alcohol 2.4a (106 mg, 50.3 Lmol) were added and the suspension was shaken in 
the dark over night. Then the resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2 and Et2O and 
suspended in cleavage mixture (2 mL, trifluoroacetic acid/water/triisopropylsilane/thioanisole 
90:5:2.5:2.5) for 18 h. The free peptide was precipitated from Et2O, redissolved in water and lyophilized 
yielding the crude peptide as a white powder. The crude peptide was purified by semi-preparative HPLC 
affording C12-UV-Tat 2.7a as a white powder after lyophilization (20 mg, 27%). MALDI-TOF [M + 
H]+ m/z: 2109.9 (calcd. 2108.2), fragment at 1778.4 and 1718.9 (the UV-cleavable linker was cleaved by 
the MALDI laser). 
 
Synthesis of C16-UV-Tat (2.7b) 
The title compound was prepared as described above for C12-UV-cleavable anchor Tat 2.7a from Tat 
resin (333 mg, loading 0.59 mmol/g, 57.8 Lmol peptide), activated benzyl alcohol 2.4b (186 mg, 317 
Lmol) and DMAP (5 mg, 40.9 Lmol) affording C16-UV-Tat 2.7b as a white powder after lyophilization 
(81 mg, 65%). MALDI-TOF [M + H]+ m/z: 2165.3 (calcd. 2164.3), fragment at 1787.7 and 1718.2 (the 
UV-cleavable linker was cleaved by the MALDI laser). 
 
Synthesis of C12 Tat (2.8a) 
Tat on Wang resin (300 mg, loading 0.59 mmol/g, 52.1 Lmol peptide) was suspended in DMF for 5 min, 
then DMF was removed and the resin re-suspended in fresh DMF. Dodecanoic acid (75 mg, 337 Lmol), 
DIPEA (120 LL, 1.25 mmol) and benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium 
hexafluorophosphate (BOP; 155 mg, 350 Lmol) were added and the suspension was shaken over night. 
Then the resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2 and Et2O and suspended in cleavage 
mixture (2 mL, trifluoroacetic acid/water/triisopropylsilane/thioanisole 90:5:2.5:2.5) for 18 h. The free 
peptide was precipitated from Et2O, redissolved in water and lyophilized affording a white powder. The 
crude peptide was purified by semi-preparative HPLC affording C12-Tat 2.8a as a white powder after 
lyophilization (10 mg, 10%). MALDI-TOF [M + H]+ m/z: 1900.3 (calcd. 1900.2). 
 
Synthesis of C16 Tat (2.8b) 
The title compound was prepared as described above for C12 Tat 2.8a from Tat on Wang resin (300 
mg, loading 0.59 mmol/g, 52.1 Lmol peptide), hexadecanoic acid (87 mg, 339 Lmol), DIPEA (120 LL, 
1.25 mmol) and BOP (155 mg, 350 Lmol) affording C16 Tat 2.8b as a white powder (20 mg, 19%). 
MALDI-TOF [M + H]+ m/z: 1957.4 (calcd. 1956.2). 
 
Optimization of irradiation time 
A solution of Atto655 (22.5 Lg/mL) was prepared in HEPES buffer. This corresponds to the expected 
concentration in the liposome preparations assuming a statistical encapsulation of the dye. This solution 
was irradiated with a Bluepoint2 UV-lamp (Dr. Hönle, Münich, Germany) placed directly above the 
quartz cuvette containing the solution for the following time intervals: 0 sec, 15 sec, 30 sec, 1 min, 2 min, 
3 min, 4 min and 5 min. After each irradiation step a fluorescence spectrum was acquired on an LS55 
fluorescence spectrometer (PerkinElmer, Groningen, The Netherlands) using the following settings: 
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excitation at 600 nm, excitation slit 5.0 nm, emission slit 7.0 nm, scan range 620-850 nm, scan speed 100 
nm/min. Unless stated otherwise irradiation, when required, was performed for 2 min throughout this 
work. 
 
Liposome preparation  
The liposomes were prepared via the reversed-phase evaporation method[28] as follows: Egg-derived 
hydrogenated phosphatidylcholine (62 mg, 81.4 Gmol), 1,2-distearoyl-SN-glycero-3-phospho-
ethanolamine-N-[methoxy(polyethylene glycol)-2000] (12.5 mg, 4.5 Gmol), 1,2-distearoyl-SN-glycero-3-
phosphoethanolamine-N-[maleimido(polyethylene glycol)-2000] (13.3 mg, 4.5 Gmol) and cholesterol (17 
mg, 44.0 Gmol) were dissolved in CHCl3 (6.66 mL). A solution of Atto655 (0.8 mL, 0.5 mg/mL) was 
added as well as 10 mM HEPES buffer (4.54 mL, 10 mM HEPES, 1 mM EDTA, 0.8% NaCl, pH 7.5). 
The resulting two-phase system was vortexed to form a blue emulsion. The majority of the CHCl3 was 
removed in vacuo and the remainder removed by flushing with N2. Vortexing with a few glass beads was 
performed to aid formation of a homogeneous colloidal suspension. Water (0.5 mL) was added to 
compensate for loss during evaporation. The suspension was extruded through polycarbonate filters 
(3×600 nm and 6×200 nm) using a Lipex high-pressure extruder (Northern Lipids, Vancouver, Canada) 
and the size of the resulting liposome suspension was evaluated by dynamic light scattering (Zetasizer 
Nano-S, Malvern Instruments, Malvern, UK). A diameter of 194 nm and a polydispersity index of 0.11 
were found (average of three measurements). 
 
Functionalization of liposomes and zeta-potential determination 
The freshly prepared liposome suspensions were split in seven equal aliquots. To each of six aliquots (one 
aliquot was saved as a control) was added a solution in HEPES buffer (100 GL) of the peptide (1.0 eq. 
relative to maleimido-groups) to be conjugated to the liposomes and a solution of tris(2-carboxy-
ethyl)phosphine (10 GL, 0.5 M) was added. The reactions were shaken 1 h at rt, then 1 h at 40°C and 
finally incubated at 4 °C over night. The liposome suspensions were diluted with HEPES buffer and 
ultracentrifuged for 40 min at 50,000 rpm and 4 °C (Sorvall Discovery-100, Thermo Scientific, Breda, 
The Netherlands). The resulting pellets were resuspended in HEPES buffer (500 GL). The zeta-potential 
of the liposome preparations was measured on a Malvern Zetasizer Nano-Z (Malvern Instruments, 
Malvern, UK) on liposome samples (50 GL) diluted into water (1.5 mL). The reported value is an average 
of three measurements.  
 
Phosphate concentration determination 
The phosphate concentration was determined according to Rouser’s method.[29] Briefly, a standard 
dilution series of NaH2PO4 was set up in triplicate (0-160 GL of a 0.5 mM NaH2PO4 solution) and treated 
the same way as the samples (triplicate). The samples were dried at 180 °C, then perchloric acid (0.3 mL, 
70%) was added to each, and the samples were incubated at 180 °C. Water (1.0 mL), a solution of 
(NH3)6Mo7)24 (0.5 mL, 1.2% w/v) and ascorbic acid (0.5 mL, 5% w/v) were added to each sample and 
these were incubated at 100 °C for 5 min. The absorbance at 797 nm was measured after cooling with 
cold water. The phosphate concentration could then be determined by means of the standard dilution 
series.   
 
Analysis of cellular uptake by flow cytometry 
HeLa cells were grown in DMEM supplemented with antibiotics/antimycotics and 10% heat-inactivated 
FBS. Cells were maintained at 37 °C in a 5% CO2 humidified air atmosphere and split twice weekly. 
Cells were confirmed to be free from mycoplasm by periodical testing with a MycoAlert® Mycoplasma 
Detection Kit (Lonza, Verviers, Belgium). 
Cells were harvested by trypsin/EDTA treatment, counted and diluted in cold medium to a 
concentration of 106 cells/mL. Liposome samples were diluted to 1 mM or 0.5 mM in PBS and 100 GL 
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liposome sample was pipetted in triplicate into a 96-well plate. 100 EL cell suspension was added to the 
liposome suspensions and incubated 1h at 4 ºC protected from light. Samples were centrifuged for 5 min 
at 250×g at 4 °C. After removal of the supernatant, cells were washed with ice-cold PBS (3×200 EL, each 
centrifugation step at 250×g for 5 min at 4 °C). Cells were resuspended in 200 El icecold PBS and kept 
on ice until time of analysis. Flow cytometric analysis was performed on a FACSCantoII (Becton and 
Dickinson, Mountain View, CA, USA) equipped with a 488 nm 20 mW Solid State diode laser and a 633 
nm 20 mW HeNe laser. 10,000 cells were recorded per sample to determine Atto655 signal (APC/Cy7 
channel).  
 
Confocal laser scanning microscopy 
The cellular uptake experiments were done with HeLa cells, which were seeded one day before the 
experiment in 8-well microscopy chambers (Nunc, Wiesbaden, Germany) at a density of 40,000 
cells/well. At the time of the experiment, cells had grown to approximately 50% confluence. The 
liposome samples (100 nmol phosphate equivalents – typically around 10 EL) were diluted with DMEM 
supplemented with 10% fetal calf serum (380 EL) and added to the cells, which were incubated for 2 h at 
37 °C. The cells were washed with DMEM (3×400 EL) and imaged immediately. Confocal laser scanning 
microscopy was performed using a Leica Microsystems TCS SP2 AOBS system (Mannheim, Germany). 
Excitation of Atto655 was achieved with an argon laser [488 nm (52%), 514 nm (65%) and 561 nm 
(63%)] and the resulting emission was acquired between 575 and 800 nm as an average of four scans. 
Staining of the cell membrane and colocalization study 
As a further verification of cellular uptake of the UV-C16 Tat-liposomes, cells were labeled with 
CellMask to stain their plasma membranes. Prior to the confocal laser scanning microscopy imaging 
CellMask Orange (8 EL, 1 mg/mL) was added to the cell medium and the cells were imaged 
immediately. Excitation of Atto655 and CellMask was achieved with an argon laser [476 nm (33%) and 
561 nm (57%)] and the resulting emission was acquired between 490 and 525 nm (CellMask) and 600 
and 700 nm (Atto655). The acquired image was an average of four scans. 
 
Dynamic light scattering of liposomes in medium 
The liposome samples (100 nmol phosphate equivalents – typically around 5 EL) were diluted with 
DMEM, HEPES (200 EL) or HEPES supplemented with bovine serum albumin (200 EL, 4 mg/mL) and 
measured by dynamic light scattering. The DMEM and HEPES supplemented with bovine serum 
albumin solutions were also measured.  
 
Doxorubicin-loaded liposomes 
Liposomes for doxorubicin loading were prepared as follows: distearoylphosphatidylcholine (28.4 mg, 
35.9 Emol), 1,2-distearoyl-SN-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(5.6 mg, 2.0 Emol), 1,2-distearoyl-SN-glycero-3-phosphoethanolamine-N-[maleimido(polyethylene glycol)-
2000] (5.9 mg, 2.0 Emol) and cholesterol (17.0 mg, 44.0 Emol) were dissolved in CHCl3 (3 mL). The 
solvent was removed in vacuo and the resulting film flushed with N2 for 10 min. The film was then 
hydrated for 30 min at 60 °C with (NH4)2SO4 (0.5 mL, 240 mM) while agitating. The suspension was 
extruded (9×400 nm and 9×200 nm) using a hand-extruder (Mini-Extruder, Avanti Polar Lipids, 
Alabaster, USA) and the size of the resulting liposome suspension evaluated by dynamic light scattering 
(Zetasizer Nano-S, Malvern Instruments, Malvern, UK). A diameter of 186 nm and a polydispersity of 
0.09 were found (average of three measurements). The (NH4)2SO4 solution was replaced with a HEPES 
buffer via size exclusion purification using a sepharose CL-4B column packed in HEPES buffer. C16-
UV-Tat was coupled to the liposomes and purified by ultracentrifugation as described above. The 
resulting pellet was redissolved in HEPES buffer (0.5 mL) and a filtered doxorubicin solution was added 
(0.5 mL, 3 mg/mL in HEPES). This was incubated at 60 °C for 1 h and purified using a CL-4B size 
exclusion column (the unencapsulated doxorubicin fraction was collected and saved). The size of the 
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doxorubicin-loaded liposomes was evaluated by dynamic light scattering giving a size of 208 nm and a 
polydispersity index of 0.20. 
The doxorubicin encapsulation efficiency was determined as follows (in triplicate): a liposome sample 
(100 KL) was diluted with a HCl/i-PrOH solution (900 KL, 0.075 M HCl in 90% i-PrOH) and incubated 
at 60 °C for 1.5 h. Then the absorption at 480 nm of this sample along with the unencapsulated 
doxorubicin was measured. From the volume of liposome suspension and unencapsulated doxorubicin an 
encapsulation efficiency of 93% was calculated using an extinction coefficient of 12,500.[30] 
 
MTT cell viability assay 
10,000 HeLa cells were seeded in each well in a 96-well plate and incubated at 37 °C for two days. The 
cells were then incubated for 7 h at 37 °C with a triplicate dilution series in DMEM of free doxorubicin 
(stock solution prepared in DMSO) and liposomes (irradiated for 2×2 min and non-irradiated) ranging 
from 1 to 100 KM in doxorubicin. After incubation with the doxorubicin samples, the medium was 
refreshed and incubation continued for another two days. The medium was removed and a solution of 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 100 KL, 5 mg/mL in phosphate 
buffered saline buffer) was added. After incubation for 4 h at 37 °C the MTT solution was removed 
gently and replaced with DMSO-water (200 KL, 50%) followed by incubation for 10 min at 37 °C. The 
absorbance at 530 nm was measured immediately using a plate reader (Wallac Victor2 1420 multilabel 
counter, PerkinElmer, Benelux Scientific, Ochten, The Netherlands).  
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3.1  Introduction 
Quantum dots (QD) are single crystals typically made from heavy metals and semiconductors.[1] 
These nanocrystals are very attractive as fluorescent markers for cellular imaging studies because 
of their excellent optical properties such as high brightness, broad excitation and narrow 
emission spectra, long fluorescence lifetime and high photochemical stability.[2] In this regard 
they outperform conventional organic fluorophores, which are susceptible to photobleaching, as 
was also observed during our study of a UV-activatable liposome delivery system discussed in 
chapter 2. 
These properties come with a price, however, as QDs have been reported to be cytotoxic 
due to leakage of heavy metals and aggregation with serum proteins.[3] The former is still under 
debate though, as different cell lines and/or different ligands on the QD surface seem to 
determine the observed toxicity.[4]  
With respect to imaging, tumors are known to be notoriously difficult to image due to their 
pervious nature resulting in fast clearance of the imaging agents. Despite the immensity of QDs 
compared to organic dyes, QDs are yet too small to be retained in pervious tumor tissue.[5] To 
address the fast clearance and the cytotoxicity issues of QDs, these have been encapsulated in 
liposomes protecting the body from the QDs and increasing the size of the imaging agent, which 
led to increased retention in the tumor.[6] This, on the other hand, calls for efficient purification 
 
 
Scheme 3.1. Illustration of ion-exchange column purification of QD-loaded liposomes. A crude suspension 
of QD-loaded liposomes and unencapsulated QDs (left) can be purified by means of ion-exchange 
chromatography. The anionic QDs bind to the cationic ion-exchange resin and QD-loaded liposomes free  
of unencapsulated QDs (right) can be eluted from the ion-exchange column. Not drawn to scale. 
protocols as quantitative encapsulation[7][8] of QDs in liposomes cannot be achieved and 
unencapsulated QDs will need to be removed. Until now, this matter has been resolved partly 
either by size exclusion chromatography leading to incomplete separation[6d,9] or by application 
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of a lengthy and complex gradient ultracentrifugation.[6c] In this chapter we report on a quick, 
easy and efficient protocol to remove unencapsulated anionic QDs from neutral or moderately 
anionic liposomes using ion-exchange beads, yielding pure and photostable QD-filled liposomes 
(scheme 3.1).  
 
3 .2  Results and discussion 
3.2.1  Preparation of QD-loaded or empty l iposomes 
Two different types of liposomes were prepared, neutral non-PEGylated liposomes and 
moderately anionic PEGylated liposomes, as we envisioned that the QDs might adhere to 
PEGylated liposomes as the QDs also contained surface PEG-chains (PEG-QDs). Both types 
(empty or QD-loaded) were prepared via the reverse-phase evaporation method, as this 
procedure has been reported to improve loading of big particles in liposomes compared to the 
traditional thin-film hydration method.[10] Briefly, an aqueous solution (containing carboxyl-
PEG-QDs if applicable) was mixed in the dark with a chloroform solution containing the lipids, 
to prevent photodegradation, and the mixture vortexed. Chloroform was removed in vacuo from 
the emulsion formed, and the resulting lipid suspension was extruded affording liposomes of 
approximately 200 nm in diameter. 
 
3.2.2 Scavenging of QDs by ion-exchange 
First, the applicability of an ion-exchange (IE) resin as a QD scavenger was tested with empty 
liposomes (PEGylated and non-PEGylated) mixed with free anionic QDs. All purifications were 
performed using a strong anion IE resin (DEAE sephadex A-25) in two different ways: via a short 
isocratic column or via a pull-down (PD) purification. In the PD purification approach, the IE 
resin was added directly to the liposome suspension to scavenge the free QDs and subsequently 
filtered off. The efficiency of the purification was assessed via agarose gel electrophoresis as QDs 
are small enough to penetrate the gel in contrast to the liposomes, which remain in the well.[7a] 
Thereafter, IR-scanning and fluorescence-imaging of the resulting gel was applied to visualize 
the QDs and liposomes (labeled with a fluorescent lipid), respectively. 
From figure 1 it is clear that free QDs could be scavenged efficiently by column IE (lane 11) 
or IE pull-down (lane 12) purification, as no bands from free QDs were observed. Similarly, 
QDs could be removed from a mixture of free QDs and empty PEGylated (lanes 5, 6 and 7) or 
non-PEGylated liposomes (lanes 8, 9 and 10). This furthermore implies that QDs do not adhere 
to preformed liposomes – neither PEGylated nor non-PEGylated. In addition, dynamic light 
scattering showed that the integrity of the liposomes was not compromised by the IE treatments, 
as the polydispersity index and mean size before and after purification were 0.12/201 nm and 
0.13/208 nm, respectively. 
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Figure 3.1. Scavenging of free QDs and QDs from mixtures of empty liposomes and free QDs by means of 
ion-exchange. Lane 1-4: QD dilution series with particle concentrations of 80 nM, 8 nM, 800 pM and 80 
pM, respectively (QDs). Lane 5-7: PEGylated liposomes (+PEG) mixed with free QDs at a final QD 
concentration of 320 nM before purification (cr), after column ion-exchange (col) and after pull-down ion-
exchange (PD). Lane 8-10: same as lane 5-7 only with non-PEGylated liposomes (-PEG). Lane 11-12: 
column and pull-down ion-exchange purification of a 320 nM QD suspension (QDs). The agarose gel was 
imaged by fluorescence-imaging (top gel) and IR-scanning (bottom gel). The insert shows lane 1-4 scanned 
with increased exposure time to increase the sensitivity of the QD imaging. 
 
Remarkably, the sensitivity of the IR-scanner allowed detection of QDs at concentrations as low 
as 800 pM, when the IR-scanning exposure time was increased (insert, lane 3, Fig. 3.1). This 
concentration is 100 times lower than the QD concentration used in the liposome samples and 
still no (free) QDs could be detected, emphasizing the high efficiency of the IE purification. 
 
3.2.3 Purification of QD-loaded liposomes 
Having shown that an anion IE resin can be used to scavenge anionic QDs, this purification 
procedure was employed on a crude suspension of QD-loaded liposomes, which also contained 
unencapsulated QDs (Fig. 3.2, lanes 2 and 5). As expected, both column and pull-down 
purification successfully removed all free QDs from both PEGylated and non-PEGylated 
liposomes, as QD fluorescence was only observed in the wells together with the liposomes (lanes 
3, 4, 6 and 7). Hence, unencapsulated QDs can easily be removed from QD-loaded liposomes 
leaving QD-loaded liposomes behind exclusively. 
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Figure 3.2. Scavenging of QDs from mixtures of unencapsulated QDs and QD-loaded liposomes by means 
of ion-exchange. Lane 1: 8 nM QD suspension (QD). Lane 2-4: QD-loaded PEGylated liposomes (+ PEG) at 
a final QD concentration of 320 nM before purification (cr), after column ion-exchange (col) and after pull-
down ion-exchange (PD). Lane 5-7: same as lane 2-4 only with non-PEGylated liposomes (-PEG). The 
agarose gel was imaged by fluorescence-imaging (top gel) and IR-scanning (bottom gel). 
 
3.2.4 Quenching of non-encapsulated QDs 
Above, it was shown that QDs do not adhere to preformed liposomes (Fig. 3.1). However, 
formation of the QD-loaded liposomes involves a chloroform-water two-phase system as well as 
an extrusion process, either of which might induce such adherence events. This might give rise 
to fluorescent QD bands in the wells colocalized with the liposomes, and consequently can lead 
to erroneous assumptions regarding the QD encapsulation. To rule this out, a selective QD 
quenching experiment was performed.  
The desired selective quenching of all unencapsulated QDs was achieved by addition of 
copper(II) ions to the agarose gel electrophoresis buffers, since these ions have been reported to 
quench QD fluorescence.[11] As evident from figure 3.3, QD fluorescence from free QDs could 
be quenched completely when analyzed by copper-supplemented agarose gel electrophoresis 
(compare lane 1 in Fig. 3.3A-B). For crude QD-loaded liposomes a similar quenching of 
unencapsulated QDs was seen, whereas fluorescence could still be observed in the well. Hence, it 
can be concluded that the fluorescent signals observed in the copper-supplemented gel (Fig. 
3.3B) arise from encapsulated QDs. This indicates that the QDs detected in the purified QD-
loaded liposome samples (with or without copper-supplementation) are indeed encapsulated 
(compare lanes 3 and 4 Fig. 3.3A-B).  
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Figure 3.3. Selective quenching of non-encapsulated QDs by Cu(II)-supplemented agarose gel 
electrophoresis. A) Normal agarose gel electrophoresis (-Cu2+) of crude and purified QD-loaded liposomes. 
and B) Cu(II)-supplemented (+Cu2+) agarose gel electrophoresis Lane 1: 8 nM QD suspension (QD). Lane 2-
4: QD-loaded PEGylated liposomes (+PEG) at a final QD concentration of 320 nM before purification (cr), 
after column ion-exchange (col) and after pull-down ion-exchange (PD). The agarose gel was imaged by 
fluorescence-imaging (top gel) and IR-scanning (bottom gel). 
 
3.2.5 Liposome recovery 
To establish the extent of liposome recovery after IE purification, the phosphate content was 
determined before and after IE purification.[12] Furthermore, the recovery degree from a size 
exclusion chromatographic (SEC) purification of the same crude liposome preparation was 
determined and compared to the IE purification. In figure 3.4, the relative phosphate content 
(total phosphate content in the sample relative to the crude preparation) is presented in bold 
numbers at the bottom of agarose gels showing the analysis of the SEC and IE purifications 
(insert). As expected, SEC did not separate the QDs and liposomes very well, and only fraction 
two seemed to be reasonably pure, though some large QD-containing aggregates were observed 
just below the well. However, fraction two only contained 17% of the liposomes present in the 
crude preparation, whereas IE column and pull-down purification yielded QD-loaded liposomes 
devoid of any QD-impurities with recoveries of 71 and 67%, respectively. Although these 
recoveries are lower than the total liposome recovery including QD-impurities (85%) obtained 
from the SEC purification, it should be noted that in case of SEC an additional purification step 
is required. Furthermore 85% is an unusual good recovery degree as SEC often yields recoveries 
of 60-70%.[13] 
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Figure 3.4.  Comparison of the relative liposome recovery after size exclusion chromatography and ion-
exchange chromatography. Lane 1-9: Fraction 1-9 from size exclusion chromatography (SEC) of QD-loaded 
PEGylated liposomes. The crude QD-loaded liposomes (cr) and free QDs (QDs) were included in two 
separate lanes. The insert shows the same sample before (cr) and after ion-exchange purification (col and 
pd). The phosphate concentration was measured in all samples, and the relative recovery determined 
(indicated by numbers in bold). 
 
3.2.6 Estimation of l iposome QD-loading 
To estimate how many QDs were encapsulated in the liposomes, the average number of QDs 
per liposome was determined by means of inductively coupled plasma mass spectrometry (ICP-
MS) and particle counting using a NanoSight particle tracking instrument.  
First, the Cd-content (component of the QDs) in a standard QD-suspension of known 
concentration as well as a sample of column-purified QD-loaded liposomes was determined (top 
row, Table 3.1). Thus, from the known QD-concentration and the ratio of the measured Cd 
contents, the number of QDs in the QD-loaded liposomes could be computed (second row, 
Table 3.1). Next, the concentration of liposomes was determined using a NanoSight particle 
tracking instrument (third row, Table 3.1), which allowed straightforward computation of the 
number of QDs pr. liposome (bottom row, Table 3.1). From these calculations a loading of 3.8 
QDs per liposome (on average) was obtained. This rather low number seems plausible 
considering the hydrodynamic diameters of the QDs and liposomes, which were 20 and 208 nm, 
respectively. Fortunately, the high brightness of the QDs still allows facile detection, as 
demonstrated via fluorescence scanning.  
Although QD encapsulation efficiencies have been reported before, to our knowledge, this is 
the first time that the number of QDs encapsulated in liposomes is quantified, while excluding 
the possibility of QD adherence or coaggregation with liposomes.[14]  
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Table 3.1. QD-loading of liposomesa 
 80 nM QD sol. QD-loaded liposome sol. 
Cd amount, 50 Lb 649 ± 21 19.8 ± 0.3 
Number of QDs (mL-1) 4.82 × 1013 (1.5 ± 0.3) × 1012 
Number of particles (mL-1) - (3.9 ± 0.3)c × 1011 
QDs pr. liposome - 3.8 ± 0.3 
a Numbers in italic are calculated, normal face are measured values. The error denotes half the difference between two 
independent measurements 
b Determined via ICP-MS. Average of 111Cd, 112Cd and 114Cd in ppb 
c Counted with via NanoSight particle tracking analysis 
 
 
3 .3  Conclusion 
We have shown that unencapsulated anionic quantum dots (QD) can easily be removed from 
QD-loaded liposomes by scavenging using an anion exchange resin. This could be accomplished 
either by means of short column chromatography or via a pull-down approach, in which the resin 
was added to the liposomes and removed by filtration after a short incubation period. Further, 
we justified by copper-mediated quenching of quantum dot fluorescence that the QDs were 
encapsulated inside the liposomes and thus not adhered to the surface. Finally, we determined 
the number of encapsulated QDs to be 3.8 (on average) by a combination of inductively coupled 
plasma mass spectrometry and particle counting using a NanoSight particle tracking instrument. 
 
3 .4 Experimental  procedures 
Materials 
Lipids were from Avanti Polar Lipids (Alabaster, USA) or Lipoid (Cham, Switzerland). Qdot 705 ITK 
carboxyl quantum dots were from Invitrogen (Carlsbad, CA, USA). DEAE sephadex A-25 was from 
Pharmacia Fine Chemicals (Uppsala, Sweden). Sepharose CL-4B was from Sigma-Aldrich. The following 
buffers with the stated compositions were used: Tris buffer (50 mM, pH 7.5) and 1×TBE buffer (44.5 
mM Tris base, 44.5 mM boric acid, 1.3 mM EDTA). 
 
Preparation of PEGylated liposomes (empty and QD-loaded)
The liposomes were prepared via the reversed-phase evaporation method[10] as follows: Egg-derived 
hydrogenated phosphatidylcholine (27.4 mg, 36.0 Amol), 1,2-distearoyl-SN-glycero-3-phospho-
ethanolamine-N-[methoxy(polyethylene glycol)-2000] (11.1 mg, 4.00 Amol) and cholesterol (7.7 mg, 20 
Amol) were dissolved in CHCl3 (2.12 mL). To this solution was first added a solution of N-(7-nitrobenz-2-
oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-SN-glycero-3-phosphoethanolamine in CHCl3 (NBD-PE; 1 
mg/mL, 0.4 Amol, 383 AL). Then a suspension of Qdot 705 ITK carboxyl quantum dots (80 nM) in Tris 
buffer was added (2.0 mL) and vortexed to form a suspension. NB: It is crucial to keep the suspension in the dark 
as long as the quantum dots are in contact with chloroform and keep this period as short as possible due to chloroform-
mediated photodegradation. Immediately, the majority of CHCl3 was removed in vacuo and the remainder 
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removed by flushing with N2. A few glass beads were added and the suspension vortexed to aid formation 
of a homogeneous colloidal suspension. Water was added to compensate for loss during evaporation. The 
suspension was extruded through polycarbonate filters (9×400 nm and 9×200 nm) using an Avanti Mini-
Extruder (Avanti Polar Lipids, Alabaster, AL, USA) and the size of the resulting liposome suspension was 
evaluated by dynamic light scattering (Zetasizer Nano-S, Malvern Instruments, Malvern, UK). A mean 
diameter of 201 nm and a polydispersity index of 0.12 were found (average of three measurements). 
In the case of empty liposomes, Tris buffer without quantum dots was added to the CHCl3 solution and a 
concentrated quantum dot suspension (8 FM, 20 FL) was added after formation of the liposomes. 
 
Preparation of non-PEGylated liposomes (empty and QD-loaded)
Prepared as described for PEGylated liposomes, except that more egg-derived hydrogenated 
phosphatidylcholine (30.5 mg, 40.0 Fmol) was used to replace 1,2-distearoyl-SN-glycero-3-phospho-
ethanolamine-N-[methoxy(polyethylene glycol)-2000]. 
 
Ion-exchange purification 
DEAE-sephadex A-25 (3.5 g) was suspended in Tris buffer (50 mL) and heated at 100 HC for 2 h. The 
resin was then filtered off, washed with Tris buffer (50 mL) and resuspended in Tris buffer (25 mL). 
Ion-exchange pull-down: The liposome sample (100 FL) was mixed with DEAE resin suspension (100 FL) and 
incubated for 5 min at RT. Then the resin was removed by filtration and the volume of the purified 
liposome suspension measured (to allow determination of the liposome recovery). 
Ion-exchange chromatography: A column of approx 40×5 mm was prepared in Tris buffer. The liposome 
sample (100 FL) was loaded on the column and eluted with Tris buffer. The volume of the purified 
liposome suspension was measured (to allow determination of the liposome recovery). 
 
Size exclusion chromatography  
A sepharose CL-4B column (70×20 mm) was prepared in Tris buffer. The liposome sample (750 FL) was 
loaded on the column, eluted with Tris buffer and the volume of the resulting fractions measured (to 
allow determination of the liposome recovery). 
 
Agarose gel electrophoresis and imaging (IR and UV-imager) 
Liposome samples (16 FL) were diluted with a 5×loading buffer (4 FL; 0.9 g bromophenol blue, 1 mL 
87% glycerol, 1 mL 1×TBE buffer) and loaded (10 FL) on a 1% agarose gel prepared in 0.25×TBE 
buffer. The gel was run in 0.5×TBE buffer for 60 min at 80 V and imaged with a G:Box Chemi XX8 
gel-imager (Syngene, Cambridge, UK) using the following settings: Excitation with a blue LED (465 nm), 
exposure for 1 sec and fluorescence acquisition through a SW06 filter. The same gel was also scanned 
with an Odessey IR scanner (Westburg, Leusden, The Netherlands) using the following settings: Emission 
at 700 nm was acquired at a resolution of 169 Fm with a 2 mm offset. 
 
Phosphate determination
The phosphate concentration was determined according to Rouser’s method.[15] Briefly, a standard 
dilution series of NaH2PO4 was set up in triplicate (0-160 FL of a 0.5 mM NaH2PO4 solution) and treated 
the same way as the samples (triplicate). The samples were dried at 180 °C, then perchloric acid (0.3 mL, 
70%) was added to each, and the samples were incubated at 180 °C. Water (1.0 mL), a solution of 
(NH3)6Mo7)24 (0.5 mL, 1.2% w/v) and ascorbic acid (0.5 mL, 5% w/v) were added to each sample and 
these were incubated at 100 °C for 5 min. The absorbance at 797 nm was measured after cooling the 
samples with cold water. The phosphate concentration was subsequently determined by means of the 
standard dilution series.   
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Estimation of QD-loading 
The following samples (50 IL) were added to a glass tube each and heated at 180 KC for 1 h: A 
suspension of Qdot 705 ITK carboxyl quantum dots (80 nM), column purified QD-loaded liposomes and 
Tris buffer. After cooling the tubes to room temperature, HNO3-HCl (1:3, 100 IL) was added and 
marble balls were fitted on the tubes, which were then heated at 180 KC for another 1h. The tubes were 
cooled to room temperature, HNO3 (1%, 5.00 mL) was added and the solutions analyzed for 111Cd, 112Cd 
and 114Cd content by inductively coupled plasma mass spectrometry (Xseries, Thermo Fisher, Breda, The 
Netherlands). The Cd content in the Tris buffer was subtracted from the liposome and QD samples, and 
these background-corrected values were used for the QD-calculations. 
The number of QD-loaded liposomes was determined using a NanoSight NS500 (NanoSight, Amesbury, 
UK). Briefly, the liposomes were diluted 1,000 times with filtered Tris buffer and loaded in the 
NanoSight instrument. A video sequence of 90 sec was acquired and the liposomes were tracked, counted 
and their concentration determined using the manufacturer’s software. 
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4.1 Introduction 
4.1.1  Non-covalent association systems 
Cell-penetrating peptides (CPPs) have attracted much interest in recent years as they have the 
ability to induce cellular uptake of almost any kind of cargo to which they have been attached.[1] 
CPPs are typically 8-30 residues long; in nearly all cases conjugation to the cargo of choice is 
based on covalent attachment, or association via uncontrolled charge-based interactions.[2] 
Covalent attachment can be achieved chemically or, if the cargo is a protein, via genetic fusion. 
Chemical coupling often involves conditions, which may compromise sensitive cargos like 
proteins. In addition, coupling reactions are often rather unselective, which may lead to linking 
of (multiple) CPP(s) to essential functional amino acid residues in proteins. Moreover, it may also 
lead to impairment of the cargo.[3] Genetic fusion, albeit selective, may result in low expression 
levels[4] and is a strategy that is inherently labor-intensive in case a variety of CPPs is to be 
examined. 
Non-covalent association systems, of which the streptavidin-biotin couple is the 
paradigmatic example, have been of enormous benefit for the biomolecular sciences.[5] These 
non-covalent association systems have also been implemented in cellular delivery, via a strategy 
in which the synthesis of cargo and CPP is separated, after which a supramolecular interaction 
brings both elements together in a non-covalent delivery vehicle.[6] However, the few non-
covalent delivery systems available to date have their shortcomings: streptavidin[6a,6c] is of 
considerable size and also requires the covalent modification of one interactor with biotin. 
Another system which has been employed is the interaction of oligohistidine tags with 
oligovalent nitrilotriacetic acid (NTA) tags, facilitated by metal ions.[7] In this system, some 
selectivity can be achieved by adjusting the oligovalency of NTA and histidine.[8] However, the 
presence of metal-ions may lead to binding and inactivation of protein cargos, besides the issue 
of their inherent cytotoxicity.[6b,6d,9]  
In this respect, coiled-coil forming peptides form an interesting alternative, as strong and 
specific binding can be achieved by two short, complementary interaction partners.[10] The 
leucine zipper motif, found in many transcription factors, belongs to this class of peptides.[11] 
These peptides consist of a heptad repeat, abcdefg, in which residues a and d are hydrophobic, 
packing together with a’ and d’ from the second peptide in a knobs-into-holes manner.[12] Residues e 
and g are often charged residues responsible for key i to i’+5 electrostatic interactions ensuring 
heterodimerization and providing directionality of the peptide pair (parallel vs. anti-parallel).[13] 
Very recently, such leucine zippers were used to link a small fluorescent molecule to a polymer 
non-covalently and transport the entire complex into cells.[14] However, like the streptavidin-
biotin system, this specific approach also suffers from being fairly sizable. 
 
4.1.2 Design of a non-covalent and modular transduction system 
In this chapter a novel, low-molecular weight, non-covalent and modular transduction system 
based on the strong and specific binding of two complementary leucine zippers is presented 
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(Scheme 4.1).[10b] This delivery system consists of three modules: a CPP (module 1), which can 
be conjugated via copper-catalyzed azide-alkyne ‘click chemistry’ to a leucine zipper peptide 
(module 2). Subsequently, this CPP-leucine zipper peptide can bind specifically to its 
complementary leucine zipper fused to a proteinaceous cargo (module 3). 
The advantages of this modular design over covalent systems and genetic fusion-protein 
approaches are multiple: (i) The modular assembly allows easy variation of the CPP (module 1). 
This feature could be of great interest to the field of targeted delivery to specific organs/tumours 
as different organs are targeted by different peptides.[15] (ii) The CPP can be synthesized 
independently of the cargo and leucine zipper. This fragment synthesis strategy confers a 
synthetic freedom, enabling the otherwise laborious and complicated synthesis of longer CPPs 
and leucine zippers. (iii) It is possible to use non-natural amino acids such as D-amino acids. (iv) 
Functionalities e.g. labels can be introduced on the leucine zipper (module 2) without affecting 
the cargo. 
 
 
Scheme 4.1. Overview of the modular assembly process of the leucine zipper-based non-covalent 
association and transduction system. First a CPP (module 1) is ‘clicked’ to a leucine zipper peptide (module 
2), which binds specifically to its complementary leucine zipper peptide linked to a proteinaceous cargo, 
which in this case is GFP-LZA (module 3). R = Ac or S0387. 
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4.2 Results  and discussion 
4.2.1  Preparation of leucine zipper modules 
To evaluate the effectiveness of this association system in a cell biological context an enhanced 
green fluorescent protein was conjugated non-covalently to a Tat peptide, a CPP derived from 
an HIV transactivator protein.[16] As the non-covalent association system, leucine zippers 
designed by Hodges and co-workers were used since this leucine zipper pair is one of the shortest 
coiled-coil pairs with a high affinity.[10b] This pair consists of an overall basic (KIAALKE)3 and 
an overall acidic (EIAALEK)3 leucine zipper (LZB and LZA, respectively). 
The azide-functionalized Tat peptide azido-YGRKKRRQRRRGC(Acm)[17] (4.1, module 
1) was prepared by solid phase peptide synthesis (SPPS) and a subsequent on-resin diazotization 
of the N-terminus (Scheme 4.2).[18] Further details on on-resin diazotization are described in 
chapter 5. The azide-functionalized Tat peptide was cleaved from the resin using trifluoroacetic 
acid and purified by reversed-phase HPLC. The mass and purity of the purified product were 
verified by ESI mass spectrometry and analytical reversed-phase HPLC, respectively. 
 
 
Scheme 4.2. Solid-phase synthesis of azide-functionalized Tat. The Tat peptide, YGRKKRRQRRRGC(Acm), 
was prepared by standard solid phase peptide synthesis. Treatment of the side-chain protected peptide with 
imidazole-1-sulfonyl azide hydrochloride afforded the corresponding N-terminal azide-Tat. 
The clickable leucine zipper (module 2) was prepared by coupling of propargylamine to an 
aldehyde resin via reductive amination, followed by standard SPPS using the resulting secondary 
amine as a starting point (Scheme 4.3).[19] In this way the alkyne functionality was introduced at 
the C-terminus of the acidic leucine zipper peptide (KIAALKE)3. This allowed labeling of the N-
terminus with carboxyl-S0387 (a commercially available Cy5 analog) by means of a HATU-
mediated peptide coupling. Subsequently, the S0387-labeled, alkyne-functionalized 
(KIAALKE)3 peptide was cleaved from the resin and analyzed as described above for module 1. 
Finally, S0387-labeled alkyne-functionalized (KIAALKE)3 (4.4) was ‘clicked’ to azido-Tat 
(4.1) using CuSO4/sodium ascorbate as a copper(I) source and lutidine as copper ligand 
(Scheme 4.4). The resulting S0387-(KIAALKE)3-triazolo-Tat (S0387-LZB-Tat, 4.2) conjugate 
was purified by reversed-phase HPLC and the mass and purity were verified by MALDI mass 
spectrometry and analytical HPLC, respectively. Unlabeled (KIAALKE)3-Tat (LZB-Tat, 4.6) 
was prepared in a similar way, except that this peptide was acetylated N-terminally instead of 
labeled with S0387. 
 
YGRKKRRQRRRGC(Acm) YGRKKRRQRRRGC(Acm)N3-H2N-
2) CF3COOH (90%, aq.), 18h, rt.
N
N
S
O
O
N3
DIPEA (4.5 eq.), DMF, 20h, rt.
1)
(3 eq.),
·HCl
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Scheme 4.3. Solid phase synthesis of the alkyne-functionalized acidic leucine zippers. The alkyne 
functionality was introduced on an aldehyde resin via reductive amination and used as handle for synthesis 
of the acidic leucine zipper by SPPS. The leucine zipper was either functionalized with the fluorescent label 
S0387 to afford leucine zipper 4.4 or acetylated to afford leucine zipper 4.5. 
 
 
Scheme 4.4. Conjugation of azido-Tat to the acidic leucine zippers by ‘click chemistry’. A copper-
catalyzed alkyne-azide cycloaddition was used to conjugate azido-Tat (4.1) to the labeled S0387-LZB (4.4) 
and unlabeled leucine zippers LZB (4.5). 
The GFP-leucine zipper, GFP-(EIAALEK)3, (GFP-LZA, 4.3 our model cargo) was cloned into a 
DNA plasmid as a fusion protein, expressed in and purified from E. coli by means of His-tag 
affinity chromatography.[20] The purity and mass were verified by SDS-PAGE electrophoresis 
and HR-ESI MS, respectively (Figure 4.1). 
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Figure 4.1. Analysis of the GFP-leucine zipper. A) HR-ESI mass spectrometry showed the expected mass 
(calcd. 33371.6) of the expressed GFP-LZA (4.3); B) SDS-PAGE showed that the protein was pure. 
 
4.2.2 Biophysical  analysis of  the leucine zipper interaction 
First it was verified that the two leucine zippers were able to heterodimerize after linkage to Tat 
and GFP, respectively, by measuring their binding constant by means of isothermal titration 
calorimetry (ITC, Figure 4.2).  
 
 
Figure 4.2. Isothermal calorimetry of leucine zippers. A) Raw heats acquired by titrating LZB–Tat into a 
solution of GFP–LZA or; C) unlabeled LZB into a solution of unlabeled LZA. B) and D) The integrals of the 
heat peaks were fitted to a one-site binding model to provide the association constant KA and the 
stoichiometry N. Experiments were performed in phosphate buffer (10 mM, pH 7.0). 
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The ITC data yielded a KD of 181 nM (KD=KA-1), which is similar to the dissociation constant of 
unfunctionalized leucine zippers.[21] This demonstrates that the affinity of the leucine zippers for 
each other is not affected by GFP or Tat. The derived stoichiometry of 1.14 supports a one-to-one 
heterodimerization. 
The interaction between the leucine zippers was studied further by conducting dual-color 
fluorescence cross-correlation spectroscopy (FCCS) for GFP-LZA and S0387-LZB-Tat. FCCS 
extracts information on molecular interactions of differently labeled molecules from temporal 
fluctuations of fluorescence intensity in overlapping confocal detection volumes.[22] Since FCCS 
is a method especially suitable for detecting association at low nanomolar concentrations, GFP-
LZA and S0387-LZB-Tat were first allowed to associate at 12.5 :M for 5 min at 4 °C, after 
which they were diluted to 62.5 nM. A strong cross-correlation was acquired for the two leucine 
zippers, whereas no cross-correlation was detected if one of the two leucine zippers was replaced 
by the corresponding free fluorophore (Figure 4.3A-D). 
 
 
 
Figure 4.3. Interaction of leucine zippers as detected by fluorescence cross-correlation spectroscopy. A) 
Association of GFP–LZA and S0387–LZB–Tat. B) Rhodamine Green (RhG) and Cy5 double- labeled 
oligonucleotide (ON) served as positive control. C) GFP–LZA in the presence of S0387 or D) GFP in the 
presence of S0387–LZB–Tat. (C) and (D) were used as negative controls. E) The percentage of bound fraction 
of S0387 fluorophores (ch2) and GFP (ch1) was calculated by normalizing their cross-correlation 
amplitudes to those of Cy5 and RhG from the double-labeled ON, which were defined as 100% 
association. Errors bars represent the standard deviation of ten measurements of 10 sec. 
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To quantify the fraction of associated particles, first, a double-labeled oligonucleotide was used 
as a positive reference showing maximal cross-correlation (Figure 4.3B and E). For S0387-LZB-
Tat, almost complete association with GFP-LZA was observed, whereas over half of GFP-LZA 
species were associated with S0387-LZB-Tat species. Although these results seem to indicate a 
slightly altered stoichiometry, the different values were attributed to differential affinities for the 
walls of the 384-wells plate used in the FCCS experiment, as a 3.3-fold excess of GFP-particles 
over S0387-labeled particles was detected in the solution, calculated on the basis of the estimated 
particle number in the confocal volume (1.8 for GFP and 1.1 for S0387) and the size of the 
confocal detection volume (0.3 fL for the GFP-channel and 0.6 fL for the S0387-channel).[23] 
The FCCS measurements demonstrated that the non-covalent leucine zipper complexes were 
stable at concentrations below the KD-value indicative of a slow dissociation-rate.  
 
4.2.3 Cellular uptake of the non-covalent transduction system 
Having established the potential of the leucine zipper-tag as a non-covalent conjugation system 
in a non-cellular context, its transduction competence in living cells was investigated next. 
Hence, HeLa cells were incubated with GFP-LZA:LZB-Tat complexes and uptake was 
investigated by confocal laser scanning microscopy. As expected, intracellular transduction of 
GFP-LZA was profoundly stimulated when complexed with LZB-Tat; GFP was clearly visible in 
vesicular structures inside the cells (Figure 4.4 A). Uptake was only observed for the complexes 
formed from GFP-LZA and LZB-Tat. 
 
 
Figure 4.4. Transduction of leucine zipper-GFP into HeLa cells mediated by leucine zipper-Tat. A) Leucine 
zippers (2.5 >M) were incubated with HeLa cells for 60 min at 37 °C. The plasma membrane was stained 
with CellMask Deep Red. B) HeLa cells were incubated with S0387-LZB–Tat, GFP–LZA, Tat or GFP (1.25 >M 
each) for 60 min at 37 °C. Yellow structures indicate colocalization, scale bars = 10 >m. 
CellMask Deep Red was applied to stain the plasma membrane (after incubation with the 
leucine zippers) to verify that the punctuate green structures were indeed localized inside cells 
and not fluorescent aggregates on the plasma membrane. GFP-LZA and CellMask Deep Red did 
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not co-localize, thus establishing that the punctuate green structures are predominantly localized 
intracellularly (Figure 4.4A). Washing with heparin to remove leucine zippers potentially bound 
to the cell surface did not change the appearance of the confocal images demonstrating that the 
GFP-LZA and LZ-TatB are indeed taken up by the cells. Importantly, no intracellular delivery of 
GFP was observed when free GFP (no leucine zipper) was incubated with LZB-Tat, ruling out 
the possibility that cellular uptake could be a result of an unspecific interaction between LZ-TatB 
and GFP itself. 
To exclude the possibility that GFP-LZA internalization was enhanced through unspecific 
induction of macropinocytosis by Tat,[3a] GFP-LZA was also co-incubated with unlabeled free 
Tat (no leucine zipper) (Figure 4.4B). Indeed, no internalization of GFP-LZA was observed, 
confirming that a specific interaction between LZB-Tat and GFP-LZA is indeed the primary 
driving force for internalization. 
After demonstrating that LZB-Tat is able to deliver GFP-LZA intracellularly through a 
specific non-covalent interaction, the next issue to be addressed was whether the leucine zippers 
remain associated inside cells. In an attempt to answer this question, S0387-LZB-Tat was co-
incubated with GFP-LZA (Figure 4.4B). The overlay of the confocal images from this experiment 
showed numerous yellow punctuate dots indicating subcellular co-localization of the zippers. 
However, next to yellow dots, red and green dots were observed as well, indicating that the ratio 
of GFP-LZA and S0387-LZB-Tat differs widely between intracellular vesicles. Although 
elucidating the exact intracellular fate requires a more exhaustive study, this observation suggests 
that the leucine zippers do not remain fully associated inside cells. One possibility is that the low 
endosomal pH promotes dissociation of leucine zippers.[21]  
 
4.3  Re-design of  the non-covalent delivery system: activatable 
leucine zippers 
Having demonstrated the applicability of leucine zippers (LZs) as elements in a non-covalent 
delivery system, it was envisioned to extend the system further by making it activatable. The 
motivation for this refinement is that the LZ element bearing the cell-penetrating peptide (Tat-
LZ) was constitutively active in the original design of the delivery system, and consequently taken 
up by cells even though the complementary LZ bearing the cargo (GFP-LZ) was not present. 
Hence it would be desirable to modify the LZ-Tat so cellular uptake occurs only upon binding 
with the GFP-LZ. This may be achieved by means of a transient inactivation of the Tat peptide 
by blocking its positive charges with a negatively charged peptide, as described by Tsien and co-
workers for a nona-arginine cell-penetrating peptide.[24]  
Exchange of the LZs, i.e. conjugation of the acidic LZ (EIAALEK)3 (LZA) to Tat instead of 
GFP, would introduce negatively charged residues in the same peptide. Thus, it was 
hypothesized that the negatively charged glutamate residues will interact with the positively 
charged residues in the Tat peptide and transiently inactivate it through folding of the entire 
peptide into a loop (figure 4.5). Upon addition of the complementary LZB, the stronger LZ-LZ 
interaction would subsequently lead to opening of the loop, exposure of the Tat peptide and 
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eventually cellular uptake. In this section, the synthesis of the Tat-(EIAALEK)3 LZ conjugate 
and the investigation of its activity are described in the absence and presence of the 
complementary leucine zipper. 
 
 
Scheme 4.5. Schematic overview of the activatable acidic leucine zipper-Tat peptide. Glutamate residues 
in the acidic leucine zipper LZA (red) are expected to interact with the positive residues in the Tat peptide 
(grey screw) via folding of the entire peptide. Binding of the complementary basic leucine zipper, LZB (blue) 
results in formation of a coiled-coil, releasing the Tat peptide from its transient electrostatic blockage. 
 
4.3.1  Results  and discussion 
4.3.1.1  Synthesis of  the leucine zippers 
For the synthesis of the LZA-Tat conjugate native chemical ligation was explored instead of the 
previously employed click chemistry approach. In native chemical ligation an unprotected C-
terminal peptide thioester reacts with an N-terminal cysteine from another peptide to form a 
native peptide bond between the two peptides.[25] This leaves a cysteine residue at the interface 
of the two peptide fragments, which can be used for further reactions such as labeling with a 
fluorophore. 
Unfortunately, peptide thioesters are not readily available via Fmoc-based peptide synthesis 
due to their base-intolerance.[26] Hence, it is necessary to introduce the thioester moiety after the 
peptide has been synthesized. An attractive approach on such post-thioesterification was recently 
published by Eom and Tam,[27] in which they exploited the O-S acyl transfer propensity of a 
mercaptoethyl ester to synthesize several short peptide thioesters.[28] Using this approach, the 
LZA thioester 4.9 was synthesized and coupled to a Tat-peptide containing an N-terminal 
cysteine residue 4.10 (Scheme 4.6). It should be noted that slightly different conditions (more 
thiocresol and triflic acid) were applied, as the procedure described by Eom and Tam did not 
provide any desired product. After the native chemical ligation, the cysteine residue was used as 
a handle to attach a fluorescent dye, fluorescein diacetate 5-maleimide. 
Activated Tat
Inactivated Tat
Acidic leucine zipper
Basic leucine zipper
+
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Scheme 4.6 Synthesis of the acidic leucine zipper thioester via an O-S acyl transfer approach. 
Mercaptoethanol was attached to a solid support and the resulting alcohol used as a handle for SPPS of the 
LZA. Cleavage from the resin and interception by thiocresol afforded the LZA tolyl thioester 4.9. This 
thioester was ligated to Tat 4.10 via native chemical ligation, and the resulting cysteine residue was 
functionalized with fluorescein diacetate-5-maleimide.  
First, the mercaptoethyl moiety was introduced by attaching mercaptoethanol to a Barlos resin 
(2-chlorotrityl chloride resin) via the thiol group. The resulting alcohol was then used as a handle 
for synthesis of the LZA mercaptoethyl ester. After cleavage from the resin of the LZA 
mercaptoethyl ester and HPLC purification, the desired O-S acyl transfer was facilitated by 
acidification with triflic acid in trifluoro acetic acid and intercepted by thiocresol to form the 
corresponding tolyl thioester 4.9. 
The Tat-peptide (CRKKRRQRRRG) 4.10 was synthesized by standard Fmoc chemistry 
and purified by HPLC. It was then ligated to the LZA tolyl thioester in phosphate buffer at pH 
5.3 (Scheme 4.6). This native chemical ligation only reached a conversion of 60% as determined 
by LCMS. Increasing pH to enhance the nucleophilicity of the thiol moiety of the cysteine side 
chain mainly led to increased hydrolysis of the LZA tolyl thioester. No additional attempts were 
made to improve the conversion and pure ligated Tat-LZA was acquired after HPLC 
purification. Conjugation of fluorescein diacetate 5-maleimide to the cysteine residue in Tat-LZ 
was performed in phosphate buffer, affording the desired labeled ligation product LZA-(Fl)-Tat 
4.12 after HPLC purification.  
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4.3.1.2 Conformational studies 
To obtain a first indication of the feasibility of achieving a transient Tat-inactivation, the 
conformation of LZA-(Fl)-Tat before and after addition of its complementary LZB was evaluated 
by circular dichroism (CD) spectroscopy. 
 
 
Figure 4.5. Circular dichroism spectra of the leucine zippers used in the activatable leucine zipper based 
non-covalent delivery system. The spectra of LZA-(Fl)-Tat, LZB and a LZB:LZA-(Fl)-Tat complex acquired at 
20 °C were fitted to reference spectra of poly-L-lysine exhibiting three common secondary structures: -
helix, -sheet and random coil,[29] whereby the relative contents of the three secondary structures was 
computed. 
As can be seen from figure 4.5, both LZA-(Fl)-Tat and the complementary LZB exhibit 
substantial amounts of helical conformation  of which LZA-(Fl)-Tat had the highest content. This 
is in contrast to the helical contents reported by Hodges and co-workers for the very same LZs as 
they found helicity contents of 31 and 36%, respectively. Hence, it seems that either the Tat 
peptide or the fluorescein moiety induces helical character in the acidic LZ. When the two LZs 
were mixed, however, the helical content increased substantially, as expected, suggesting that the 
two LZs did indeed induce -helical character in one another. This implies that the acidic and 
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basic LZs are able to form a coiled coil and thereby expose the Tat-peptide. The high helical 
content of LZA-(Fl)-Tat itself, on the other hand, is an indication  that the peptide is rather rigid, 
which may hamper the desired folding.  
Since the activatable LZA-(Fl)-Tat is to be used in a cellular environment, the effect of 
increased temperature on the stability of the Tat-LZ:LZ-GFP coiled coil was studied by circular 
dichroism spectroscopy (CD) (Figure 4.6). These CD-spectra showed a steady decrease of the 
helical character with a concomitant increase in random coil upon heating a pre-associated 
LZB:LZA-(Fl)-Tat complex. Already around 40 °C, a significant amount of the helical content of 
the coiled coil was lost implying that the LZs dissociate partially (Figure 4.6B). Hence, for 
cellular uptake studies at 37 °C this might limit the transduction efficiency, though for the 
original non-activatable design (section 4.2) cellular uptake did not seem to be severely 
interrupted.  
 
 
 
 
 
Figure 4.6. Circular dichroism spectra of a leucine zipper complex at varying temperatures. A) CD spectra 
when heating the LZB:LZA-(Fl)-Tat complex. B) Melting curve of LZB:LZA-(Fl)-Tat complex obtained by 
heating the complex and plotting the ellipticity at 195 nm as a function of temperature. 
 
4.3.1 .3  Cellular uptake studies 
The ultimate assessment of the activatable LZA-(Fl)-Tat is to determine whether cellular uptake 
can be induced by addition of its complementary LZB. Therefore, LZA-(Fl)-Tat and a preformed 
LZB:LZA-(Fl)-Tat complex were added to HeLa cells and the cellular uptake was assessed via 
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confocal laser scanning microscopy. Regrettably, both LZA-(Fl)-Tat and the preformed complex 
were observed in the cells as diffuse green patterns, and on the cells as more localized green 
areas (Figure 4.7).  
 
 
Figure 4.7. Uptake of activatable leucine zipper-Tat by HeLa cells. HeLa cells were incubated with LZA-
(Fl)-Tat or a preformed LZB:LZA-(Fl)-Tat complex at a concentration of 10 0M in medium for 45 min at 37 
°C. The red box indicates the close-up area. 
This implies that the LZA-(Fl)-Tat did not fold sufficiently to transiently block the positive 
charges in the Tat peptide, as expected. The uptake experiment was also performed in 
phosphate buffer and at 4 1C in medium or phosphate buffer with the same outcome, though at 
lower temperature only cell binding was observed (results not shown). Hence neither high 
temperature nor the presence of serum proteins seem to be the cause of insufficient folding. 
Rather, too weak electrostatic interactions between the Tat peptide and the LZA might prevent 
efficient folding, as only a maximum of three to four positive residues in Tat are able to interact 
with glutamate residues in the LZA at any given time. Moreover, rigidity of the peptide caused 
by its helical character, as implied in the CD findings, may hinder the folding process. 
 
4.4 Conclusion 
In conclusion, by taking advantage of the specific binding of two complementary leucine zippers, 
a modular, non-covalent delivery system for leucine zipper-functionalized cargos has been 
developed. When a cell-penetrating peptide (CPP), Tat, was attached to one leucine zipper and 
mixed with its complementary leucine zipper bearing a GFP-cargo, the resulting non-covalent 
complex was transported into cells. Importantly, cells only took up the GFP-cargo when the 
complementary leucine zipper-Tat was added. Since the delivery system is modular, the leucine 
zipper-Tat can easily be altered either by varying the CPP or by adding functionalities to the 
leucine zipper such as labels. In this proof-of-concept study it has been demonstrated that GFP 
can be introduced into cells via a non-covalent and modular transduction system. This may pave 
the way for transduction of other (therapeutically active) proteins. 
A modular and non-covalent transduction system for leucine zipper-tagged proteins 
 71 
Further, an approach was followed to make the leucine zipper bearing the CPP activatable. It 
was envisioned that by attachment of the positively charged CPP to the negatively charged 
leucine zipper, intramolecular electrostatic interactions might induce inactivation of the CPP. 
The leucine zipper-CPP was synthesized successfully by means of native chemical ligation. 
Regrettably, the combined results of circular dichroism spectroscopy and cellular uptake 
experiments showed that the leucine zipper-CPP did not fold as expected and was taken up by 
HeLa cells extensively.  
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4.6 Experimental  procedures 
General 
Aldehyde resin was purchased from Novabiochem and Fmoc-L-amino acids were from Bachem or 
Novabiochem. S0387 was purchased from Few Chemicals (Bitterfeld-Wolfen, Germany). Plain DMEM 
(Dulbecco’s modification of Eagle’s medium, with 3.7 g/L sodium bicarbonate, 1 g/L L-glucose, L-
glutamine) and antibiotics/antimycotics (penicillin, streptomycin sulphate, amphotericin B) were all from 
PAA Laboratories (Pasching, Austria). All other chemicals were purchased from Baker, Fluka or Sigma 
Aldrich and used as received. Mass spectra were recorded on a Bruker Biflex MALDI-TOF (high 
resolution 0-4000 and low resolution >4000, Bruker Daltronik, Bremen, Germany), a low resolution 
Thermo Finnigan LCQ ESI-ion trap (Thermo Fischer, Breda, The Netherlands) or a high resolution 
ESI-TOF JEOL AccuTOF (JEOL, Nieuw-Vennep, The Netherlands). Lyophilization was achieved using 
an ilShin Freeze Dryer (ilShin, Ede, The Netherlands). UV measurements were performed on a Varian 
Cary 50 Conc (Joint Analytical Systems, Eindhoven, The Netherlands). 
 
General peptide synthesis 
Peptides were synthesized on a Labortec640 (Labortec, Bubendorf, Switzerland) employing a standard 
Fmoc solid-phase peptide synthesis (SPPS) protocol. Briefly, the resin (functionalized aldehyde resin or 
Breipohl resin[30]) was swollen in DMF for 20 min. prior to use. The first and subsequent Fmoc groups 
were removed by washing the resin with piperidine in DMF (20% v/v) and then shaking for 25 min with 
another portion of piperidine in DMF. The desired sequence of amino acids was coupled to the resin 
using Fmoc-L-amino acids (3.0 eq), diisopropylcarbodiimide (DIPCDI, 3.3 eq) and N-hydroxy-
benzotriazole (HOBt, 3.6 eq). Peptide couplings were followed to completion using the Kaiser test.[31] 
After the final Fmoc removal the resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2, Et2O and air-
dried for at least 2 h. 
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RP-HPLC peptide purification and analysis 
Analytical and semi-preparative HPLC was performed on a Shimadzu LC-20A Prominence system 
(Shimadzu, ‘s-Hertogenbosch, The Netherlands) equipped with a ReproSil column (Screening Devices, 
Amersfoort, The Netherlands). Semi-preparative RP-HPLC purification of peptides was performed using 
a C18 column (250×10 mm, particle size 5 Hm, 4 mL/min flow or 150×20 mm, particle size 10 Hm, 
8mL/min flow) and a MeCN/water gradient containing 0.1% trifluoroacetic acid (0-100%, 1-31 min). 
The fractions were analyzed by ESI-ion trap mass spectrometry and analytical RP-HPLC using a C18 
column (150x3 mm, particle size 3 Hm, flow 0.4 mL/min) and a MeCN/water gradient containing 0.1% 
trifluoroacetic acid (5-100%, 1-50 min). Fractions containing the desired peptide were pooled, evaporated 
until the volume was halved and lyophilized. Finally, the purity of the lyophilized peptide was assessed by 
analytical RP-HPLC.  
 
Liquid chromatography mass spectrometry 
LCMS was performed on a Thermo Finnigan LCQ-Fleet ESI-ion trap (Thermo Fischer, Breda, The 
Netherlands) equipped with a Reprosil-Pur C18 column, 50×2 mm, particle size 3 Hm (Screening 
Devices, Amersfoort, The Netherlands) using the following elution parameters: flow 0.2 mL/min and a 
MeCN/water gradient containing 0.1% formic acid (5-100%, 1-9 min). 
 
Synthesis of azido-YGRKKRRQRRRGC(Acm)-NH2 (4.1, N3-Tat) 
The peptide was synthesized on a Breipohl resin (2 g, loading 0.59 mmol/g) using standard Fmoc SPPS 
as described above. After the final Fmoc removal, a portion of the resin (476 mg, ~ 80 Hmol) was 
removed and suspended in DMF. To this was added imidazole-1-sulfonyl azide hydrochloride[18] (52 mg, 
0.25 mmol) and CuSO4·5 H2O (6.2 mg, 25.0 Hmol) and the suspension was shaken overnight. Then the 
resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2, Et2O and dried for at least 2 h. The peptide was 
cleaved from the resin by suspension in trifluoroacetic acid/water/triisopropylsilane/thioanisole 
(90:5:2.5:2.5, 4 mL) for 23 h. The free peptide was precipitated in Et2O, air-dried, redissolved in water 
and lyophilized affording a white powder >95% pure (HPLC). The peptide was used without further 
purification. MALDI-TOF [M + H]+ m/z: 1815.4 (calcd. 1816.0), fragment at 1790.4. IR 1651 (C=O 
stretch), 2114 (N3 asymmetric stretch) and 3100-3300 (NH stretches, NH2 and guanidinium).  
 
Synthesis of S0387-(KIAALKE)3G propargyl amide (4.4) 
Propargylamine (1.13 mL, 17.6 mmol), NaCNBH3 (1.11 g, 17.6 mmol) and AcOH (1.0 mL, 17.6 mmol) 
were added to a commercially available aldehyde resin (4-(4-formyl-3-methoxyphenoxy)butyryl), (2.00 g, 
loading 0.88 mmol/g, 1.76 mmol) suspended in DMF/MeOH (50 mL, 1:1).[19] The suspension was 
stirred at 80 °C for 4 h. After cooling to room temperature the resin was washed with DMF, CH2Cl2, 
MeOH, CH2Cl2 and DMF. Fmoc-glycine (1.57g, 5.28 mmol), DIPCDI (5.81 mL, 1 M in DMF) and 
HOBt (6.34 mL, 1 M in DMF) were added to couple glycine to the resin. The suspension was shaken 
overnight. After thorough washing with DMF the resin was capped by addition of 1 mL Ac2O and 1 mL 
pyridine in 2 mL DMF and shaking for 10 min. The loading of the resin was determined in triplo by 
suspension of 1.0 mg resin in piperidine in DMF (20% v/v, 3.0 mL) for 20 min followed by measurement 
of the absorption at 290 nm. A loading of 0.34 mmol/g was calculated according to equation 1.  
 
Loading [mmol] = (A(sample)290-A(blanc)290)/(1.65×mresin)    (Eq. 1) 
 
The (KIAALKE)3 amino acid sequence was coupled to the resin by means of SPPS as described above. 
S0387 (100 mg, 0.14 mmol) was coupled to the N-terminus of the side-chain-protected resin-bound 
(KIAALKE)3G suspended in DMF by addition of N-[(1H-1,2,3-triazolo[4,5-b]pyridin-1-yloxy) 
(dimethylamino)-methylene]-N-methylmethanaminium hexafluorophosphate (HATU, 107.5 mg, 0.28 
mmol), N,N-ethyl-diisopropylamine (DIPEA, 96 HL, 0.57 mmol). The suspension was shaken in the dark 
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overnight and then washed thoroughly with DMF, CH2Cl2, i-PrOH, CH2Cl2, Et2O and dried for at least 
2 h. The peptide was cleaved from the resin by suspension in trifluoroacetic acid/water/ 
triisopropylsilane/ethanedithiol (90:5:2.5:2.5, 4 mL) for 3 h. The free peptide was precipitated from 
Et2O, redissolved in water and lyophilized affording a deep blue powder. The crude peptide was purified 
by semi-preparative HPLC affording S0387-labeled peptide 4.4 as a blue powder >99% pure (HPLC). 
ESI-ion trap m/z: [M+3H]3+ =1014.7 (calcd. 1014.2), [M+4H]4+ = 761.7 (calcd. 760.9), [M+5H]5+ = 
609.3 (calcd. 608.9). 
 
Synthesis of S0387-(KIAALKE)3G triazolo-Tat (4.2, S0387-LZB-Tat) 
S0387-labeled leucine zipper 4.4 (3 mg, 0.99 Cmol), N3-Tat 4.1 (1.8 mg, 0.99 Cmol) and CuSO4·5 H2O 
(6.0 mg, 24.0 Cmol) were dissolved in water (1 mL). Lutidine (5.7 CL, 49.4 Cmol) was suspended in the 
reaction mixture and stirred under Ar over night. Then sodium ascorbate (3.9 mg, 20.0 Cmol) was added 
and the reaction stirred for another night. The crude peptide was purified by semi-preparative HPLC 
affording S0387-LZB-Tat 4.2 as a deep blue powder 90% pure (HPLC). MALDI-TOF [M + H]+ m/z: 
4853 (calcd. 4854.7), fragments at 4822, 2853, 2702. 
 
Synthesis of Ac-(KIAALKE)3G propargyl amide (4.5) 
Acetylated leucine zipper 4.5 was synthesized as described for S0387-labeled leucine zipper 4.4. Only 
instead of addition of S0387, the resin (456 mg, ~ 83 sodium ascorbate (3.9 mg, 20.0 Cmol)) was 
acetylated by addition of Ac2O (500 CL, 4.53 mmol), pyridine (500 CL, 6.45 mmol) in DMF (1 mL) and 
shaking for 10 min. This afforded a white powder 95% pure (HPLC). ESI-ion trap m/z: [M+2H]2+ = 
1208.9 (calcd. 1208.3), [M+3H]3+ = 806.5 (calcd. 805.8), [M+4H]4+ = 605.4 (calcd. 604.6). 
 
Synthesis of Ac-(KIAALKE)3G triazolo-Tat (4.6, LZB-Tat)  
Acetylated leucine zipper 4.5 (13.5 mg, 5.60 Cmol), N3-Tat (20.3 mg, 11.2 Cmol), lutidine (26.0 CL, 0.22 
mmol) and Cu(MeCN)4PF6 (41.7 mg, 0.11 mmol) were dissolved in water/MeCN (8 mL, 1:1) and stirred 
under Ar for 2 days. The crude peptide was purified by semi-preparative HPLC affording LZB-Tat as a 
white powder >99% (HPLC). MALDI-TOF [M + H]+ m/z: 4229 (calcd. 4230.5). 
 
Synthesis of Ac-(KIAALKE)3-NH2 (4.7) and Ac-(EIAALEK)3-NH2 (4.8) 
Acetylated leucine zippers 4.7 and 4.8 were synthesized on Breipohl resin by means of SPPS as 
described above. This afforded leucine zipper 4.7 as a white powder >95% (HPLC), ESI-ion trap m/z: 
[M+H]2+ 1162.5 (calcd. 1162.6), [M+3H]3+ = 776.0 (calcd. 775.4), [M+4H]4+ = 581.7 (calcd. 581.8) and 
leucine zipper 4.8 as a white powder >90% pure (HPLC), ESI-ion trap m/z: [M+2H]2+ = 1162.7 (calcd. 
1160.8), [M+3H]3+ = 776.0 (calcd. 774.2). 
 
Synthesis of the acidic leucine zipper (EIAALEK)3-SPhMe (4.9) 
Chlorotrityl chloride resin (1.0 g, loading 0.99 mmol/g) was swollen in anhyd. CH2Cl2 for 30 min. Then 
mercaptoethanol (209 CL , 2.98 mmol) and N,N-diisopropylethylamine (1027 CL, 5.91 mmol) were added 
and this mixture was shaken for 45 minutes. After removal of the reagents, the resin was capped with 
N,N-diisopropylethylamine (500 CL) and  MeOH (1.0 mL) for 15 min. Subsequently, the resin was 
washed with DMF and the first amino acid (Fmoc-Lys, 2.97 mmol) was coupled  overnight using 
standard HOBt/DIPCDI coupling conditions catalyzed by DMAP (85.5 mg, 0.70 mmol). After washing 
the resin with DMF, the loading of the resin was determined as described for leucine zipper 4.4 and was 
found to be 0.31 mmol/g. The rest of the peptide was synthesized by standard Fmoc SPPS as described 
above. After the final Fmoc removal and washing, the peptide was cleaved from the resin by suspension 
in trifluoroacetic acid/thioanisole/PhOH/water/ethanedithiol/triisopropylsilane (81.5:5:5: 5:2.5:1), 
stirred for 2 h and purified as described above affording the leucine zipper thioester as a white powder 
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>99% pure (HPLC). ESI-ion trap m/z: [M+2H]2+ = 1194.96 (calcd. 1194.65), [M+3H]3+ = 796.92 
(calcd. 796.77), [M+4H]4+ = 597.88 (calcd. 597.83).  
 
Synthesis of CysTat-peptide (CRKKRRQRRRG) (4.10) 
The Tat peptide was synthesized on Wang-resin and purified by HPLC as described above. MALDI-
TOF [M+H]+ = 1499.0 (calcd. 1498.9). 
 
Synthesis of (EIAALEK)3-CysTat (4.11) 
The (EIAALEK)3-SPhMe thioester 4.9 (956 Gg, 400 nmol) and Cys-Tat peptide 4.10 (750 Gg, 500 nmol) 
were dissolved in degassed ligation buffer (100 GL, 6 M GdnHCl, 200 mM Na2HPO4, 20 mM 
triscarboxyetylphosphine, 200 mM thiophenol, pH 7.7). The reaction was stirred under argon at room 
temperature and the progress of the reaction was monitored by HPLC and LCMS. After stirring for 20 h 
the product was purified by preparative HPLC. ESI-ion trap m/z: [M+5H]5+ = 754.00 (calcd. 753.43), 
[M+6H]6+ = 628.32 (calcd. 628.03), [M+7H]7+ = 538.64 (calcd. 538.45), [M+8H]8+ = 471.40 (calcd. 
471.27). 
 
Synthesis of (EIAALEK)3-CysTat fluorescein diacetate 5-maleimide (4.12) 
(EIAALEK)3-CysTat 4.11 (2 mg, 531 nmol) was dissolved in degassed phosphate buffer (100 GL, 100 
mM) and fluorescein diacetate 5-maleimide (1.06 Gmol, 542 Gg) dissolved in DMSO (2 GL) was added. 
The progress of the reaction was monitored by LCMS. After stirring overnight the reaction mixture was 
diluted with water (900 GL) and purified by HPLC. HR-ESI-TOF [M+H]+= 4274.085 (calcd. 4273.25). 
 
Expression and purification of GFP-(EIAALEK)3 (4.3, GFP-LZA) 
Expression of leucine zipper-tagged GFP 
E. coli BLR (DE3) cells containing a pET-15b plasmid carrying GFP-(EIAALEK)3 as a fusion gene with 
an N-terminal His-tag[20] were streaked on an LB agar plate supplemented with ampicillin (100 mg/L) 
and incubated at 37 °C overnight. One colony was picked and used to inoculate 2×YT medium (20 mL) 
containing ampicillin (100 mg/mL). After growing for one night at 37 °C, 0.1 OD unit (8.3 mL) of this 
pre-culture was added to 2xYT medium (500 mL) supplemented with ampicillin (100 mg/mL) and 
incubated at 37 °C for 140 min. (OD = 0.7). Then protein expression was induced by addition of IPTG 
(0.5 mL, 1 M) and incubated for 5 h at 30 °C.  
 
The sequence of the His-tagged GFP-leucine zipper fusion protein: 
MGSSHHHHHH SSGLVPRGSH MLEKREAEAG RLGAGGPVAT MVSKGEELFT GVVPILVELD GDVNGHKFSV SGEGEGDATY 
GKLTLKFICT TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL 
VNRIELKGID FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA DHYQQNTPIG DGPVLLPDNH 
YLSTQSALSK DPNEKRDHMV LLEFVTAAGI TLGMDELYTL AEIAALEKEI AALEKEIAAL EK 
 
Protein purification 
The protein expression culture was pelleted at 4,000 rpm and 4 °C for 15 min using a Sorvall RC-5 
centrifuge (Thermo Fischer, Breda, The Netherlands). The supernatant was discarded and the pellet 
stored at -20 °C. After thawing, the pellet was re-suspended in lysis buffer (25 mL, 50 mM Na2HPO4, 10 
mM imidazole and 300 mM NaCl, pH 8.0) on ice. To this suspension lysozyme (225 GL, 100 mg/mL in 
water) and PMSF (225 GL, 17 mg/mL in MeOH) were added. After gentle shaking at 4 °C for 30 min 
the suspension was sonicated (2x3 min at output 6 and 40% duty cycle) using a Branson Sonifier 250 
(Marius Instruments Nieuwegein, The Netherlands). The resulting cell lysate was spun at 1,000 rpm and 
4 °C for 30 min using a Sorvall RC-5 centrifuge (Thermo Fischer, Breda, The Netherlands). The pellet 
was discarded and the supernatant incubated with Ni-NTA agarose beads (washed twice with lysis buffer) 
at 4 °C for 1 h.  This suspension was added to a filter tube and the beads were allowed to settle on the 
filter. The flow-through was collected and re-incubated with Ni-NTA beads. The column was washed 
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with 20 column volumes of washing buffer (10 mL, 50 mM phosphate, 20 mM imidazole, 300 mM NaCl, 
pH 8.0) and then 6 column volumes of elution buffer (3 mL, 50 mM phosphate, 250 mM imidazole, 300 
mM NaCl, pH 8.0) to elute the GFP-LZA. Green fractions were combined and dialyzed against buffer 
(4×500 JL 10 mM phosphate pH 7.0) using 10 kDa MWCO centrifugal filters (Millipore, Cork, Ireland). 
The mass was verified by HR-ESI-TOF [M+H]+ m/z: 33371.8 (calcd. 33371.6) and the purity was 
checked by SDS-PAGE (10% acrylamide). 
 
Infrared spectroscopy 
Infrared spectroscopy was performed on a Thermo Wattson IR300 spectrometer, fitted with a Harrick 
ATR unit (Thermo Fischer, Breda, The Netherlands). Dry samples were compressed on the ATR crystal 
with a pressure of 0.5 kg. Infrared spectra were recorded for 32 scans at 4 cm-1 resolution and a sample 
gain of 1, and background-subtracted. 
 
Circular Dichroism Spectroscopy 
Circular dichroism  spectra of the separate leucine zippers (0.129 mM for LZA-Tat and 0.05 mM for LZB 
in 10 mM phosphate buffer, pH 7.0) were acquired at 20 °C on a Jasco J (190-256 nm at 0.5 nm intervals 
with a scanning speed of 50 nm/min and 2.0 seconds integration time). A 1:1 mixture of the two leucine 
zippers was made, based on UV absorption at 220 nm and spectra were obtained while heating from 4 
°C to 84 °C and back to 4 °C by cooling (measurement at every 10 °C).  
 
Confocal laser scanning microscopy and fluorescence cross-correlation spectroscopy  
Confocal laser scanning microscopy and fluorescence cross-correlation spectroscopy (FCCS) were 
performed on a TCS SP5 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped 
with an HCX PL APO 63×N.A. 1.2 water immersion lens and a fluorescence-correlation spectroscopy 
(FCS) unit. For confocal microscopy, cells were kept at 37 °C on a temperature-controlled microscope 
stage. GFP was excited with a 488 nm argon ion laser. Emission of GFP was collected using a 500-550 
nm detection range for confocal microscopy and with a 500-550 nm band-pass filter for FCCS 
measurements. S0387 and CellMask Deep Red were excited with a 633 nm HeNe laser. Emission for 
confocal microscopy was collected between 650 and 720 nm for S0387 and between 650 and 750 nm for 
CellMask Deep Red. For FCCS, emission of S0387 was collected with a 647-703 nm filter-block. 
Autocorrelation and cross-correlation measurements for FCCS were performed in a 384-well plate (175 
mm, low-base design, MMI, Eching, Germany). Autocorrelation and cross-correlation functions were 
calculated with an ISS VISTA software package (ISS, Illinois, USA). Fitting was performed according to 
a 3D-Gaussian model containing a triplet component for GFP and S0387. The particle number obtained 
from the fit was corrected for uncorrelated background.[32] 
 
Gtot(0) = 1 + 1/Napp = 1 + (1-CPSb/CPSt)2/Ncorr  
 
A similar model without a triplet component was used for cross-correlation analysis. To correct for bleed-
through effects of GFP into the S0387 channel, the true, corrected relative cross-correlation amplitude 
0;x/G0,g (green channel) was calculated by the method described by Bacia et al.[33] 
 
Relative cross-correlation amplitude (green) = 0;x/G0,g = ((G0;x/G0,g)  kGr(CPSg/CPSr))/(1  
kGr(CPSg/CPSr)) 
 
Where G0;x is the uncorrected cross-correlation amplitude at the diffusional autocorrelation time ()=0 
and G0,g the autocorrelation amplitude of GFP at =0. kGr corresponds to the bleed-through ratio of GFP 
from the green into the red channel, determined by taking the ratio of the counts per second (CPS) values 
in the red (S0387) and green (GFP) channel  (CPSr/CPSg). The relative cross-correlation amplitude for 
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the red channel was determined by dividing the corrected cross-correlation amplitude 0;x by the 
autocorrelation amplitude G0,r in the red channel: 
  
Relative cross-correlation amplitude (red) = 0;x/G0,g  
 
Since the dimensions of confocal detection volumes are wavelength-dependent, the relative cross-
correlation values never reach 1.0. Therefore, a double-labeled oligonucleotide, containing rhodamine 
green (RhG) and Cy5 as fluorophores, similar to an oligonucleotide published previously,[34] was included 
as positive control. To calculate the number of particles in a complex, values obtained with the double-
labeled oligonucleotide were used as a reference and defined as 100% association. 
 
Cellular uptake experiments 
Non-covalent and modular transduction 
Leucine zipper complexes were prepared in two steps. First, the leucine zippers (25 mM each) were 
mixed and incubated in phosphate buffer (10 mM, pH 7.0) at 4 °C for at least 5 min. Subsequently, 
complexes were diluted in HBS (10 mM HEPES, 135 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM 
CaCl2, pH 7.4) containing 5 mM glucose to the indicated concentrations. Controls with GFP and Tat 
were prepared in the same way, i.e. by first mixing solutions of these molecules with S0387-LZB-Tat or 
GFP-LZA respectively, followed by a dilution into HBS with glucose. Likewise, when incubation was 
carried out with GFP-LZA only, GFP-LZA was also first diluted to 25 mM and then further diluted into 
glucose-containing HBS to the indicated concentration. All cellular experiments were conducted with 
HeLa cells, which were seeded two days before the experiment in 8-well microscopy chambers (Nunc, 
Wiesbaden, Germany) at a density of 20,000 cells/well. At the time of the experiment, cells had grown to 
75% confluence. To determine whether cellular uptake of GFP-LZA was mediated by LZB-Tat, cells were 
first incubated with leucine zipper complexes (2.5 GM) or controls for 60 min at 37 °C, washed with 
serum-containing medium, and incubated for 5 min with the plasma membrane stain CellMask Deep 
Red (10 GL, 5 mg/ml). Then, cells were washed three times with serum-containing medium and imaged 
immediately by confocal laser scanning microscopy. This experiment was also performed with two 
additional heparin washes included (2×5 min with heparin, 500 mg/ml in HBS supplemented with 
glucose) to remove cell surface-bound leucine zippers with no apparent decrease in unspecific binding. 
To determine colocalisation of leucine zipper-tagged molecules, HeLa cells were incubated with GFP-
LZA and S0387-LZB-Tat (both 1.25 mM) for 60 min, washed three times with serum-containing medium 
and visualized by confocal laser scanning microscopy.  
Activatable leucine zipper-Tat 
Both fluorescent (EIAALEK)3-CysTat and the basic leucine zipper were dissolved in water at a 
concentration of 0.5 mM. The leucine zippers were mixed according to the scheme below, added to 
HeLa cells and incubated for 45 minutes at 37 °C. 
 
 (EIAALEK)3-CysTat / 
[GL] LZB / [GL] 
DMEM + 10% FCS 
(GL) 
LZA-Tat only 8 - 392 
LZA-Tat:LZB (1:1) 8 8 384 
LZA-Tat:LZB (1:10) 8 80 312 
 
The HeLa cells were seeded one day before the experiment in 8-well microscopy chambers (Nunc, 
Wiesbaden, Germany) at a density of 40,000 cells/well. At the time of the experiment, cells had grown to 
approximately 50% confluence. 
After incubation, the HeLa cells were washed with DMEM (3×400 (GL) and imaged immediately. 
Confocal laser scanning microscopy was performed using a Leica Microsystems TCS SP2 AOBS system 
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(Mannheim, Germany). Excitation of fluorescein was achieved with an argon laser [476 nm (29%), 488 
nm (39%), 496 nm (40%)] and the resulting emission was acquired between 510 and 700 nm as an 
average of two scans. 
The experiment was repeated in phosphate buffer (50 mM, pH 7.0) instead of medium, and also at 4 °C 
instead of 37 °C. 
 
Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) was carried out on an ITC200 (MicroCal, Northhampton, MA, 
USA). Peptides and proteins were dissolved in 10 mM phosphate buffer pH 7.0 and the desired samples 
were loaded into the sample cell and injection needle respectively after thorough cleaning of the 
instrument according to the manufacturer’s description. The reference cell was filled with 10 mM 
phosphate buffer pH 7.0. The titration experiment was carried out at 5 °C and stirring at 500 rpm as a 
series of 39 injections of 1.0 OL with a duration of 2.0 s and a spacing of 240 s. The integrals of the 
measured heat peaks were fitted to a one-site binding model using Origin 7.0 with a MicroCal ITC plug-
in, and the binding stoichiometry (N), association constant (K), molar enthalpy (H) and entropy (S) of 
binding were extracted. The following concentrations were used in the experiments described in this 
chapter:  
 
Titrant 0.23 mM Ac-(KIAALKE)3-NH2 (4.7) to 18.6 OM Ac-(EIAALEK)3-NH2 (4.8) in the sample cell. 
Titrant 0.24 mM LZB-Tat (4.6) to 24.0 OM GFP-LZA (4.3) in the sample cell. 
 
Blank measurements, in which 0.23 mM Ac-(KIAALKE)3-NH2 (4.7) or 0.24 mM LZB-Tat (4.6) was 
titrated into phosphate buffer, were also conducted to determine the heat contribution from dilution of 
the titrant. However, these heats were hardly detectable so the ITC experiments were not corrected for 
this insignificant contribution.  
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5.1  Introduction 
The popularity of the azide functionality has rocketed since the early 2000s with the discovery of 
the Staudinger ligation[1] and azide-alkyne click chemistry[2], which both involve azide reactants. 
These two ligation methodologies have proven particularly advantageous for ligation of 
biomolecules because of their chemo-specificity and mild conditions. Thus access to azide-
functionalized biomolecules is vital to exploit the full scope of these azide ligation methodologies.  
In peptide chemistry, azido-peptides are usually prepared by incorporation of 
azidonorleucine residues,[3] coupling azidocarboxylic acids to the N-terminus of the completed 
peptide[4] or azide functionalization of aldehyde resins affording C-terminal azido-peptides[5]. 
Alternatively, the N-terminus itself can be converted into an azide via a metal-catalyzed 
diazotransfer reaction using triflyl azide.[6] This reagent, however, is unstable and potentially 
explosive and requires a metal-ion catalyst which may be difficult to remove, even after HPLC 
purification.[6a] Recently, a number of safer, shelf-stable and easily prepared diazotransfer 
reagents have been developed,[7] of which imidazole-1-sulfonyl azide[7c,d] has been used to 
introduce azide moieties in proteins under copper-free conditions.[8] This diazotransfer reagent 
has not been applied in solid phase peptide chemistry before, except in a single transformation 
reported previously by us in chapter 4[9] and by Defrancq and co-workers to introduce azide 
moieties in a model oligonucleotide in a moderate yield.[10] 
Furthermore, diazotransfer reactions on solid support are poorly described in literature, so 
to acquire more knowledge on this matter it was decided to examine the scope of this reaction. 
For this exploration the focus was set on a fully PEG-based resin (NovaPEG) because of its 
supposedly superior properties compared to polystyrene based resins. This includes smoother 
synthesis of complex peptides on PEG-resins,[11] and very good swelling in a wide range of 
solvents including water[11-12], for example. The latter is of particular interest as imidazole-1-
sulfonyl azide is usually used under aqueous conditions or in polar organic solvents.[8,10,13]   
In this chapter, a protocol for a quick, easy and copper-free access to N-terminal azido-
peptides using imidazole-1-sulfonyl azide as a diazotransfer reagent is described. 
 
5 .2  Results  and discussion 
To study the solid phase diazotization of peptides using imidazole-1-sulfonyl azide 
hydrochloride[7c] (Scheme 5.1), a protected model peptide ALYKAG was prepared by standard 
Fmoc solid phase peptide synthesis[14] on a NovaPEG Rink resin (purity > 99%). The same 
ALYKAG-batch and the same resin/solvent ratio were used in all the experiments described 
below to allow a direct comparison of the diazotization results (a separate ALYKAG batch was 
prepared on polystyrene resin). To facilitate decarboxylation of any possible N-terminal 
carbamate moieties (leftover from Fmoc removal), the resin was washed with an HOBt solution 
prior to the diazotization. After the diazotransfer reaction the peptides were cleaved off the resin 
with trifluoroacetic acid containing thioanisole and triisopropylsilane as scavengers. It should be
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Scheme 5.1. The diazotization of XLYKAG on solid phase using imidazole-1-sulfonyl azide. Diazotization 
is performed on the side-chain protected peptide on solid phase, which subsequently is liberated from the 
resin. Throughout this report XAz denotes any of the 19 standard amino acids (excl. proline) containing an 
azide moiety as N-terminus. 
noted that thiol-scavengers must be avoided as these have been reported to reduce azides to 
amines.[15] The peptides were then precipitated in diethyl ether and analyzed by analytical 
reversed-phase HPLC. The amino-ALYKAG (ALYKAG) and azido-ALYKAG (AAzLYKAG) 
peaks were assigned by means of LCMS and the conversion efficiency was reported as the 
relative amount of azido-ALYKAG to amino-ALYKAG based on integration of their UV-
absorption peaks (assuming no significant change in the extinction coefficient of the peptides at 
215 nm). 
Mostly, the HPLC chromatograms showed only the two peaks from azido- and amino-
ALYKAG, though occasionally residual trifluoroacetic acid or thioanisole gave rise to an 
additional peak (Figure 5.1). 
 
 
Figure 5.1. Typical HPLC profile of diazotization of ALYKAG. The HPLC profile shows the ALYKAG 
peptides after 5 min of diazotransfer reaction with 3 equivalents of imidazole-1-sulfonyl azide 
hydrochloride. Amino-ALYKAG appears at 4 min and azido-ALYKAG at 13 min. 
 
5.2.1  Influence of copper on the reaction speed 
The diazotransfer reaction is known to be catalyzed by transition metals such as copper(II), so to 
establish the effect of copper(II) and the time frame of the diazotransfer reaction in general, a 
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kinetic experiment was performed. Two reactions were set up: one including a copper(II)-
catalyst and one without, from which samples of the resin-suspension were removed in the 
course of the reaction. After resin-cleavage and HPLC analysis, the conversion of amino-
ALYKAG to azido-ALYKAG was plotted as a function of time (Figure 5.2). As is clear from 
figure 5.2, the diazotransfer reaction is very fast as it reached its conversion maximum of around 
95% already after 10 min. Surprisingly, copper(II) does not seem to have a favorable effect on 
this conversion, neither on the rate nor on the overall conversion. Hence, copper(II) can be left 
out of the reaction, and accordingly the following experiments were performed without 
copper(II). Copper-free preparation of azido-peptides might be particularly interesting when the 
azido-peptides are to be used in cellular experiments, as copper is known to be cytotoxic even at 
low concentrations and complete removal of copper can be troublesome.[6a,16] 
 
 
Figure 5.2. Kinetics of the diazotization of ALYKAG on solid support. The conversion of amino-ALYKAG to 
azido-ALYKAG using 3 eq. imidazole-1-sulfonyl azide hydrochloride and 4.5 eq. K2CO3 in water was 
monitored over time. Each data point represents the relative conversion of amino-ALYKAG to azido-
ALYKAG (mean ± SD; n = 4). 
 
5.2.2 Variation of the amount of  diazotransfer reagent 
Even though a conversion of 95% is satisfactory, full conversion might be achieved if more 
diazotransfer reagent is used in the reaction. Hence, the diazotization efficiency was studied 
using one, three or five equivalents of the diazotransfer reagent (Figure 5.3). Since the volume 
was kept the same in all cases this equals a three- and fivefold increase in concentration going 
from one to three or five equivalents, respectively. From this study, it is clear that for the rate of 
reaction ‘more is better’ as one equivalent gives less conversion than three equivalents, which 
again gives less than five within a 30 min time frame. After 30 min there is, however, almost no 
difference in conversion between three and five equivalents, which gives 97 and 98%, 
respectively. This also points to the fact that in our hands even with five equivalents it was not 
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possible to achieve full conversion. It was speculated that the diazotransfer reagent might be 
rather unstable and might break down before all ALYKAG peptides have had time to react 
(though no breakdown of the diazotransfer reagent in solution was observed over time according 
to NMR, result not shown).  
 
 
Figure 5.3. Variation of the amount of diazotransfer reagent. The conversion of amino-ALYKAG to azido-
ALYKAG using 1, 3 or 5 equivalents of imidazole-1-sulfonyl azide hydrochloride and 1.5, 4.5 or 7.5 eq. 
K2CO3 in water was studied. Each bar (value shown inside the bars) represents the relative conversion of 
amino-ALYKAG to azido-ALYKAG (mean mean ± SD; n = 4). Error bars are within the bars when not 
visible.  
 
Figure 5.4. Two cycles of diazotization. A reaction with 3 eq. of imidazole-1-sulfonyl azide hydrochloride 
and 4.5 eq. K2CO3 was run for 30 min, after which the reaction mixture was replaced with a fresh solution 
of imidazole-1-sulfonyl azide hydrochloride and K2CO3. Samples were then taken after 1, 5 and 30 min. 
Each bar (value shown inside the bars) represents the relative conversion of amino-ALYKAG to azido-
ALYKAG (mean ± SD; n = 3). Error bars are within the bars when not visible. 
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Therefore, a reaction with three equivalents of diazotransfer reagent was run for 30 min after 
which the diazotransfer reagent was replaced with a fresh solution and samples were taken after 
1, 5 and 30 min (Figure 5.4). Unfortunately, this ‘double diazotransfer reaction’ cycle did not 
lead to full conversion either, as ‘only’ 98% conversion was observed.  
To assure that the remaining 2% of amino-ALYKAG was not caused by reduction of the 
azide-moiety during the resin cleavage reaction and thereby regeneration of the starting 
material, pure azido-ALYKAG peptide was subjected to the same cleavage conditions. 
However, no amino-ALYKAG or other byproducts were observed confirming that no reduction 
takes place (result not shown). A less likely explanation could be formation of imidazole-SO2-
NH-peptide or N3-SO2-NH-peptide byproducts, which hydrolyze back to the corresponding 
amine peptide during the cleavage reaction. However, to our knowledge, these species have 
never been reported when imidazole-1-sulfonyl azide is used in solution. Unfortunately, this 
leaves us with no explanation on why 2% of the amino-ALYKAG peptides evade diazotization. 
 
5.2.3 Variation of the N-terminal amino acid 
To verify that the diazotransfer reaction is not limited to Ala residues, XLYKAG (where X = 19 
different proteinogenic amino acids; Pro was omitted as this contains a secondary amine, which 
does not undergo diazotization) was prepared and diazotized (Figure 5.5). Of these 19 peptides 
only Cys(Trt) and Met did not produce clear amine to azide conversions. Met showed 
reasonable conversions, but LCMS analysis revealed that diazotization was accompanied by 
  
 
Figure 5.5. Variation of the N-terminal amino acid. Reactions with 3 eq. of imidazole-1-sulfonyl azide 
hydrochloride and 4.5 eq. K2CO3 for each XLYKAG (X = 18 diff. amino acids, excl. Pro) were set up and 
samples were taken after 1, 5 and 30 min. Each bar represents the relative conversion of amino-XLYKAG to 
azido-XLYKAG (mean ± SD; n = 3). Error bars are within the bars when not visible. 
Simple and efficient solid-phase preparation of azido-peptides 
 87 
oxidation of the Met moiety. No measures were taken, however, to circumvent or reverse this 
oxidation, e.g. by addition of mild reductants. That is, it might be possible to achieve non-
oxidized MLYKAG by optimizing the reaction conditions and/or cleavage cocktail.[17] 
HPLC analysis of diazotized CLYKAG showed that the diazotransfer reaction had led to 
formation of multiple products (not shown). Further analysis by LCMS indicated that these 
products might be disulfide-linked peptides consisting of amino- and azido-CLYKAG peptides 
(CAzLYKAG). Due to the complexity of the HPLC profiles no quantification of the conversion 
efficiency was attempted.  
The remaining 17 XLYKAG peptides, on the other hand, showed clear conversions 
between 60 and 97% (after 30 min). Remarkably, eight of these peptides exceeded conversions 
of 90% including some with the more sterically hindered amino acids such as His(Trt), Arg(pbf) 
and Leu at the N-terminus. However, Gly, the least hindered of all the amino acids, reached a 
conversion of only 81%. Mediocre conversions of glycine residues relative to other amino acids is 
not unprecedented in literature though. Van Woerkom and van Nispen, for example, reported 
average acylation efficiencies of Gly in their study of peptide couplings involving various N-
terminal amino acids on a growing peptide.[18] 
In this regard, it should be noted that a full kinetic experiment was not carried out for each 
of these XLYKAG peptides (only 1, 5 and 30 min as shown were included), so the reduced 
conversion efficiencies might as well reflect more sluggish reaction kinetics. Nevertheless, most of 
the peptides showing the lowest conversion efficiencies (Asn, Thr, Ser, Met) share a common 
feature, it seems, namely the presence of a hetero-atom in a short side-chain. Unfortunately, the 
lack of an exact mechanism of the diazotransfer reaction makes speculations on the role of these 
hetero-atoms futile.[19]  
 
5.2.4 Diazotization on polystyrene resin 
Since polystyrene resins are widely used in peptide synthesis, diazotization of ALYKAG was also 
attempted on a polystyrene resin. However, because of the hydrophobic nature of polystyrene, 
water could not be used as the main solvent, so DMF was used instead. K2CO3 was added to the 
reaction mixture as an aqueous solution to ease dissolution of K2CO3 (final solvent composition 
DMF-water 6.3:1). After 30 min only 26% conversion was observed on a polystyrene resin and 
surprisingly no conversion at all when NovaPEG resin was used under the same conditions 
(Figure 5.6A). 
It is not fully understood why the conversion efficiencies are so low but it might be related to the 
choice of base, K2CO3, which may exist as not fully dissociated ions under these rather non-
aqueous conditions. Eventually, this could lead to incomplete neutralization of the diazotransfer 
reagent hydrochloride salt, which would lead to severely reduced conversion efficiencies (result 
not shown). Consequently, K2CO3 was replaced with Hünig’s base (N,N-diisopropylethylamine), 
which in case of diazotransfer reactions on polystyrene resin gave conversions matching the best 
results obtained with NovaPEG resin under aqueous conditions (Figures 5.6B and 5.3). 
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Hence, peptides on polystyrene resin can also be diazotized using imidazole-1-sulfonyl azide 
under copper-free conditions with very good conversion efficiencies. NovaPEG resin also 
performed much better in DMF after substitution of K2CO3 with DIPEA though neither 
reaching the high levels achieved under aqueous conditions nor the level of the polystyrene resin 
under DMF/DIPEA conditions. This clearly indicates that DMF is not a good solvent for this 
PEG-based resin. 
 
A       B 
 
Figure 5.6. Diazotization of ALYKAG on polystyrene or NovaPEG resin using DMF and two different 
bases. A reaction with 3 eq. of imidazole-1-sulfonyl azide hydrochloride and 4.5 eq. K2CO3 (A) or DIPEA 
(B) was set up and samples were taken after 1, 5 and 30 min. Each bar (value shown inside the bars) 
represents the relative conversion of amino-ALYKAG to azido-ALYKAG (mean ± SD; n = 3). Error bars are 
within the bars when not visible. Bars representing NovaPEG coincide with the x-axis. 
 
5 .2.5 Solvent dependence 
In addition to the two solvents already used (DMF and water) for diazotransfer reactions on 
NovaPEG resin, dichloromethane and methanol were also evaluated. Dichloromethane was 
chosen to include an apolar solvent and because this solvent is often used in peptide chemistry. 
Methanol was included since this solvent is protic and ranks between dichloromethane and 
DMF in polarity (Figure 5.7). In dichloromethane azido-ALYKAG was barely detectable after 5 
min and after 30 min only 5% conversion was observed. In methanol the diazotization worked 
better, though still substandard, achieving a conversion of only 40% after 30 min. By 
comparison of all four solvents a clear trend seems to manifest itself: increasing solvent polarity 
leads to increased conversion efficiency. Solvent proticity on the other hand, seems to be less 
important for high conversions as DMF (non-protic) was better than methanol (protic solvent). 
These findings clearly demonstrate that water is the solvent of choice for diazotransfer reactions 
using the NovaPEG resin.  
DIPEA K2CO3 
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Figure 5.7. Diazotization of ALYKAG on NovaPEG in different solvents. A reaction with 3 eq. of imidazole-
1-sulfonyl azide hydrochloride and 4.5 eq. DIPEA (K2CO3 was used in the case of water) was set up and 
samples were taken after 1, 5 and 30 min. Each bar (value shown inside the bars) represents the relative 
conversion of amino-ALYKAG to azido-ALYKAG (mean ± SD; n = 3). Error bars are within the bars when 
not visible. 
 
5 .3  Conclusion 
It was demonstrated that imidazole-1-sulfonyl azide hydrochloride can be used to transform the 
N-terminus of a model peptide, ALYKAG, on a solid support into an azide moiety. This is 
accomplished in a quick, simple and efficient way and under metal-free conditions. Several 
solvent and resin combinations were tested of which NovaPEG resin under aqueous conditions 
and polystyrene resin in DMF were found to give the highest conversions, up to 98 and 95%, 
respectively.  
Thus, easy access to azido-peptides can be furnished by the easily prepared and shelf-stable 
imidazole-1-sulfonyl azide hydrochloride. This might earn this diazotransfer reagent a spot next 
to the Fmoc/Boc amino acids in the peptide lab, as azide introduction now can be accomplished 
without the need for azido amino acids or special preparation. 
 
5 .4 Experimental  procedures 
General 
NovaPEG Rink amide resin and polystyrene Rink amide resin were purchased from Novabiochem and 
Fmoc-L-amino acids from Bachem (Bubendorf, Switzerland) or Novabiochem (EMD Chemicals, 
Gibbstown, USA). All other chemicals were purchased from Baker, Fluka or Sigma Aldrich and used as 
received. Mass spectra were acquired on a Thermo Finnigan LCQ-Advantage MAX ESI-ion trap. 
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Peptide synthesis 
The peptides were synthesized on NovaPEG Rink amide or polystyrene Rink amide resins using a 
Labortec640 peptide synthesizer (Labortec, Bubendorf, Switzerland) and employing a standard Fmoc 
solid-phase peptide synthesis (SPPS) protocol.[14] Briefly, the resin was swollen in DMF for 20 min prior 
to use. The first and subsequent Fmoc groups were removed by washing the resin with piperidine in 
DMF (20%, v/v) and then shaking for 25 min with another portion of piperidine in DMF. The desired 
sequence of amino acids was coupled to the resin using Fmoc-L-amino acids (3.0 eq), 
diisopropylcarbodiimide (DIPCDI, 3.3 eq) and N-hydroxybenzotriazole (HOBt, 3.6 eq). Peptide 
couplings were followed to completion using the Kaiser test.[20]  After the final Fmoc removal the resin 
was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2, Et2O and air-dried for at least 2 h. 
 
Synthesis of ALYKAG 
The peptide was synthesized as describe above and a small amount of ALYKAG on resin (approx. 20 
mg) was suspended in cleavage mixture (500 EL, trifluoroacetic acid/water/triisopropyl-
silane/thioanisole 90:5:2.5:2.5) for 3 h. The free peptide was precipitated in Et2O, redissolved in water 
and analyzed by analytical HPLC. Retention time 3.88 min (99% pure). ESI-ion trap m/z: [M+H]+ = 
621.3 (calcd. 621.4), [M+2H]2+ = 311.3 (calcd. 311.2). 
 
Synthesis of XLYKAG (X = 18 different proteinogenic l amino acids, excluding Pro, Ala) 
A common batch of LYKAG (2.24 g resin, loading 0.23 mmol/g) was synthesized as described above and 
split into 18 portions of 100 mg each after the final Fmoc removal, solvent washes and air-drying. To 
each portion was coupled one of the 18 different amino acids using standard coupling conditions. After 
Fmoc removal a small amount of the XLYKAG on resin (approx. 20 mg each) was suspended in cleavage 
mixture (500 EL, trifluoroacetic acid/water/triisopropylsilane/thioanisole 90:5:2.5:2.5) for 3 h. The free 
peptide was precipitated from Et2O, redissolved in water and analyzed by analytical HPLC (typically 
99% pure). Analytical data (Table 5.1): 
 
 
Table 5.1. XLYKAG MS and HPLC data 
X = Calculated Measured Retention time (min) 
Arg 
[M+H]+ = 706.5, 
[M+2H]2+ = 353.8 
[M+H]+ = 706.4, 
[M+2H]2+ = 353.7 
3.2 
Asn 
[M+H]+ = 664.4, 
[M+2H]2+ = 332.7 
[M+H]+ = 664.3, 
[M+2H]2+ = 332.7 
3.8 
Asp [M+H]+ = 665.4 [M+H]+ = 665.3 3.8 
Cys 
(SS-dimer) 
[M+2H]2+ = 651.4, 
[M+3H]3+ = 434.6 
[M+2H]2+ = 652.4, 
[M+3H]3+ = 435.3 
12.5 
Gln 
[M+H]+ = 678.4, 
[M+2H]2+ = 339.7 
[M+H]2+ = 678.3, 
[M+2H]2+ = 339.7 
3.7 
Glu 
[M+H]+ = 679.4, 
[M+2H]2+ = 340.2 
[M+H]+ = 679.3, 
[M+2H]2+ = 340.2 
3.8 
Gly 
[M+H]+ = 607.4, 
[M+2H]2+ = 304.2 
[M+H]+ = 607.3, 
[M+2H]2+ = 304.2 
3.8 
His 
[M+H]+ = 687.4, 
[M+2H]2+ = 344.2 
[M+H]+ = 687.3, 
[M+2H]2+ = 344.3 
3.1 
Ile 
[M+H]+ = 663.4, 
[M+2H]2+ = 332.2 
[M+H]+ = 663.4, 
[M+2H]2+ = 332.3 
5.6 
Leu 
[M+H]+ = 663.4, 
[M+2H]2+ = 332.2 
[M+H]+ = 663.4, 
[M+2H]2+ = 332.3 
7.1 
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Lys 
[M+H]+ = 678.4, 
[M+2H]2+ = 339.7 
[M+H]+ = 678.4, 
[M+2H]2+ = 339.7 
3.0 
Met* 
[M+H]+ = 681.4, 
[M+2H]2+ = 341.2 
[M+H]+ = 681.3, 
[M+2H]2+ = 341.2 
5.6 
Phe 
[M+H]+ = 697.4, 
[M+2H]2+ = 349.2 
[M+H]+ = 697.3, 
[M+2H]2+ = 349.2 
11.6 
Ser 
[M+H]+ = 637.4, 
[M+2H]2+ = 319.2 
[M+H]+ = 637.4, 
[M+2H]2+ = 319.3 
3.9 
Thr 
[M+H]+ = 651.4, 
[M+2H]2+ = 326.2 
[M+H]+ = 651.3, 
[M+2H]2+ = 326.2 
3.7 
Trp 
[M+H]+ = 736.4, 
[M+2H]2+ = 368.7 
[M+H]+ = 736.3, 
[M+2H]2+ = 368.7 
12.5 
Tyr 
[M+H]+ = 713.4, 
[M+2H]2+ = 357.2 
[M+H]+ = 713.4, 
[M+2H]2+ = 357.3 
6.3 
Val 
[M+H]+ = 649.4, 
[M+2H]2+ = 325.2 
[M+H]+ = 649.3, 
[M+2H]2+ = 325.3 
4.2 
 
 
Reverse phase HPLC analysis and LCMS 
Analytical HPLC was performed on a Shimadzu LC-20A Prominence system (Shimadzu, ‘s- 
Hertogenbosch, The Netherlands) equipped with a C18 ReproSil column, 150×3 mm, particle size 3 Gm 
(Screening Devices, Amersfoort, The Netherlands). Elution of the peptides was achieved with 
MeCN/water gradient containing 0.1% trifluoroacetic acid (5-100%, 1-50 min, flow 0.4 mL/min). The 
desired peaks were integrated manually using a LabSolutions software package (Shimadzu, ‘s- 
Hertogenbosch, The Netherlands). LCMS was performed on a Thermo Finnigan LCQ-Fleet ESI-ion 
trap (Thermo Fischer, Breda, The Netherlands) equipped with an Alltima C18 column, 2.1×150 mm, 
particle size 3 Gm (Alltech Applied Sciences BV, Breda, Netherlands) using the same gradient as used for 
HPLC, only trifluoroacetic acid was replaced with formic acid. 
 
General procedure for on-resin diazotization  
The ALYKAG peptide on NovaPEG resin was swollen in DMF for 5 min and then incubated in HOBt 
(1 M in DMF) for 30 min. Subsequently, the resin was washed with 20% piperidine in DMF, DMF, 
CH2Cl2, i-PrOH, CH2Cl2, i-PrOH, water (in case of reactions in MeOH or CH2Cl2, water was replaced 
with MeOH or CH2Cl2, respectively). In all experiments the ratio between resin and solvent (water) was 
kept constant at 12 GL solvent/mg resin. In most experiments (indicated if otherwise) imidazole-1-sulfonyl 
azide hydrochloride (3.0 eq.) and K2CO3 (4.5 eq.) were prepared as two separate aqueous solutions each 
corresponding to 12.5% of the total volume (freshly made prior to each experiment[21]). The remaining 
water (75% of the total volume) was added to the resin and the mixture was shaken for 5 min. The 
reaction was initiated by addition of the imidazole-1-sulfonyl azide hydrochloride and K2CO3 solutions to 
the resin and the resulting suspension was shaken. After a desired amount of time, a sample was removed 
with a pipette, added to a filter tube and washed extensively with water. After removal of the last sample, 
all samples were washed with i-PrOH, CH2Cl2, i-PrOH, CH2Cl2, Et2O and air-dried for at least 2 h. The 
dry resins were then suspended in cleavage mixture (500 GL, trifluoroacetic acid/water/triisopropyl-
silane/thioanisole 90:5:2.5:2.5) for 3h. The free peptide was precipitated from Et2O, redissolved in water 
and analyzed by analytical HPLC. Analytical data for azido-ALYKAG: Retention time 13.72 min (99% 
pure). ESI-ion trap m/z: [M+H]+ = 648.28 (calcd. 647.34). 
All diazotization reactions described herein follow this general protocol. Only deviations from this 
protocol are described below. 
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When amounts of resin are stated in the sections below, this represents the total weight of resin, peptide 
and protecting groups, whereas the molar amounts refer to the molar amount of peptide. 
 
Kinetics of diazotization 
ALYKAG on NovaPEG resin (150 mg, loading 0.23 mmol/g, 29.4 Amol) was suspended in water (1.8 
mL) and K2CO3 (132 Amol, 24.3 mg) and imidazole-1-sulfonyl azide hydrochloride (87.9 Amol, 18.4 mg) 
were added in this order. Samples (150 AL) were taken after 15 sec., 30 sec., 1 min, 2 min, 3 min, 4 min, 
5 min, 7 min, 10 min, 30 min and 60 min. A similar reaction was carried out in which CuSO4 (2.9 Amol, 
0.73 mg) was added as well before addition of imidazole-1-sulfonyl azide hydrochloride. All experiments 
were performed in quadruplicate. 
 
Variation of the amount of diazotransfer reagent 
Three experiments with 1, 3 or 5 equivalents of imidazole-1-sulfonyl azide hydrochloride (n = 1, 3 or 5) 
were performed. ALYKAG on NovaPEG resin (50 mg, loading 0.23 mmol/g, 9.76 Amol) was suspended 
in water (600 – [20 + 22.2]×n) AL. Then an aqueous solution (0.88 M) of K2CO3 (22.2×n) AL was added, 
followed by an aqueous solution (0.49 M) of imidazole-1-sulfonyl azide hydrochloride (20×n) AL. Samples 
(200 AL) were taken after 1, 5 and 30 min. All experiments were performed in quadruplicate. 
 
Two cycles of diazotization 
ALYKAG on NovaPEG resin (40 mg, loading 0.23 mmol/g, 7.81 Amol) was suspended in water (392 
AL). Then an aqueous solution of K2CO3 (0.88 M, 35.2 Amol, 40 AL) was added, followed by an aqueous 
solution of imidazole-1-sulfonyl azide hydrochloride (0.49 M, 23.5 Amol, 48 AL). The reaction was shaken 
for 30 min after which the reaction solution was removed and the resin washed extensively with water. 
Fresh amounts of water, imidazole-1-sulfonyl azide hydrochloride and K2CO3 were added and samples 
(160 AL) were taken after 1, 5 and 30 min. All experiments were performed in triplicate. 
 
Diazotization on NovaPEG or polystyrene resin in DMF using K2CO3 as base 
ALYKAG on polystyrene resin (50 mg, loading 0.39 mmol/g, 15.0 Amol) was suspended in DMF (417 
AL). Then an aqueous solution of K2CO3 (0.88 M, 67.4 Amol, 76.6 AL) was added, followed by a solution 
of imidazole-1-sulfonyl azide hydrochloride in DMF (0.49 M, 45.0 Amol, 91.9 AL). ALYKAG on 
NovaPEG (50 mg, loading 0.23 mmol/g, 9.76 Amol) was treated similarly, only less reagents were added 
as the loading was lower, hence water and DMF were added to compensate for this. Samples (200 AL) 
were taken after 1, 5 and 30 min. All experiments were performed in triplicate. 
 
Diazotization on NovaPEG or polystyrene resin in DMF using DIPEA as base 
ALYKAG on polystyrene resin (50 mg, loading 0.39 mmol/g, 15.0 Amol) was suspended in DMF (496 
AL). Then DIPEA (67.4 Amol, 11.7 AL) was added followed by a solution (0.49 M) of imidazole-1-sulfonyl 
azide hydrochloride in DMF (0.49 M, 45.0 Amol, 91.9 AL). ALYKAG on NovaPEG (50 mg, loading 0.23 
mmol/g, 9.76 Amol) was treated similarly, only less reagents were added as the resin loading was lower, 
hence DMF was added to compensate for this. Samples (200 AL) were taken after 1, 5 and 30 min. All 
experiments were performed in triplicate. 
 
Diazotization on NovaPEG resin in MeOH using DIPEA as base 
Performed as described above for NovaPEG resin in DMF. 
 
Diazotization on NovaPEG resin in CH2Cl2 using DIPEA as base 
Imidazole-1-sulfonyl azide hydrochloride only dissolves sparingly in CH2Cl2 so to overcome this DIPEA 
(366 Amol, 63.8 AL) was added to a suspension of imidazole-1-sulfonyl azide hydrochloride (51.2 mg, 244 
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Gmol) in CH2Cl2 (436 GL) leading to a clear solution. The required amount of this solution (60 GL) was 
added immediately to ALYKAG on NovaPEG resin (50 mg, loading 0.23 mmol/g, 9.76 Gmol) suspended 
in CH2Cl2 (540 GL) and the remainder disposed. Samples (200 GL) were taken after 1, 5 and 30 min. All 
experiments were performed in triplicate. 
 
Diazotization of XLYKAG – variation of the N-terminal amino acid 
XLYKAG (20 mg, loading 0.23 Gmol/g) on NovaPEG resin was suspended in water (196 GL). Then an 
aqueous solution of K2CO3 (0.88 M, 17.5 Gmol, 19.9 GL) was added, followed by an aqueous solution of 
imidazole-1-sulfonyl azide hydrochloride (0.49 M, 11.7 Gmol, 23.9 GL). Samples (80 GL) were taken after 
1, 5 and 30 min. All experiments were performed in triplicate. Analytical data (Table 5.2). 
 

Table 5.2. XAzLYKAG MS and HPLC data  
X = Caculated Measured Retention time (min) 
Arg 
[M+H]+ = 732.42, 
[M+2H]2+ = 366.71 
[M+H]+ = 732.28 
[M+2H]2+ = 366.68 
11.64 
Asn 
[M+H]+ = 690.36, 
[M+2H]2+ = 345.68 
[M+H]+ = 690.32, 
[M+2H]2+ = 345.52 
11.88 
Asp [M+H]+ = 691.35 [M+H]+ = 691.32 11.83 
Cys* 
(SS-dimer) 
[M+H]+ = 678.33 [M+H]+ = 678.36 22.18 
Gln 
[M+H]+ = 704.38, 
[M+2H]2+ = 352.69 
[M+H]+ = 704.32, 
[M+2H]2+ = 352.48 
11.60 
Glu [M+H]+ = 705.36 [M+H]+ = 705.32 13.42 
Gly [M+H]+ = 633.34 [M+H]+ = 633.28 11.92 
His 
[M+H]+ = 713.38, 
[M+2H]2+ = 357.19 
[M+H]+ = 713.20, 
[M+2H]2+ = 357.12 
7.32 
Ile [M+H]+ = 689.40 [M+H]+ = 689.36 20.99 
Leu [M+H]+ = 689.40 [M+H]+ = 689.36 16.99 
Lys 
[M+H]+ = 704.41, 
[M+2H]2+ = 352.71 
[M+H]+ = 352.64, 
[M+2H]2+ = 704.24 
11.22 
MetO and 
MetO2 
[M+H]+ = 723.35, 
[M+H]+ =739.35 
[M+H]+ = 723.28, 
[M+H]+ =739.28 
MetO2: 12.43 
MetO: 13.10 
Phe [M+H]+ = 723.39 [M+H]+ = 723.32 17.21 
Ser [M+H]+ = 663.35 [M+H]+ = 663.28 11.16 
Thr [M+H]+ = 677.37 [M+H]+ = 677.32 10.98 
Trp [M+H]+ = 762.40 [M+H]+ = 762.36 17.34 
Tyr [M+H]+ = 739.38 [M+H]+ = 739.32 15.33 
Val [M+H]+ = 675.39 [M+H]+ = 675.32 15.90 
* Contains mixtures of disulfide-linked peptides. 
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6.1  Introduction 
Cell-penetrating peptides (CPPs) have shown great potential in delivery of a large variety of 
objects into cells, ranging from small molecules to large supra-molecular assemblies like 
liposomes.[1] For this reason they have received a lot of interest as prospective drug delivery 
agents. However, the inherent lack of cell-specificity of CPPs has limited their pharmaceutical 
usage so far.[2] For this reason several strategies to add specificity to CPP-based delivery systems 
have been developed, based on pH-[3] or enzyme-induced CPP activation[4] as well as on fusion 
of cell-specific targeting peptides[5] to the CPPs.[6]  
In a pH controlled activation strategy the pH drop in the microenvironment around tumor 
tissue is exploited either to trigger a deshielding of CPPs immobilized on a delivery vehicle[3b-f] or 
to protonate the CPPs enabling cell adhesion.[3a] This is a very efficient way of CPP activation, 
though it necessitates a pH difference between the target tissue and normal tissue, which only 
applies to a limited number of pathological conditions.[7]    
Fusion of CPPs to cell targeting peptides on the other hand offers very selective targeting of 
the desired tissue as cells present surface proteins, which are unique to particular cell-types.[8] 
The disadvantage of this strategy, however, is that these surface proteins are often present in low 
numbers and that binding to these may interfere with cell signaling pathways.[5b,9] 
Enzyme activatable CPPs serve as a particular interesting targeting strategy since they 
combine the best of both worlds, i.e. the efficiency of the pH activation approach and specificity 
of cell targeting peptides. In this regard, the specificity and efficiency stem from the activation 
process, which is catalyzed by specific cell-surface enzymes potentially leading to activation of 
CPPs in a very short time and in a designated area. As a result, the CPPs will be taken up 
primarily in areas where the specific surface enzymes are present. 
Interestingly, a mutation study of Tat, RKKRRQRRR, by Wender and colleagues has 
shown that substitution of either one of the two lysine residues with alanine leads to severe 
reduction of its cell adhesion ability.[10] Hence it might be anticipated that attachment of 
enzyme-cleavable sequences at these lysine side-chains will lead to a similar ‘inactivation’. To 
put this unprecedented enzyme-strategy to the test the two surface-expressed peptidase enzymes, 
aminopeptidase N (APN)[11] and dipeptidyl peptidase IV (DPPIV)[12], were selected as model-
enzymes as both are involved in various pathological conditions. That is, expression of both 
DPPIV and APN is upregulated on multiple types of cancer cells.[13] Moreover, APN serves as a 
receptor for some virus infections[14] and DPPIV is expressed on several immune cells when 
these are activated during immune responses.[15] 
These two peptidases also exhibit very interesting substrate selectivities with a degree of 
complementarity as DPPIV preferentially cleaves Xxx-Pro dipeptides from the N-terminus of 
peptides,[16] whereas APN cleaves almost all unacylated amino acids except proline.[17] Hence 
Tat peptides inactivated with sequences recognized by these enzymes might serve as a way to 
target these particular pathological conditions. 
In this chapter an approach to inactivate a cell-penetrating peptide, Tat, by conjugating di- 
or tri-peptides to the lysine side-chains in Tat is described. Subsequently, the Tat peptide can be 
reactivated by cleaving off the peptides by treatment with the appropriate enzyme (Scheme 6.1).  
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Scheme 6.1. Enzymatic activation of an inactivated Tat peptide. Di- or tri-peptides (represented as dark 
grey strands) on the lysine side-chains in the cell-penetrating peptide Tat (represented as a light grey screw) 
lead to its inactivation. Enzymatic removal (represented as two handsaws) of the di- or tri-peptides results in 
reactivation of the Tat peptide. 
 
6.2 Results and discussion 
6.2.1  Preparation of enzyme-activatable Tat-peptides 
Three different enzyme-activatable Tat-peptides with dipeptides (RP or GP) or tripeptides 
(AFK) coupled to the lysine side-chains were prepared. These are denoted Tat(2×GP), 
Tat(2×RP) and Tat(2×AFK) hereinafter. Furthermore, the peptides were acetylated at the N-
terminus to prevent degradation of the Tat peptide by the peptidases. The dipeptide RP was 
selected because Mutter and colleagues were able to use DPPIV to cleave RP from the N-
terminus of an unnatural O-acyl isopeptide.[18] However, the introduction of two arginine 
residues might not be the best approach for inactivation of Tat, as arginine residues favor cell-
adhesion. Hence a dipeptide, GP, without charged side-chains was also included. AFK modified 
Tat peptides were available already, as they had been prepared for other purposes. Nevertheless, 
they were expected to emerge as good substrates for APN, as this enzyme exhibits rather broad 
substrate specificity.   
To prepare the desired enzyme-activatable Tat-peptides, one common Tat peptide 6.1 
containing two lysine residues with Alloc-protected side-chains was prepared by standard Fmoc 
solid phase peptide synthesis (SPPS, Scheme 6.2). After acetylation of the N-terminus, the Alloc-
groups were removed in a palladium-catalyzed allylic substitution reaction (Tsuji-Trost 
reaction).[19] Subsequently, the lysine side-chains were modified with two RP, GP or AFK 
tripeptides via SPPS ending with an N-terminally Boc-protected amino acid. The latter ensures 
that global deprotection and cleavage from the resin affords Tat peptides with the RP-, GP- and 
AFK-modifications having free N-termini 6.4-6.7. A Tat peptide containing two azido-
norleucine, Tat(2×N3) residues 6.8 was prepared as well to investigate the importance of the 
lysine side-chain amino-groups on cellular uptake. This peptide was prepared by solid-phase 
diazotization (see chapter 4) after removal of the Alloc-protection groups (Scheme 6.2-6.3). The 
peptides were then treated with trifluoroacetic acid to deprotect them globally and cleave them 
from the resin. After precipitation in diethyl ether, the peptides were conjugated to fluorescein 
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diacetate 5-maleimide in solution (Scheme 6.3) and purified by HPLC. Only Tat, Tat(2×N3), 
Tat(1×AFK) and Tat(2×AFK) were labeled due to time constraints. 
 
 
 
 
Scheme 6.2. Preparation of the enzyme-activatable Tat peptides. The common Tat peptide 6.1 was 
synthesized via SPPS and the lysine side-chains deprotected allowing branching of the Tat peptide with 
AFK, RP or GP sequences (6.4-6.7). Diazotization of the lysine side-chains afforded Tat-peptides containing 
azido-norleucine residues denoted in the scheme as a formal addition of N2
+ and loss of a proton (6.8). 
 
 
 
 
Scheme 6.3. Solution labeling of the Tat-peptides. Fluorescein diacetate 5-maleimide was conjugated to 
the cysteine residue in the peptides. 
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6.2.2 Functionality evaluation of the inactivated Tat-peptides 
The functionality of the Tat-peptides, i.e. their ability to adhere to and penetrate cells, was 
evaluated by means of flow cytometry and confocal laser scanning microscopy (CLSM), 
respectively. Flow cytometry (Fig. 6.1) showed that Tat peptides with unmodified lysine side-
chains 6.9 were taken up extensively, as expected. This is in sharp contrast to the Tat(2×AFK) 
peptides containing two AFK tripeptides 6.11, which showed almost complete loss of their cell 
penetration ability. That is, the Tat peptides were successfully inactivated by modification of the 
lysine side-chains. Interestingly, Tat-peptides containing only one AFK-tripeptide 6.10 
(probably as a mixture of the two AFK regio-isomers, as this was obtained as a side-product) 
were blocked as efficiently as Tat with two AFK tripeptides. When this result is compared to the 
alanine mutation study by Wender,[10] it appears that blocking a single lysine with AFK is more 
than double as effective as one lysinealanine substitution. Unfortunately, double mutations 
were not reported in this study. This clearly demonstrates the potential of (temporarily) blocking 
the lysine side-chains in Tat; in fact, blocking just a single lysine side-chain seems to be sufficient 
to inactivate it. Presumably, the mere presence of a branch in the Tat peptide prevents the 
intimate contact with the cell membrane required for cell adhesion and uptake. This is 
supported by the fact that cellular uptake decreased despite the total positive charge of Tat 
increased because of the AFK tripeptides. The most efficient inactivation, however, was 
observed for Tat peptides with decreased positive charge [Tat(2×N3), 6.12] caused by 
diazotization of the leucine residues. Additional experiments might reveal whether the 
differences between the Tat peptides with AFK tripeptides and Tat(2×N3) are in fact significant. 
Overall, these findings emphasize the importance of the two lysine side-chain amino-groups for 
the activity of Tat, as neither their charge (azido-norleucine replacement) nor steric position 
 
 
Figure 6.1. Cellular uptake of the Tat peptides. Adherent HeLa cells were treated with fluorescein-labeled 
Tat-peptides, detached by treatment with trypsin and the cellular fluorescence intensity measured by flow 
cytometry. Results are from a single experiment.   
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Figure 6.2. Cellular adhesion and uptake. HeLa cells were treated with the different Tat-peptides and the 
adhesion and uptake were evaluated by confocal laser scanning microscopy by means of fluorescein 
fluorescence (red color). The top left and right corners show the fluorescence and transmission images, 
respectively. The lower left corner shows an overlay of these two images  
AFK modification) could be compromised. The successful inactivation approach was also 
studied by CLSM as this technique allows visualization of Tat peptides inside cells as well as 
peptides adhered to the cell surfaces. The reason for this is that in CLSM, contrary to flow 
cytometry, no trypsin treatment is applied, which hydrolyzes surface-adhered peptides. The 
CLSM images (Fig. 6.2) showed that Tat peptides with unmodified lysine side-chains showed 
extensive cell-adhesion and uptake confirming the flow cytometry findings. Similarly, none of the 
other peptides (AFK modified Tat peptides [1× and 2×AFK] or Tat peptides containing azido-
norleucine) showed any binding or uptake demonstrating that their cell binding ability was 
completely abolished. 
 
6.2.3 Enzymatic activation of the inactivated Tat-peptides 
To test whether the RP-, GP- and AFK-inactivated Tat-peptides can be re-activated 
enzymatically, unlabeled Tat peptides 6.3-6.7 were treated with aminopeptidase N (APN) and 
dipeptidyl peptidase IV (DPPIV), and studied by liquid chromatography mass spectrometry 
(LCMS). 
First, APN and DPPIV were examined for peptidase activity towards acetylated Tat 6.3 to 
verify that Tat itself withstands the peptidases. As expected, no conversion could be observed for 
either of the two peptidases (result not shown). In addition, APN and DPPIV did not exhibit any 
cross-reactivities; i.e. APN and DPPIV did not cleave Tat modified with RP/GP dipeptides or 
AFK tripeptides, respectively. 
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Figure 6.3. Enzymatic activation of Tat(2×AFK) with aminopeptidase N. Crude Tat(2×AFK) was analyzed 
by LCMS before (top) and after (bottom) treatment with aminopeptidase N (only MS component shown). 
The raw MS spectrum (left) was deconvoluted yielding the spectrum at the right, in which the expected 
masses of the assigned peaks are shown in parentheses.    
Unfortunately, AFK-inactivated Tat 6.5 did not appear to be a very good substrate for APN 
either, despite the free amino-termini at the AFK-tripeptides (Fig. 6.3). In fact, only a single 
alanine residue seemed to be cleaved off by APN. Both peptides co-eluted in the LCMS so no 
proper quantification of the conversion degree could be performed, but according to the MS 
component of the LCMS this imperfect activation of Tat was not even complete. To clarify 
whether this lack of APN activity is a result of AFK being a poor substrate or the inability of 
APN to process sequences linked to the lysine side-chains, other peptide sequences will have to 
be examined. In this regard, it would also be interesting to study to which extent a single amino 
acid on one of the two lysine residues is able to inactivate Tat, as this would require cleavage of a 
single peptide bond only to activate the Tat peptide. 
DPPIV, however, showed notable activity towards its substrates, as neither Tat(2×RP) 6.6 
nor Tat(2×GP) 6.7 peptides could be detected by MS after incubation with the peptidase 
(LCMS did not provide any separation of the peptides). Remarkably, DPPIV facilitated 
complete conversion into Tat when Tat(2×RP) peptides were evaluated. For Tat(2×GP) 
peptides efficient conversion was observed, yielding a mixture of Tat and Tat(1×GP) peptides.
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Figure 6.4. Enzymatic activation of Tat(2×RP) with dipeptidyl peptidase IV. Crude Tat(2×RP) was analyzed 
by LCMS before (top) and after (bottom) treatment with dipeptidyl peptidase IV (only MS component 
shown).  The raw MS spectrum (left) was deconvoluted yielding the spectrum at the right, in which the 
expected masses of the assigned peaks are shown in parentheses. 
However, a less despite being the best substrate for DPPIV, Tat(2×RP) might not be the best 
candidate for inactivation of Tat as the introduction of two arginine residues might increase cell 
adhesion. To answer this question, additional flow cytometry and confocal laser scanning 
microscopy experiments are required; these will be carried out in time to come. In case 
substantial cell adhesion is observed, inactivation of Tat using only one RP or GP dipeptide 
might be an effective strategy, as flow cytometry of Tat(1×AFK) 6.10 showed that blocking one 
lysine residue in Tat is sufficient to inactivate it. 
Overall, these preliminary studies have demonstrated that blocking the lysine side-chains in 
Tat with small enzyme-cleavable peptide sequences is a very promising strategy for the 
development of enzyme-activatable Tat peptides.  
However, one important issue which needs to be addressed is the stability of the inactivated 
Tat peptides in vivo, where the presence of a multitude of proteases may lead to premature 
activation, and thereby loss of the targeting potential. 
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Figure 6.5. Enzymatic activation of Tat(2×GP) with dipeptidyl peptidase IV. Crude Tat(2×GP) was 
analyzed by LCMS before (top) and after (bottom) treatment with dipeptidyl peptidase IV (only MS 
component shown). 
 
6.3 Conclusion 
The preliminary study presented in this chapter on the development of a novel enzyme-
activatable cell-penetrating peptide, demonstrated the potential of temporarily blocking the 
lysine residues in the cell-penetrating peptide, Tat. Flow cytometry and confocal laser scanning 
microscopy showed that blocking one or two of the lysine residues with AFK tripeptides led to 
almost complete loss of cell adhesion and uptake. Regrettably, the AFK tripeptide could not be 
removed enzymatically using the model enzyme aminopeptidase N (APN). Two dipeptides GP 
and RP, on the other hand, could be removed by the enzyme dipeptidyl peptidase IV (DPPIV) 
thereby demonstrating the feasibility of this strategy.  
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6.4 Experimental  procedures 
General 
NovaPEG Rink amide resin was purchased from Novabiochem and Fmoc-L-amino acids from Bachem 
(Bubendorf, Switzerland) or Novabiochem (EMD Chemicals, Gibbstown, USA). Dipeptidyl peptidase IV 
(porcine kidney, EC 3.4.14.5) was from Sigma Aldrich and aminopeptidase N (Rat, EC 3.4.11.2) from 
Calbiochem (Merck, Darmstadt, Germany). All other chemicals were purchased from Baker, Fluka or 
Sigma Aldrich and used as received.  
 
Reverse phase HPLC peptide purification and liquid chromatography mass spectrometry 
Semi-preparative HPLC was performed on a Shimadzu LC-20A Prominence system (Shimadzu, ‘s-
Hertogenbosch, The Netherlands) equipped with a C18 ReproSil column, 250x10 mm, particle size 5 
m (Screening Devices, Amersfoort, The Netherlands). Elution of the peptides was achieved with a 
MeCN/water gradient containing 0.1% trifluoroacetic acid (5-100%, 1-50 min, flow 4 mL/min). The 
fractions were analyzed by liquid chromatography mass spectrometry using a Thermo Finnigan LCQ-
Fleet ESI-ion trap (Thermo Fischer, Breda, The Netherlands) equipped with an Alltima C18 column, 
2.1×150 mm, particle size 3 m or an Alltima C18 column, 2×50 mm (Alltech Applied Sciences BV, 
Breda, Netherlands) using the same gradient as used for HPLC (trifluoroacetic acid was replaced with 
formic acid) or a shorter gradient (3-100%, 3-10 min), respectively. The collected fractions containing the 
desired peptide were pooled, evaporated until the volume was halved and lyophilized.  
 
Synthesis of Alloc-protected Tat (6.1) 
The Alloc-protected Tat peptide 6.1 with the sequence Ac-Gly-Arg-Lys-(Alloc)-Lys(Alloc)-Arg-Arg-Gln-
Arg-Arg-Arg-(-Ahx)-Cys-NH2 was synthesized on a NovaPEG Rink amide resin (2 mmol scale) using a 
Labortec640 peptide synthesizer (Labortec, Bubendorf, Switzerland) and employing a standard Fmoc 
solid-phase peptide synthesis (SPPS) protocol.[20] Briefly, the resin was swollen in DMF for 20 min prior 
to use. The first and subsequent Fmoc groups were removed by washing the resin with piperidine in 
DMF (20%, v/v) and then shaking for 25 min with another portion of piperidine in DMF. The desired 
sequence of amino acids was coupled to the resin using Fmoc-L-amino acids (3.0 eq), 
diisopropylcarbodiimide (DIPCDI, 3.3 eq) and N-hydroxybenzotriazole (HOBt, 3.6 eq). Peptide 
couplings were followed to completion using the Kaiser test.[21]  After the final Fmoc removal the N-
terminus was acetylated by agitation in a mixture of pyridine (1 mL) and acetic anhydride (1 mL) in DMF 
for 5 min. Afterwards, the resin was washed with DMF, CH2Cl2, i-PrOH, CH2Cl2, Et2O and dried in 
vacuo. A small sample of the resin (~ 10 mg) was removed to verify the peptide composition, suspended in 
trifluoroacetic acid/water/triisopropylsilane/thioanisole (90:5:2.5:2.5, v/v) and stirred for 20 h at rt. 
Then the resin was filtered off and the filtrate was precipitated from Et2O, redissolved in water and 
lyophilized yielding the crude peptide 6.1 as a white powder. ESI-ion trap m/z: [M+3H]3+ = 608.56 
(calcd. 608.02), [M+4H]4+ = 456.96 (calcd. 456.26), [M+5H]5+ = 365.92 (calcd. 365.21). 
 
Alloc removal and synthesis of Tat (6.2 and 6.3) 
The NovaPEG resin carrying Alloc-protected Tat 6.1 was suspended in CHCl3/AcOH/N-
methylmorpholine (37:2:1) in a flame-dried round-bottomed flask. Pd(PPh3)4 (389 Gmol, 450 mg) from a 
new bottle was added and stirred for 20 h under Ar at rt. The resin was then washed with the following 
sequence of solvents: CH2Cl2, DMF, 0.5% DIPEA in DMF (v/v), DMF, water, 1% EDTA in water 
(w/w), water, DMF, 0.5% DIPEA in DMF (v/v), DMF, 1 M HOBt in DMF, DMF, CH2Cl2, i-PrOH, 
CH2Cl2, Et2O affording lysine deprotected Tat on NovaPEG resin 6.2. A sample of the resin (200 mg) 
was removed and suspended in trifluoroacetic acid/water/triisopropylsilane/thioanisole (90:5:2.5:2.5, 
v/v) and stirred for 20 h at rt. Then the resin was filtered off and the filtrate was precipitated from Et2O, 
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redissolved in water and lyophilized yielding the crude peptide 6.3 as a white powder. ESI-ion trap m/z: 
[M+3H]3+ = 552.56 (calcd. 552.00), [M+4H]4+ = 414.84 (calcd. 414.25), [M+5H]5+ = 332.24 (calcd. 
331.60). 
 
Branching of Tat (6.4-6.7) 
GP, RP and AFK were coupled to the free lysine side-chains in Tat 6.2 by standard SPPS (0.5 mmol 
scale) and cleaved from the resins as described above. Analytical data on the crude peptides: 
Tat (1×AFK) 6.4: ESI-ion trap m/z: [M+3H]3+ = 668.12 (calcd. 667.40), [M+4H]4+ = 501.32 (calcd. 
500.80), [M+5H]5+ = 401.36 (calcd. 400.84). 
Tat (2×AFK) 6.5: ESI-ion trap m/z: [M+3H]3+ = 783.40 (calcd. 782.80), [M+4H]4+ = 587.80 (calcd. 
587.35), [M+5H]5+ = 470.60 (calcd. 470.08). 
Tat (2×RP) 6.6: ESI-ion trap m/z: [M+3H]3+ = 721.28 (calcd. 720.77), [M+4H]4+ = 541.48 (calcd. 
540.83), [M+5H]5+ = 433.48 (calcd. 432.86), [M+6H]6+ = 361.48 (calcd. 360.89). 
Tat (2×GP) 6.7: ESI-ion trap m/z: [M+2H]2+ = 982.24 (calcd. 981.58), [M+3H]3+ = 655.20 (calcd. 
654.72), [M+4H]4+ = 491.76 (calcd. 491.29), [M+5H]5+ = 393.84 (calcd. 393.23). 
NB: Tat (1×AFK) 6.4 was collected as a side-product from the synthesis of Tat (2×AFK) 6.5. 
 
Solid phase diazotization of Tat (6.8) 
Tat NovaPEG resin 6.2 (0.2 mmol scale) was swollen in water (8.0 mL) for 30 min. Then imidazole-1-
sulfonyl azide hydrochloride[22] (82 mg, 391 Cmol) and K2CO3 (82 mg, 593 Cmol) were added and shaken 
for 1 h.[23] This was repeated another two times followed by washing with water, i-PrOH, CH2Cl2, i-
PrOH, CH2Cl2 and Et2O and air-dried for at least 2 h. The dry resin was then suspended in 
trifluoroacetic acid/water/triisopropylsilane/thioanisole 90:5:2.5:2.5 for 20 h. The resin was filtered off 
and the filtrate was precipitated in Et2O, air-dried and lyophilized yielding the crude Tat(2×N3) peptide 
6.8 as a white powder. ESI-ion trap m/z: [M+3H]3+ = 569.88 (calcd. 569.33), [M+4H]4+ = 427.80 
(calcd. 427.25), [M+5H]5+ = 342.36 (calcd. 342.00). 
 
Solution labeling of the Tat peptides (6.9-6.12) 
Tat(2×AFK) 6.5 (54 mg, 23 Cmol) and triscarboxyethylphosphine (12 mg, 48 Cmol) were dissolved in 
water-DMF (1:1, 6 mL). Then fluorescein diacetate 5-maleimide (17 mg, 33 Cmol) was added and the 
reaction mixture was stirred at 60 DC for 24 h. Next, the reaction mixture was evaporated to dryness, 
redissolved in water-formic acid (1:1) and purified by HPLC (see above) affording the labeled 
Tat(2×AFK) peptide 6.11 as a white powder. ESI-ion trap m/z: 
[M+Na+H]2+ = 1439.12 (calcd. 1440.25), [M+Na+2H]3+ = 959.96 (calcd. 960.47), [M+Na+3H]4+ = 
720.48 (calcd. 720.62), [M+Na+4H]5+ = 576.60 (calcd. 576.70), [M+Na+5H]6+ = 480.72 (calcd. 480.75). 
 
The fluorescein-labeled peptides Tat 6.9, Tat(1×AFK) 6.10 and Tat(2×N3) 6.12 were prepared as 
described above for Tat(2×AFK) 6.11. Analytical data on the crude peptides: 
Tat 6.9: ESI-ion trap m/z: [M+3H]3+ = 722.84 (calcd. 722.37), [M+4H]4+ = 542.44 (calcd. 542.03), 
[M+5H]5+ = 434.20 (calcd. 433.82), [M+6H]6+ = 361.92 (calcd. 361.68). 
Tat(1×AFK) 6.10: ESI-ion trap m/z: [M+Na+H]2+ = 1266.08 (calcd. 1267.15), M+Na+2H]3+ = 844.60 
(calcd. 845.10), [M+Na+3H]4+ = 633.76 (calcd. 634.07), [M+Na+4H]5+ = 507.32 (calcd. 507.46), 
[M+Na+5H]6+ = 422.96 (calcd. 423.05). 
Tat(2×N3) 6.12: ESI-ion trap m/z: [M+3H]3+ = 740.32 (calcd. 740.37), [M+4H]4+ = 555.48 (calcd. 
555.53), [M+5H]5+ = 444.60 (calcd. 444.62). 
 
Confocal laser scanning microscopy 
HeLa cells were grown in DMEM supplemented with antibiotics/antimycotics and 10% heat-inactivated 
FBS. Cells were maintained at 37 °C in a 5% CO2 humidified air atmosphere and split twice weekly. 
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One day before the experiment HeLa cells were seeded in DMEM in an 8-well microscopy chamber 
(Nunc, Wiesbaden, Germany) coated with gelatin at a density of 40,000 cells/well. At the time of the 
experiment, cells had grown to approximately 50% confluence. 
The peptides were dissolved in water and diluted with DMEM to a final volume and concentration of 
400 ML and 10 MM, respectively. These solutions was added to the cells, which were incubated for 2 h at 
37 °C. The cells were washed with DMEM (3×400 ML) and imaged immediately by means of confocal 
laser scanning microscopy using a Leica Microsystems TCS SP5 confocal microscope, equipped with an 
HCX PL APO 63×N.A. 1.2 water immersion lens (Mannheim, Germany. Excitation of the fluorescein 
was achieved with an argon laser [488 nm (46%) and 496 nm (46%)] and the resulting emission was 
acquired between 520 and 600 nm as an average of four scans. 
 
Flow cytometry 
The same samples used in confocal laser scanning microscopy were used to quantify cellular uptake by 
flow cytometry. The medium was removed and the cells washed with PBS followed by trypsination for 30 
min at 37 OC to detach the cells and remove surface-bound peptides. PBS supplemented with 1% BSA (1 
mL) was added to each well and the solution was pipetted up and down several times to promote cell 
detachment. The cells were collected by centrifugation (2,700 rpm, 5 min), and washed once more with 
PBS buffer supplemented with 1% BSA (1.00 mL) by centrifugation. Finally, the cells were resuspended 
in fresh PBS buffer (1% BSA; 1.00 mL) and analysed by flow cytometry. For all samples, the cellular 
fluorescence of 5,000 cells was measured on a Beckman Coulter CyAn ADP 7 Color flow cytometer, 
equipped with 488, 561 and 643 nm lasers (Woerden, The Netherlands). The fluorescence response, 
gated on the basis of forward and sideward scatter, was analyzed with Fort Collins Summit software. 
 
Enzymatic reactions 
The peptides Tat 6.3, Tat(2×AFK) 6.5, Tat(2×RP) 6.6 and Tat(2×GP) 6.7 were dissolved in Tris buffer 
(200 mM, pH 7.2; for APN) or (100 mM, pH 8.0; for DPPIV) at a concentration of 1 mg/mL and 
aliquoted into portions of 200 ML. Aminopeptidase N (APN; 2 ML, 0.12 U) or dipeptidyl peptidase IV 
(DPPIV; 5 ML, 0.045 U) were added to the different aliquots, shaken for 24 h at 37 OC and analyzed by 
LCMS. 
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Summary 
Cell-penetrating peptides (CPP) have become widely recognized as a powerful tool for improving 
cellular uptake of molecular cargoes, which are not readily taken up by cells such as most 
biomacromolecules. Unfortunately, CPP-based delivery systems are uncontrollable and lack cell 
specificity so not only the desired (diseased) cells take up the cargo. In this thesis this issue has 
been addressed by development of strategies to control the functionality of a model cell 
penetrating peptide. 
In chapter 2, a novel method is described, in which a constrained UV-activatable CPP was 
used to trigger transport of liposomes into cells upon UV-irradiation. The CPP was modified on 
both termini with an alkyl chain and anchored to the liposomal surface in a constrained and 
inaccessible structure. Since one of the two alkyl chains was connected to the peptide via a UV-
cleavable linker, disconnection of this alkyl chain upon irradiation led to exposure of the CPP, 
and mediated the transport of the entire liposome particle into cells. Further, it was shown in a 
proof-of-concept experiment that this UV-activatable delivery system could be used to deliver 
the cytotoxic agent doxorubicin into HeLa cells when UV irradiation was applied. In the course 
of this work, the susceptibility of conventional organic fluorophores to photobleaching posed a 
problem to the study of the UV-activatable liposome delivery system. For this reason, a project 
of loading liposomes with quantum dots, which are more photostable than organic fluorophores, 
was initiated. However, the substantial size of quantum dots necessitated development of new 
purification procedures to separate liposomes from free quantum dots. Chapter 3 describes the 
development of such a procedure, which enable quick and efficient removal of free quantum 
dots based on electrostatic binding of quantum dots to ion exchange beads. The purification 
efficiency was assessed via analytical gel electrophoresis, and by copper-mediated quenching of 
quantum dot fluorescence it was established that the quantum dots were not adhered to the 
liposomes but residing inside these. Furthermore, a method was presented to quantify the 
number of quantum dots loaded inside the liposomes by the combined efforts of particle 
counting and inductively coupled plasma mass spectrometry. 
In chapter 4, the cell permeation ability of a CPP was combined with the specific non-
covalent interaction of two leucine zipper peptides to prepare a modular non-covalent delivery 
system for leucine zipper-tagged proteins. One leucine zipper was conjugated to a CPP via the 
well-known copper(I)-catalyzed 1,3-dipolar cycloaddition and the other was fused to green 
fluorescent protein (GFP). Cellular uptake of leucine zipper-tagged GFP took place only when 
the CPP functionalized leucine zipper was added. Further, it was attempted to make the CPP 
bearing the leucine zipper activatable. It was envisioned that by attachment of the positively 
charged CPP to the negatively charged leucine zipper, intramolecular electrostatic interactions 
might induce inactivation of the CPP. In this regard, addition of the complementary leucine 
zipper was expected to reactivate the CPP by formation of a coiled coil with the leucine zipper 
moiety. Regrettably, the combined results of circular dichroism spectroscopy and cellular uptake 
experiments suggested that the leucine zipper-CPP did not fold as expected and full functionality 
of the CPP was observed, regardless of the presence of the complementary leucine zipper.  
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The copper(I)-catalyzed 1,3-dipolar cycloaddition used to conjugate the leucine zipper and the 
CPP described in chapter 4 required the preparation of N-terminal azido-peptides. This was 
accomplished by means of transformation of the N-terminus using a shelf-stable and easily 
prepared diazotransfer reagent, imidazole-1-sulfonyl azide hydrochloride. Chapter 5 describes in 
more detail how this diazotransfer reagent could be used to transform the N-terminus of model 
peptides into azide moieties on solid phase. Further, it was demonstrated that this conversion 
was completed within 30 min with high efficiency under aqueous conditions on a NovaPEG 
resin as well as in DMF on polystyrene beads. 
The ideal strategy to control CPPs and direct them to the area of interest is to exploit the 
unique microenvironment surrounding the various tissues in vivo. One such approach involves 
targeting of surface enzymes present on specific tissues that activate an inactivated CPP. In 
chapter 6 preliminary results from the development of an enzyme-activatable CPP are 
described. Inactivation was achieved by temporarily blocking the lysine residues in the CPP, Tat, 
with di- and tripeptides. Flow cytometry and confocal laser scanning microscopy showed that 
blocking one or two of the lysine residues with AFK tripeptides led to almost complete loss of cell 
adhesion and uptake. Regrettably, the AFK tripeptide could not be removed enzymatically using 
the model enzyme aminopeptidase N (APN). Two dipeptides GP and RP, on the other hand, 
could be removed by the enzyme dipeptidyl peptidase IV (DPPIV) thereby demonstrating the 
feasibility of this strategy.  
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Samenvatting 
Cel-penetrerende peptides (CPP’s) worden beschouwd als een effectief middel om de cellulaire 
opname van moleculen te verbeteren. Helaas zijn afgiftesystemen gebaseerd op CPP’s niet te 
controleren. Specificiteit met betrekking tot de soort cel ontbreekt, zodat niet alleen de gewenste 
(zieke) cellen het af te leveren molecuul opnemen. In dit proefschrift wordt dit probleem 
aangepakt. De ontwikkeling van een aantal strategieën wordt beschreven die het mogelijk maken 
de functie van een cel-penetrerend peptide te beïnvloeden.  
Hoofdstuk 2 beschrijft een nieuwe methode waarin een gespannen (constrained) UV-
activeerbaar CPP wordt gebruikt om liposomen met behulp van UV-straling de cel in te 
transporteren. Beide uiteindes van het CPP werden gemodificeerd met een alkylketen. Hierdoor 
werd het peptide in een onder spanning staande conformatie en op ontoegankelijke wijze 
verankerd in het liposoomoppervlak. Aangezien een van de twee alkylketens via een met UV-
licht te verbreken verbinding met het peptide verbonden was, kon de alkylketen door middel van 
bestraling losgekoppled worden. Zo werd het CPP blootgesteld en kon het gehele liposoom de 
cel in worden getransporteerd. Er werd aangetoond dat dit UV-activeerbare afgiftesysteem 
gebruikt kon worden om het cytotoxische middel doxorubicine af te geven aan HeLa cellen na 
bestraling met UV-licht.  
In de loop van het onderzoek zorgde de gevoeligheid van conventionele organische 
fluoroforen voor photobleaching (dat wil zeggen de fotochemische afbraak van een fluoroscent 
molecuul) voor problemen bij het bestuderen van dit UV-activeerbare liposoom-afgiftesysteem. 
Daarom werd een project opgezet waarbij liposomen geladen werden met quantum dots, 
moleculen die beter bestand zijn tegen photobleaching dan organische fluoroforen. Doordat 
quantum dots vergelijkbaar in grootte zijn met liposomen, was het nodig om een nieuwe 
zuiveringsprocedure te ontwikkelen om liposomen van niet-ingebouwde quantum dots te scheiden. 
Hoofdstuk 3 beschrijft de ontwikkeling van een dergelijke methode, waarmee op snelle en 
efficiënte wijze losse quantum dots konden worden verwijderd gebruikmakend van de 
electrostatische interactie van quantum dots met ionenuitwisselingsmateriaal. De efficiëntie van de 
zuivering werd getoetst met behulp van analytische gel-electrophorese. Gebruikmakend van het 
principe dat de fluorescentie van quantum dots wordt uitgedoofd door koper, werd aangetoond dat 
de quantum dots niet bleven plakken aan de buitenkant van liposomen maar daadwerkelijk 
binnenin deze capsules zaten. Daarnaast wordt een methode beschreven om de belading van 
quantum dots in liposomen te kwantificeren door het tellen van het aantal deeltjes te combineren 
met inductief gekoppeld plasma massaspectrometrie. 
In hoofdstuk 4 werd de mogelijkheid van een CPP om een cel binnen te dringen 
gecombineerd met de specifieke, niet-covalente interactie van twee leucine zipper peptides. Zo 
werd een modulair, niet-covalent afgiftesysteem gecreëerd voor eiwitten gelabeld met een leucine 
zipper. Eén leucine zipper werd gekoppeld aan een CPP via de welbekende koper(I)-gekatalyseerde 
1,3-dipolaire cycloadditie, en de andere werd gefuseerd aan het groen-fluorescerende eiwit GFP. 
Cellulaire opname van GFP gelabeld met de leucine zipper vond alleen plaats wanneer de tweede, 
CPP-bevattende leucine zipper werd toegevoegd. Er werd getracht het CPP dat gekoppeld was aan 
de leucine zipper activeerbaar te maken. Het idee was dat intramoleculaire, electrostatische 
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interacties tussen het positief geladen CPP en de negatief geladen leucine zipper, inactivatie van het 
CPP induceerde. Vanuit dit oogpunt werd verwacht dat na toevoeging van de complementaire 
leucine zipper het CPP weer actief zou worden, omdat in dit geval de twee leucine zippers een 
interactie met elkaar zouden aangaan. Helaas suggereerden resultaten verkregen met circulair 
dichroïsme spectroscopie en cel-opname experimenten dat het CPP-leucine zipper construct niet 
de verwachte vouwing had. Het CPP bleek volledig functioneel te zijn, onafhankelijk van de 
aanwezigheid van de complementaire leucine zipper.  
De koper(I)-gekatalyseerde 1,3-dipolaire cycloadditie die gebruikt werd om de leucine zipper 
aan het CPP te koppelen, zoals beschreven in hoofdstuk 4, vereiste de bereiding van peptides 
met een azide aan de N-terminus. Dit werd bewerkstelligt door modificatie van de N-terminus 
gebruikmakend van het stabiele en makkelijk te bereiden diazotransfer reagens imidazole-1-
sulfonyl azide hydrochloride. Hoofdstuk 5 beschrijft in meer detail hoe dit diazotransfer reagens 
gebruikt kon worden om de N-terminus van modelpeptides, gekoppeld aan vast dragermateriaal, 
te veranderen in azides. Er werd bovendien aangetoond dat deze omzetting op efficiënte wijze, 
zowel in water gebruikmakend van NovaPEG dragermateriaal als in dimethylformamide met 
behulp van polystyreen als dragermateriaal, binnen 30 minuten voltooid was. 
De ideale strategie om CPP’s te controleren en te dirigeren naar de locatie waar ze hun 
functie dienen uit te voeren, is om te profiteren van het feit dat de omgeving rondom 
verschillende weefsels in vivo uniek is. Een voorbeeld van een dergelijke benadering is gericht op 
enzymen die zich bevinden op het oppervlak van specifieke weefsels en die in staat zijn om 
inactieve CPP’s te activeren. In hoofdstuk 6 worden de voorlopige resultaten beschreven van de 
ontwikkeling van een enzym-activeerbaar CPP. Inactivatie werd mogelijk gemaakt door de 
lysine-residuen in het CPP Tat te blokkeren met di- en tripeptides. Flow cytometrie en confocale 
laser scanning microscopie toonden aan dat het blokkeren van één of twee lysines met 
tripeptides opgebouwd uit alanine, phenylalanine en lysine (AFK) tot vrijwel volledig verlies van 
celbinding en –opname leidde. Helaas kon het tripeptide AFK niet op enzymatisch wijze worden 
verwijderd wanneer het modelenzym aminopeptidase N gebruikt werd. In een vervolgstap werd 
aangetoond dat twee dipeptides, opgebouwd uit glycine en proline, en arginine en proline, 
verwijderd konden worden door het enzym dipeptidyl peptidase IV. Zo werd de haalbaarheid 
van deze strategie alsnog aangetoond. 
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Outlook 
In this thesis three new approaches based on cell-penetrating peptides to deliver 
(biomacromolecular) cargos into cells have been presented: i) UV-controlled delivery of 
liposomes, ii) modular non-covalent delivery of proteins and iii) enzyme-activatable cell-
penetrating peptides (CPP). Throughout this work, the focus was on development and 
examination of the fundamental concepts, whereas less attention was paid to improvements of 
the concepts. This section will recompense this brevity by addressing issues which need 
improvement as well as future directions of the delivery systems. 
 
Endosomal escape of l iposomes 
It was demonstrated in chapter 2 that UV-controlled delivery of liposomes into cells could be 
accomplished by exploiting a constrained UV-activatable Tat peptide. However, when a 
cytotoxic drug was encapsulated and delivered into the cells, the effect of the drug was minimal. 
Most likely, this modest effect was due to entrapment of the liposomes in endosomal vesicles, 
from which the release into the cytosol was minimal. Hence, it is debatable whether the term 
delivery is appropriate, as this implies that the cargo has reached its recipient. In fact, it is 
sometimes claimed that » (…) the inside of the endosome is essentially the outside of the cell; no biological 
response will be elicited simply by uptake into vesicles. «[2] Thus, it might be argued that no intracellular 
transport took place at all. To address this issue the UV-activatable Tat liposomes might be 
modified with endolytic lipids or peptides, which facilitate release of the liposomes (or their 
content) from the endosomes into the cytosol.[3] Further, the enzyme-activatable Tat peptides 
can be used to replace the UV-activatable Tat to prepare a drug delivery vehicle, which targets 
specific cells and delivers its cargo into the cytosol. 
 
Modular non-covalent delivery 
The applicability of leucine zippers (LZ) as a non-covalent linkage between a CPP, Tat, and its 
cargo was established by means of intracellular delivery of LZ-tagged green fluorescent protein 
(GFP-LZ; chapter 4). However, the LZ bearing Tat was constitutively active in the original 
design of the delivery system, and consequently taken up by cells even though the 
complementary LZ bearing the cargo was not present. Hence it was attempted to block the 
negative charge of Tat by conjugation of the negatively charged LZ to it. Unfortunately, Tat 
remained functional and was able to penetrate cells, seemingly because the LZ did not fold back 
onto the Tat component of the conjugate. Efficient folding might be achieved by increasing the 
number of electrostatic interactions between the Tat peptide and the LZ. This could be 
accomplished via several routes such as by using LZs, which have a higher negative charge 
density or ultimately by applying the deactivation strategy developed by Tsien and co-workers.[1] 
In their strategy the electrostatic interaction between a nona-glutamate peptide and a nona-
arginine CPP connected by a cleavable loop was exploited to deactivate the latter. If this loop is 
replaced with a LZ, re-activation of the nona-arginine peptide might be attainable by addition of 
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the complementary LZ, as the resulting coiled-coil formation should open the loop and expose 
the nona-arginine peptide. 
 
Enzyme-activatable Tat-peptides 
Preliminary results showed that blocking the lysine side-chains in the CPP, Tat, with di- or tri-
peptides has great potential for the development of enzyme-activatable CPPs (chapter 6). In this 
regard, the cellular uptake was efficiently abolished when one or two lysine side-chains were 
blocked with an AFK tri-peptide. However, enzymatic re-activation by means of removal of the 
tri-peptide was unsuccessful. RP and GP dipeptides on the other hand, were removed efficiently, 
showing great promise for future cellular uptake studies. Moreover, it was found that blocking 
one lysine side-chain was as efficient as blocking two, hence even more efficient reactivation 
reactions might be observed if only one di-peptide has to be removed. Alternatively, two 
different (di-) peptides, which are cleaved by different enzymes present on the same cell-type, 
could be used to develop an enzyme-activatable CPP with ultimate specificity. Ultimately, these 
enzyme-activatable Tat-peptides are intended for targeted delivery in vivo, so it is crucial to 
investigate the biodistribution of the peptides. This could be carried out in a mouse cancer 
model, for example, whereby the targeted delivery specificity in vivo could be assessed. 
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